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Status of Alternative Approaches to Animal Testing
Abstract
Replacement, Reduction and Refinement (Three Rs) of the use of animals for scientific purposes is required by 
EU legislation. Integrated Approaches to Testing and Assessment that incorporate multiple data streams derived 
from new sources such as in vitro methods and computational ('in silico') modelling are advancing to translate 
mechanistic understanding of toxicity into safety testing strategies avoiding traditional animal testing for chemicals 
safety testing.  In addition, effective knowledge sharing activities on alternatives in the areas of basic and applied 
research in life sciences as well as education and training are growing in scope, oureach and impact. 
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1The European Union Reference Laboratory for alterna-
tives to animal testing (EURL ECVAM) is an integral part of 
the European Commission's Joint Research Centre (JRC). 
This annual EURL ECVAM status report provides updates 
on the progress being made in the development, valida-
tion and regulatory acceptance of alternative-to-animal 
methods and approaches and their dissemination.
In the areas of toxicology and safety assessment, sig-
nificant progress has been made in demonstrating how 
in vitro and computational methods can be combined 
to 'read-across' toxicological properties between similar 
chemicals to avoid unnecessary animal testing. Alter-
native methods are also being increasingly employed 
for the identification of endocrine disruptors and the 
assessment of chemical mixtures. However the use of 
alternative methods alone to fully characterise complex 
toxicological properties of chemicals, such as chronic 
systemic health effects, remains a formidable chal-
lenge. Recommendations have been published on how 
to improve multi-centre validation studies of alternative 
methods for the quality control of vaccines and how 
the data generated can be used for product specific 
validation by vaccine manufacturers. Recent advances 
in the ecotoxicology field include the development of a 
Threshold of Toxicological Concern approach (eco-TTC) 
for environmental safety assessment and the use of 
integrated non-animal methods to predict the bioaccu-
mulation potential of chemicals in fish. Addressing the 
biomedical research domain, EURL ECVAM launched a 
major study to review the use of alternative methods and 
models for understanding biology and disease and for 
developing novel approaches to diagnosis and therapy.
The validation of alternative methods intended for 
regulatory use has progressed on a number of fronts 
including novel methods for predicting the skin sensi-
tisation potential of chemicals, assessing the leaching 
(bioelution) of chemicals from metal alloys, and for 
determining acute toxicity in fish. Two EURL ECVAM val-
idation studies deal with methods for the identification 
of endocrine disruptors and involve the EU Network of 
Laboratories for the Validation of Alternative Methods 
(EU-NETVAL). Several multi-stakeholder discussions on 
validation took place in various fora which indicate that 
although well-established validation principles are still 
relevant today, the process of validation needs to be 
continually adapted to keep pace with scientific and 
technological progress. Reflecting the potential applica-
tion and impact of emerging organ-on-chip devices, EURL 
ECVAM conducted an international survey of developers 
and stakeholders to identify the issues determining end-
user confidence and to solicit opinions on how best to 
approach validation to facilitate uptake and acceptance. 
The EURL ECVAM Scientific Advisory Committee (ESAC) 
was renewed during 2018 and one of its first mandated 
tasks is to deliver an opinion on the scientific validity of 
antibodies and non-antibody affinity reagents gener-
ated using animal-free technologies used in research 
and diagnostics.
In the context of international regulatory acceptance 
and promotion of alternative methods for safety assess-
ment, several initiatives at the Organisation of Economic 
Cooperation and Development (OECD) are breaking new 
ground and delivering impact. In addition to new test 
guidelines and guidance documents to support non-an-
imal approaches to assess chemical toxicity in fish, the 
OECD published guidance on Good In Vitro Method Prac-
tices (GIVIMP) to ensure the reliability and integrity of in 
vitro data intended for regulatory use. The OECD project 
to develop a Guideline for 'Defined Approaches' for skin 
sensitisation assessment which combine both in vitro 
and computational methods has made steady progress 
and a draft has recently undergone commenting by OECD 
member country experts. The Adverse Outcome Pathway 
(AOP) programme is growing and 2018 saw the publica-
tion of a second set of AOPs for complex endpoints that 
were endorsed by OECD expert groups. Further initiatives 
on Integrated Approaches to Testing and Assessment 
(IATA) included a new cycle of IATA case studies and the 
launch of a project to map relevant guidance documents. 
Incorporation of alternative approaches into regulatory 
frameworks has also been addressed by other inter-
national bodies such as the International Cooperation 
on Cosmetics Regulation (ICCR) and the United Nations 
sub-committee on the Globally Harmonised System 
(GHS) of classification and labelling of chemicals.
Finally, sharing of expert knowledge remains a central 
pursuit to advance alternatives and a variety of col-
laborative initiatives are ongoing within the European 
Partnership for Alternative Approaches to Animal Testing 
(EPAA) and the International Cooperation on Alterna-
tive Tests Methods (ICATM). In addition, EURL ECVAM 
has been working with its network of EU and Member 
State regulatory bodies (PARERE) and its stakeholder 
forum (ESTAF) to identify opportunities for enhancing 
knowledge sharing in the fields of regulatory toxicology, 
biomedical research and education and training.
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4The European Union Reference Laboratory for Alterna-
tives to Animal Testing (EURL ECVAM) is an integral part 
of the European Commission's Joint Research Centre 
(JRC). The EURL ECVAM status report provides updates 
on the progress made in the development, validation and 
regulatory acceptance and use of alternative methods 
and approaches and their dissemination. The status 
report describes research, development and validation 
activities, as well as initiatives that promote the regu-
latory and international adoption and use of alternative 
approaches and their dissemination.
The mandate of EURL ECVAM is described in Directive 
2010/63/EU (EU, 2010) on the protection of animals 
used for scientific purposes and includes a number of 
duties (Article 48 and Annex VII) to advance the Replace-
ment, Reduction and Refinement (the Three Rs) of animal 
testing. The current activities of EURL ECVAM build on 
over 25 years of JRC support to the Three Rs (EC, 1991) 
and include participation in research projects; coordina-
tion and undertaking of validation studies; dissemination 
and sharing of information on the Three Rs; and the 
promotion of dialogue towards the international accept-
ance and uptake of alternative methods and approaches. 
Besides Directive 2010/63/EU, EU chemicals legislation 
such as REACH (EC, 2008) and the Cosmetics Regulation 
(EC, 2009) have had an important impact on the Three 
Rs by increasing the pace and the number of methods 
being developed, validated and proposed for interna-
tional adoption. 
Other pieces of EU chemicals and products legislation 
refer to alternative approaches and allow them to be 
used in hazard and risk assessment, including: Regula-
tion (EC) No 1272/2008 on Classification, Labelling and 
Packaging of substances and mixtures (CLP); Regulation 
(EC) No 1107/2009 concerning the placing of plant pro-
tection products on the market; Regulation 283/2013 
on data requirements for active substances; Regulation 
284/2013 on data requirements for plant protection 
products; Regulation 528/2012 concerning the making 
available on the market and use of biocidal products; 
Directive 2001/83/EC (and its amendments) on the Com-
munity code relating to medicinal products for human 
use; and Directive 2001/82/EC (and its amendments) on 
the Community code relating to medicinal products for 
veterinary use. In addition, the Commission Communi-
cation on the combined effects of chemicals - chemical 
mixtures (EC, 2012) and the EU strategy on Endocrine 
Disruptors (EC, 2018) are also important drivers of EURL 
ECVAM’s work since they present significant opportuni-
ties for the use of non-animal methods to address safety 
assessment challenges.
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5INTRODUCTION
The EURL ECVAM status report describes primarily, but 
not exclusively, all the activities it has undertaken or 
has been involved in since the publication of the last 
report in November 2017. It is intended to inform EURL 
ECVAM stakeholders and any interested parties on 
on-going activities in the field of alternative approaches 
and serves multiple purposes. This includes providing 
input to the annual Commission report on the progress 
made in the development, validation and regulatory 
acceptance of alternative methods and approaches that 
is prepared in the framework of Regulation 1223/2009 
on cosmetic products. It also supports the monitoring and 
implementation of provisions on alternatives included in 
Directive 2010/63/EU on the protection of animals used 
for scientific purposes and in other EU legislation related 
to chemicals and products.
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82.1 EU-ToxRisk 
EU-ToxRisk is a European collaborative project funded 
by the EU Framework Programme for Research and 
Innovation, Horizon 2020, to advance mechanism-based 
toxicity testing and risk assessment. The JRC has a formal 
collaboration agreement in place with the consortium to 
support its science programme and to aid in the eventual 
translation of research results into application. For more 
information on the project, a detailed description has 
been provided in the EURL ECVAM status report 2017 
(see section 2.2 in Zuang et al., 2017).
With the aim of encouraging early engagement of the 
regulatory hazard and safety assessment community, 
EURL ECVAM launched a consultation within the Pre-
liminary Assessment of Regulatory Relevance (PARERE) 
network to get their opinion on the regulatory relevance 
of safety assessment case studies being developed 
within the consortium. The EU-ToxRisk case study strat-
egy and an overview of four representative case studies 
were shared with the PARERE members, including:
1) Prediction of microvesicular liver steatosis - a read-
across case study with (un-)branched carboxylic acids,
2) Valproic acid analogues and developmental and repro-
ductive toxicity (DART) liabilities,
3) Prediction of Parkinsonian-like liabilities based on AOP 
aligned testing linked to mitochondrial toxicity and
4) Repeated-dose toxicity: Popcorn Lung – read-across 
on diketones.
Overall, the PARERE opinion was that such engagement 
was very beneficial for all parties and that New Approach 
Methodologies (NAMs; ECHA, 2016) have indeed a lot 
of potential for use in regulatory toxicology, although to 
what extent this would be possible in the short-term was 
unclear (see also section 4).
EURL ECVAM is actively supporting the consortium in a 
number of areas including: providing training and advice 
on the development of Adverse Outcome Pathways 
(AOPs); the centralised provision of reference chemicals 
for cross-laboratory generation of key datasets; the use 
of modelling for in vitro to in vivo extrapolation; and the 
definition and design of new case studies.
Research and Development 
Activities on Alternative Methods 
and Approaches
2.
©
 T
ob
ia
s 
Ar
he
lg
er
-A
bo
de
St
oc
k.
co
m
9RESEARCH AND DEVELOPMENT ACT IV IT IES ON ALTERNATIVE METHODS AND APPROACHES
Collaboration also covers the inclusion of selected proto-
cols developed within the EU-ToxRisk consortium into the 
EURL ECVAM Database on alternative methods (DB-ALM). 
Currently, the following protocols have been revised and 
published, with more protocols in the pipeline:
• cMINC assay to test migration inhibition compounds 
on human iPSC-derived neural crest cells (NCCs).
• UKN3b assay to test compound-derived neurite 
integrity impairment in human mature dopaminergic 
neurons.
• Automated CALUX reporter gene assay procedure.
READ MORE
m EU-ToxRisk: www.eu-toxrisk.eu
m Horizon 2020: europa.eu/!Fm38rr
2.2 European Research Projects on 
Chemical Mixtures
Several EU funded Horizon2020 and FP7 research 
projects that are relevant in the context of chemical 
mixtures are currently ongoing.
In 2017, the projects EDC-MixRisk, EuroMix, EU-ToxRisk, 
HBM4EU, and SOLUTIONS joined forces together with 
EURL ECVAM, other Commission Services (DG Research 
and Innovation, DG Environment) and European agen-
cies (EFSA, ECHA, EEA) to organise a joint workshop on 
"Advancing the Assessment of Chemical Mixtures and 
their Risks for Human Health and the Environment". The 
workshop was prepared in collaboration and finally held 
29 to 30 May 2018 at JRC Ispra, bringing together 60 
experts in the field of chemical mixtures (see box 2.1 and 
fig. 2.1). The aim of the workshop was to discuss among 
researches and regulators mixture risk assessment from 
the different perspectives, to evaluate the progress 
achieved and identify further gaps to be addressed.
The workshop provided a forum to discuss the latest 
advancements in science, as well as research and policy 
needs, in order to make progress in mixture risk assess-
ment and management. The topics of the workshop 
included hazard and exposure assessment, data and 
tools, and risk analysis and governance. To consider also 
the wider international perspective, experts from Japan, 
United States (US) and the Organisation for Economic 
Cooperation and Development (OECD) joined to pres-
ent the way they are tackling mixtures. Although much 
progress has been achieved over the recent years, the 
participants stated that it is evident that more needs 
to be done to better address the combined exposure 
of multiple chemicals, both in terms of intentional 
mixtures (manufactured products such as pesticide 
formulations and cosmetic products) and unintentional 
mixtures (e.g., surface water pollutants). One of the 
major gaps continues to be the lack and availability of 
data. The Information Platform for Chemical Monitoring, 
IPCHeM, is addressing 
the gap for chemical 
monitoring data. How-
ever, another big 
challenge remains in 
the accessibility and 
quality of data on (eco)
toxicological properties 
and on the types of 
use of chemicals. In 
the group and plenary 
discussions, ideas were 
brought up on improv-
ing governance aspects 
to better protect public health and environment from 
hazardous chemical mixtures. The workshop outcome 
and future research needs will be summarised and 
published later in 2019. An overview of the current EU 
projects on mixtures and mapping of their activities to 
the different aspects of mixture risk assessment can 
be found in Bopp et al., 2018a.
Another aspect of this collaboration was to discuss the 
use of the European Commission’s Information Platform 
for Chemical Monitoring (IPCHeM) as a tool to provide 
occurrence data and to facilitate the exposure assessment 
for multiple chemicals.
A dedicated workshop with the above-mentioned pro-
ject partners, held at JRC Ispra in December 2017, gave 
the opportunity to present and discuss the most recent 
enhancements and tools of IPCHeM. It was useful to 
gather requirements for revising and extending IPCHeM’s 
functionalities and tools to best meet the needs of users 
The aim of the 
workshop was to 
discuss mixture risk 
assessment from the 
different perspectives, 
to evaluate the 
progress achieved and 
identify further gaps 
to be addressed
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interested/working on risk assessment of combination 
effects of chemicals (Dalla Costa et al., 2018).
READ MORE
m EDC-MixRisk: edcmixrisk.ki.se
m EuroMix: www.euromixproject.eu
m EU-ToxRisk: www.eu-toxrisk.eu
m HBM4EU: www.hbm4eu.eu
m SOLUTIONS: www.solutions-project.eu 
m IPCHeM: ipchem.jrc.ec.europa.eu
m Horizon 2020: europa.eu/!pc39Fj
m 7th Framework Programme: europa.eu/!QH99KW
m Towards improved safety assessment of combined expo-
sure to chemicals - News item: europa.eu/!xv48tN
2.3 European Research Projects on 
Endocrine Disruptors
A call1 was recently launched under the EU Horizon 2020 
framework programme for research and innovation, for 
new screening and testing methods to identify endocrine 
disrupting substances. According to the call text, the 
proposals should focus on methods where regulatory 
1  Call number: SC1-BHC-27-2018
needs are greatest, addressing targets such as the 
thyroid axis, developmental neurotoxicity, metabolic 
disorders and non-genotoxic carcinogenicity. The out-
come of the projects should contribute to international 
activities on Endocrine Disruptors (ED) at OECD level 
(see sections 5.1, 5.3.13 and 5.3.14) and, in order to 
facilitate regulatory uptake, the inclusion of a valida-
tion step in the proposals was considered essential. It 
is envisaged that JRC/EURL ECVAM will provide support 
to the selected projects on the translation of research 
results into regulatory application.
READ MORE
m New testing and screening methods to identify endocrine 
disrupting chemicals (call SC1-BHC-27-2018): europa.
eu/!rj96gx
2.4 Acute Systemic Toxicity
The need for mechanistic based approaches and meth-
odologies that could potentially replace animal use for 
acute systemic regulatory-required testing is well rec-
ognised (Prieto et al., 2014; Hamm et al., 2017; ICCVAM, 
2018; Clippinger et al., 2018a). With the ultimate aim 
of supporting the development of Adverse Outcome 
Figure 2.1  Workshop on "Advancing the Assessment of Chemical Mixtures and their Risks for Human Health and the Environ-
ment" held in May 2018 at JRC Ispra.
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Chemical mixtures – EU research consortia take 
stock of the science-policy landscape
The JRC has worked with five EU funded research consortia, EC 
department for Research and Innovation, the European Envi-
ronment Agency and the European Food Safety Authority to 
produce a paper (Bopp et al., 2018a) which identifies research 
and policy needs to deal with the assessment and management 
of potential risks posed by chemical mixtures to human health 
and the environment.
There are several major research projects currently ongoing 
at European level that aim to improve the assessment and 
management of combined exposures to multiple chemicals, 
including the European FP7 and Horizon 2020 research consor-
tia: SOLUTIONS, EuroMix, HBM4EU, EDC-MixRisk and EU-ToxRisk. 
The paper was prepared in the context of the Joint Horizon 
2020 workshop, "Advancing the Assessment of Chemical Mix-
tures and their Risks for Human Health and the Environment” 
which the JRC co-organised and hosted in May 2018 (see fig. 
2.1). The workshop brought together the research community 
with Commission services and EU Agencies to assess the state 
of the science, to map the research strategies of EU consortia 
against policy needs, and to prioritise areas for collaboration 
at the science-policy interface.
Every day we are exposed to low levels of hundreds of differ-
ent man-made chemicals present, for example, in our food, 
consumer products, and the air we breathe. Our environ-
ment too is exposed to a high number of chemical mixtures, 
originating from numerous sources (Carvalho et al., 2014). 
Box 2.1
This combined exposure to multiple chemicals can lead to 
health and environmental effects, which might be overlooked 
in regulatory assessments. This is because current safety 
assessment practice is primarily based on understanding the 
potential risk posed by single substances, rather than their 
"real life" combinations.
To better protect human health and the environment through 
the assessment of chemical mixtures, a number of scientific 
and policy challenges need to be addressed. These have been 
described in a series of publications, including a JRC policy brief 
(Bopp et al., 2018b), JRC technical report (Kienzler et al., 2014), 
and scientific paper (Kortenkamp & Faust, 2018). The European 
Commission is investing significantly in scientific and technical 
developments, primarily through its Framework Programme for 
Research and Innovation.
Pathways (AOPs) and IATA in the area of acute systemic 
toxicity, EURL ECVAM analysed mechanistic information 
collected on eight organs (nervous system, cardiovas-
cular system, liver, kidney, lung, blood, gastrointestinal 
system and immune system) identified as relevant for 
acute oral toxicity and using a set of chemicals inducing 
acute toxicity after oral exposure (see box 2.2).
As anticipated in the EURL ECVAM status report 2017 
(see section 2.9 in Zuang et al., 2017), from the analysis 
performed, it can be concluded that cytotoxicity is an 
important determinant of acute systemic toxicity. Fur-
thermore, the nervous and the cardiovascular systems 
are the most frequent targets for chemicals inducing 
acute oral toxicity. Changes in neurotransmission and 
altered ion flow appeared as important mechanisms often 
associated with acute neurotoxicity and cardiotoxicity, 
respectively. However, no clear relationship emerged 
between specific mechanisms of target organ toxicity 
and the level (category) of toxicity. Mechanistic infor-
mation and kinetic 
c ons i de ra t i on s 
are clearly useful 
to explain in vitro 
misclassifications 
obtained with the 
cytotoxicity assay. 
Nevertheless, the 
number of acute 
oral toxicity cate-
gories under the 
EU Classification, 
Labelling and Packaging (CLP) Regulation (EC, 2008) 
and the associated LD50 ranges, which are not based 
As anticipated in the 
EURL ECVAM status 
report 2017, from the 
analysis performed, 
it can be concluded 
that cytotoxicity is an 
important determinant of 
acute systemic toxicity
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Figure 2.2  Workshop on current practices for acute inhalation toxicity testing co-hosted by PETA International Science Consortium 
(PISC) and the US NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) in September 2016.
How do chemicals cause acute oral toxicity via 
organ-specific mechanisms? 
EURL ECVAM scientists collected and analysed mechanistic 
information on the effects of chemicals on eight organs iden-
tified as relevant for acute systemic toxicity in humans. The 
ultimate aim is the replacement of the use of animals in the 
regulatory assessment of acute oral toxicity. This knowledge 
is expected to support the development and application of 
adverse outcome pathways (AOPs) and mechanistically rele-
vant new approach assessment methodologies.
The replacement of animals in acute systemic toxicity test-
ing, which is a core component of the safety assessment of 
Box 2.2
substances, remains a considerable challenge. This is partially 
due to the incomplete mechanistic understanding of the key 
acute toxicity pathways in humans, some of which are specific 
for different cell types (e.g., neuronal, cardiac, liver or kidney), 
while others are broadly applicable (e.g., general cytotoxicity). 
Therefore, improving the knowledge of the numerous mecha-
nisms involved would be useful to developers of test methods 
and other predictive tools as well as to validation and regu-
latory bodies.
EURL ECVAM analysed the relevant literature and confirmed 
that general cytotoxicity is an important determinant of acute 
systemic toxicity. While the nervous and the cardiovascular 
systems are the most frequent targets, a clear pattern was 
not found with regard to which specific mechanisms of target 
organ toxicity are representative of compounds in the different 
potency classes. For this analysis, the potency classes were 
based on the EU regulatory system for classifying chemicals 
for acute oral toxicity, namely the Classification, Labelling and 
Packaging (CLP) categories.
At present, the regulatory classification is based on animal 
(mainly rodent) studies. Building on all the collected infor-
mation, it is worth trying to develop an alternative way of 
classifying chemicals for acute oral toxicity based mainly on 
cytotoxicity and kinetic information, and complemented, if 
needed, with relevant organ-specific mechanisms of toxicity 
(Prieto et al., 2018).
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on a particular mechanistic rationale, cannot be ignored 
when evaluating alternative approaches for the pur-
poses of regulatory classifications. Work is continuing 
to explore alternative, mechanistic-based criteria for 
classifying chemicals for acute oral toxicity based 
mainly on cytotoxicity and kinetic information and, if 
needed, complemented with relevant organ specific 
mechanisms of toxicity (Prieto et al., 2018).
Current testing requirements and major needs in rela-
tion to alternative approaches for acute inhalation 
toxicity testing were discussed during an international 
workshop in 2016 (Clippinger et al., 2018a) attended 
by EURL ECVAM (see fig. 2.2). In response to one of the 
workshop's recommendations, an expert working group 
reviewed the state-of-the-science concerning mecha-
nistic information or relevant AOPs and assays available 
and emerging to assess acute inhalation toxicity and 
how the existing knowledge could be used to design 
effective non-animal testing approaches (Clippinger et 
al., 2018b; see box 2.3).
2.5 The VAC2VAC Project
The VAC2VAC project - "Vaccine batch to vaccine batch 
comparison by consistency testing" brings together 21 
public and private partners including the JRC represented 
by EURL ECVAM. This five years project (2016 – 2021) is 
funded under the Innovative Medicines Initiative 2 (IMI 
2), a joint undertaking of the EU Horizon 2020 Research 
and Innovation Programme and the European Federation 
of Pharmaceutical Industries and Associations (EFPIA).
VAC2VAC
The focus is on the use of the consistency approach for 
quality control of established vaccines for human and 
veterinary use. For this purpose, VAC2VAC partners are 
developing, optimising and evaluating non-animal meth-
ods for routine batch quality, safety and efficacy testing of 
vaccines, in collaboration and consultation with regulatory 
agencies. EURL ECVAM is participating in the project as 
leader of the work package related to validation, and 
supports project activities related to international dis-
semination, harmonisation and regulatory acceptance of 
consistency approaches. 
In order to discuss ways of improving multi-centre val-
idation studies and making use of the data generated 
for product-specific validation purposes, EURL ECVAM 
organised with VAC2VAC partners a workshop in 2017 
New approaches needed to assess the effects of 
inhaled substances on human health
In 2016 EURL ECVAM joined a working group, together with 
other international experts, to assess acute inhalation toxic-
ity (see fig. 2.2). They discussed how existing knowledge can 
be used to design effective non-animal testing approaches 
(Clippinger et al., 2018b). Experts described Adverse Outcome 
Pathways (AOPs) and the toolbox of non-animal approaches 
that could be used to investigate relevant mechanisms leading 
to acute inhalation toxicity. The review proposes a decision tree 
to help guide consideration of exposure parameters and the 
design of an integrated strategy for inhalation testing.
Some important challenges need to be addressed on the way 
towards meaningful progress in implementing non-animal 
approaches:
• Curating data in user-friendly databases
• Evaluating of existing QSAR models and developing new ones
• Advancing mechanistic dosimetry models for in vitro to in 
vivo extrapolation
• Developing and sharing AOPs
Box 2.3
• Optimising in vitro systems
• Designing and testing integrated approaches
These mechanistic based non-animal approaches will provide a 
predictive tool and likely more information to risk assessors than 
a median lethal concentration (LC50) or other in vivo observations.
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at the JRC, Ispra, Italy (see fig. 2.3). The summary of the 
discussions and recommendations agreed upon by 30 
experts from veterinary and human vaccine manufac-
turers, official medicines control laboratories, academia, 
translational research organisations, and vaccinology 
alliances have been published in 2018 (Halder et al., 
2018a; see box 2.4).
Recommendations encourage manufacturers to play 
a more active role by identifying suitable non-animal 
methods, providing relevant samples, or by sponsoring 
of studies. Both 
multi-centre val-
idation studies 
and product-spe-
cific validation 
are technically 
demanding and 
time and resource 
intensive, availa-
bility of sufficient 
resources for vali-
dation studies and 
implementation of 
new methods is 
crucial. Moreover, the availability of critical reagents and 
reference preparations should be secured.
There are several new documents available supporting 
the substitution of animal tests for the quality control 
of vaccines (Council of Europe, 2018) and the use of 
data generated in multi-centre validation studies for 
product-specific validation (EMA, 2017).
READ MORE
m VAC2VAC: www.vac2vac.eu
m Innovative Medicine Initiative (IMI): www.imi.europa.eu
m European Federation of Pharmaceutical Industries and 
Associations (EFPIA): www.efpia.eu
m Horizon 2020: europa.eu/!pc39Fj
m JRC hosts the VAC2VAC workshop on validation of 
non-animal methods for quality control of vaccines - 
News item: europa.eu/!nc73BM
2.6 EURL ECVAM Laboratory Studies
EURL ECVAM hosts a specialised laboratory for in vitro 
toxicity testing. A detailed description of the laboratory 
capabilities is provided in the EURL ECVAM status report 
2017 (see section 2.5 in Zuang et al., 2017). The lab-
oratory includes a High Throughput Screening facility 
that covers all general activities related to non-routine 
or non-standardised processes and procedures, linked 
mainly to method optimisation and high throughput and 
high content screening. The laboratory hosts also a Good 
Laboratory Practice (GLP) facility that covers primarily 
Figure 2.3  VAC2VAC workshop on validation of non-animal methods for quality control of vaccines held at the JRC Ispra in 
February 2017.
There are several new 
documents available 
supporting the substitution 
of animal tests for the 
quality control of vaccines 
and the use of data 
generated in multi-centre 
validation studies for 
product-specific validation
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formal validation studies to assess the performance of 
standardised methods. The laboratory directly supports 
the EURL ECVAM mandate as stipulated in Directive 
2010/63/EU and also serves collaboration and internal 
projects. Examples of experimental studies, implemented 
in-house, are given below.
The AR-CALUX in vitro method, developed for the detec-
tion of compounds with androgenic and anti-androgenic 
potential (see section 4.1), has been implemented in EURL 
ECVAM's High Throughput Screening facility. The meth-
od's protocol developed for manual implementation has 
been adapted for automated operation in quantitative 
High-Throughput Screening (qHTS) format. Besides the 
higher throughput achieved, and owing to a higher range 
of concentrations tested, this implementation allows to 
combine both the pre-screen and the comprehensive test-
ing, eliminating the requirement of a preliminary range 
finding experiment to determine the proper concentration 
range. To this end, modifications of the manual protocol 
were made to allow for an optimal use of the automated 
equipment and these included a plate layout allowing the 
testing of about 40 chemicals per run. The acceptance 
criteria were also revised accordingly. About 60 chemicals 
were tested in agonistic and antagonistic mode.
The EURL ECVAM Laboratory is also engaged in pro-
gressing research and development of new alternative 
methods to animal testing. Nowadays, automated 
screening technologies and informatics are available to 
screen high numbers of chemicals to identify important 
biological processes that may be disturbed or disrupted. 
At EURL ECVAM, a 
pilot study for 
the genera-
tion and use of 
High-Throughput 
Transc r ip tom-
ics data using 
Targeted RNA-Se-
quencing has 
been conducted, 
with the aim of 
supporting chem-
ical grouping 
and read-across. This pilot study aimed at producing 
transcriptomics (RNA sequencing) data from hepatic 
(HepaRG) cells treated with 20 selected chemicals at 
seven concentrations. The data generated (approx. 
20 million data points) was complemented with High 
Content Imaging data using automated fluorescence 
Optimising validation studies of non-animal 
methods for vaccine testing 
A new report (Halder et al., 2018a) summarises the outcome of 
a workshop organised by EURL ECVAM and VAC2VAC partners 
on the design of multi-centre validation studies.
The VAC2VAC project aims to develop and validate non-animal 
based methods for the quality control of vaccines. In order to 
incorporate a new method into a monograph or a guideline 
used for regulatory purposes, the method has to be shown 
to be reproducible and to have the ability to detect vaccine 
batches of insufficient quality. Moreover, any new method 
introduced for the quality control of a vaccine needs to undergo 
product-specific validation. In the light of this, workshop par-
ticipants coming together in early 2017 discussed ways of 
optimising the design of validation studies and making use of 
the data generated for product-specific validation purposes 
(see section 2.4 in Zuang et al., 2017 and see also fig. 2.3).
Recommendations encourage manufacturers to play a more 
active role by identifying suitable non-animal methods, pro-
viding relevant samples, or by sponsoring of studies. Since 
Box 2.4
multi-centre validation studies and product-specific validation 
are technically demanding and time and resource intensive, 
availability of sufficient resources for validation studies and 
implementation of new methods is crucial. Moreover, the 
availability of critical reagents and reference preparations 
should be secured. There are several new documents avail-
able or under development which support the substitution 
of animal tests for the quality control of vaccines and the 
use of data generated in multi-centre validation studies for 
product-specific validation.
The AR-CALUX in vitro 
method, developed for the 
detection of compounds 
with androgenic and anti-
androgenic potential, has 
been implemented in EURL 
ECVAM's High Throughput 
Screening facility
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microscopy. The study has been executed in a qHTS 
format for an initial assessment of the performance 
of the targeted RNA-sequencing technology and the 
feasibility of its application in in vitro toxicity testing. A 
follow-up experiment is planned to continue to build a 
deeper understanding in the application of RNA sequenc-
ing with a special focus on time course data.
READ MORE
m EURL ECVAM Laboratory: europa.eu/!PQ33Rv
2.7 Fish Toxicity and Bioaccumulation 
Research and Development Projects 
Several R&D projects related to fish toxicity and bioaccu-
mulation, which are of specific interest to EURL ECVAM, 
are described below. 
2.7.1 Use of a Fish Cell Line-Based Cytotoxicity 
Assay for Acute Fish Toxicity Testing
An ISO guideline (ISO/DIS 21115) using the RTgill-W1 
cells for water quality testing was adopted in 2018 (ISO, 
2018). The RTgill-W1 cell line assay is also under assess-
ment by EURL ECVAM (see section 3.6).
READ MORE
m  ECO8.3-NC3Rs-EAWAG: Round-robin test of the RTgill-W1 
cell line assay to study its robustness in establishment 
and inter-laboratory comparability: cefic-lri.org/projects/
eco8-3-nc3rs-eawag-round-robin-test-of-the-rtgill-w1-cell-
line-assay-to-study-its-robustness-in-establishment-and-
inter-laboratory-comparability
2.7.2 Development of Adverse Outcome 
Pathways for Chronic Fish Toxicity Testing
Several research groups are working on the identification 
and description of potential AOPs relevant to chronic fish 
toxicity, which is currently assessed with a fish early 
life-stage (FELS) test (OECD, 2013a). Summaries of the 
outcome of two Cefic Long-range Research Initiative 
(LRI)-funded project (LRI-ECO20-UA; LRI-ECO20.2) are 
available on the Cefic LRI website.
Two FELS relevant AOPs (AOP on AhR activation and 
AOP on thyroperoxidase and/or deiodinase inhibition 
leading to impaired swim bladder inflation in fish during 
early life stages) have been included into the OECD 
AOP work plan.
READ MORE
m Cefic’s Long-range Research Initiative (LRI): cefic-lri.org
m ECO20-UA: Development of an alternative testing 
strategy for the fish early life-stage test for predicting 
chronic toxicity: cefic-lri.org/projects/lri-eco20-ua-develop-
ment-of-an-alternative-testing-strategy-for-the-fish-early-
life-stage-test-for-predicting-chronic-toxicity
m ECO20.2: Development of an alternative testing 
strategy for the fish early life-stage test for predicting 
chronic toxicity - assay validation: cefic-lri.org/projects/
eco20-2-development-of-an-alternative-testing-strate-
gy-for-the-fish-early-life-stage-test-for-predicting-chron-
ic-toxicity-assay-validation
2.7.3 Threshold of Toxicological Concern in 
Aquatic Toxicity Assessment
The ecological Threshold of Toxicological Concern 
(eco-TTC) has been proposed for environmental risk 
assessment as extension to the well-established human 
safety TTC concept (Belanger et al., 2015).
An international collaboration/working group under the 
Health and Environmental Sciences Institute (HESI) 
has been established who developed the EnviroTox, a 
database of approx-
imately 91,000 
unique ecotoxicolog-
ical records, 4,000 
chemicals and 1,500 
species from three 
trophic levels (fish, 
invertebrates, algae/
plants). An on-line 
analytical tool has 
been developed, 
which aims to calcu-
late threshold values 
based on statistical distributions of two types, Predicted 
No Effect Concentration (PNEC) distribution or ecotoxico-
logical data distribution, according to particular research 
criteria. The EnviroTox database and the analytical tool 
are now finalised and have been made publicly available 
in November 2018. 
EURL ECVAM is contributing to this initiative, and worked 
in particular on the evaluation of the existing aquatic 
mode of action classification frameworks, their overlap 
and possibilities to move forward (Kienzler et al., 2017).
READ MORE
m Health and Environmental Sciences Institute (HESI): hes-
iglobal.org
m EnviroTox Database & Tools: envirotoxdatabase.org
An international 
collaboration/working 
group under the Health 
and Environmental 
Sciences Institute (HESI) 
has been established 
who developed the 
EnviroTox
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2.7.4 Aquatic and Terrestrial Bioaccumulation
2.7.4.1 Development of a Biotransformation 
Database
As announced in section 2.6.6 in Zuang et al. (2017), 
EURL ECVAM launched in 2016 the development of a 
biotransformation database involving an external con-
tractor. The project was finalised in 2018. 
The database (organised in four Excel sheets) contains 
in vivo and in vitro biotransformation data from various 
species (mouse, rat, fish) and provides a valuable data 
source for model developers (e.g., for in vitro to in vivo 
extrapolation models, kinetic models, models to predict 
exposure and internal concentration in an organism) as 
well as for chemical assessors. The database can be 
downloaded from the JRC Data Catalogue (Halder et al., 
2018b and see also section 6.1.4).
READ MORE
m EURL ECVAM Fish In Vitro Intrinsic Clearance 
Database: data.jrc.ec.europa.eu/dataset/
jrc-eurl-ecvam-fish-in-vitro-intr-clear-db
2.7.4.2 Development of a Tiered Testing Strategy 
for Fish Bioaccumulation Testing Based on in vitro 
Approaches
This Cefic LRI-funded project (LRI-ECO34) started in 
2016 and combines various in vitro approaches using 
fish cell lines to estimate chemical uptake and biotrans-
formation with toxicokinetic and quantitative structure 
activity relationship models. The aim is to develop a 
tiered approach for the assessment of the bioaccumu-
lation potential of chemicals. The principle of this work 
is further described in Stadnicka-Michalak et al., (2018). 
READ MORE
m LRI ECO34: A tiered testing strategy for rapid estimation 
of bioaccumulation by a combined modelling – in vitro 
testing approach: cefic-lri.org/projects/eco34-a-tiered-test-
ing-strategy-for-rapid-estimation-of-bioaccumula-
tion-by-a-combined-modelling-in-vitro-testing-approach
2.7.4.3 Integrating Bioaccumulation Assessment 
Tools for Mammals 
This Cefic LRI-funded project (LRI-ECO44) started in 
2018 and aims at developing a toxicokinetic modelling 
framework for bioaccumulation assessment in mam-
mals, combining in vitro and in vivo physiologically-based 
toxicokinetic (PBTK) data, field collected bioaccumulation 
data, and quantitative structure activity relationship 
models. Within the context of this project, toxicokinetic 
models for mammals will also be developed and the 
state of the science and available data streams will be 
synthesised in order to develop an integrated testing 
strategy for priority chemicals.
READ MORE
m LRI ECO44: A toxicokinetic mammalian modelling 
framework for bioaccumulation assessment: cefic-lri.org/
request-for-proposals/lri-eco44-a-toxicokinetic-mammali-
an-modelling-framework-for-b-assessment
2.8 Review of Non-animal Methods Used 
for Biomedical Research
According to the last report on animal use in EU Member 
States (EC, 2013), more than 60% of animals were used 
for research and development in the fields of human 
and veterinary medicine, and in biological studies of 
fundamental nature. However, the significant failure 
rate in translating results of preclinical animal studies 
into human disease treatments remains very concerning 
(Langley, 2014; Holmes et al., 2011).
To address these concerns, EURL ECVAM has launched a 
study to review non-animal models and methods already 
in use for basic and applied research, starting with 
r e s p i r a t o r y 
tract diseases 
and neuro-
degenerative 
disorders (see 
section 2.7 
in Zuang et 
al., 2017). A 
second call 
for tender was 
published on 1 
October 2018, 
in five addi-
tional research areas, namely, cardiovascular diseases, 
breast cancer, immunogenicity testing for advanced 
therapy medicinal products, autoimmune diseases and 
immune oncology models (see box 2.5).
The intention is to understand when research approaches 
involving alternatives have been successful and how it is 
possible to benefit from the significant advances made 
in recent years in novel non-animal procedures and 
techniques (e.g., in vitro, in silico) development, providing 
mechanistic information and modelling human-specific 
processes and conditions. These new methodologies rep-
resent a huge resource for enhancing the comprehension 
EURL ECVAM has launched 
a study to review non-
animal models and methods 
already in use for basic 
and applied research, 
starting with respiratory 
tract diseases and 
neurodegenerative disorders
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of human-specific biological processes and pathologies. 
The outcome of the study will be important to create a 
basis to advance uptake, implementation and promotion 
of non-animal methodologies in biomedical sciences by 
performing systematic reviews on selected human dis-
ease areas and thereby contributing to the reduction of 
the reliance on animal use and the betterment of science. 
The first review is expected to be completed during 
2019 and the information gathered will be made pub-
licly available. It will cover existing and in-development 
non-animal approaches including, but not confined to, in 
vitro, in silico and ex vivo approaches.
READ MORE
m Reviewing the use of alternative methods in biomedical 
research - News item: europa.eu/!Fw33hq
2.9 Chemistry Framework
The Chemistry Framework is being developed to improve 
the way in which sets of reference chemicals, i.e., the 
chemicals that are used to validate the reliability (repro-
ducibility) and relevance of an alternative method, are 
assessed. The approach is to explore how individual 
chemicals can be considered as representing regions in 
a 'similar chemical space', and thus represent more than 
a single chemical in a validation study.
The framework focuses on the biological and physic-
ochemical properties of chemicals in addition to their 
structure. For instance, in the context of skin sensitisation 
(Asturiol et al., 2016), a given chemical might represent 
generically a chemical that is soluble in water and has 
the properties 
to react with 
proteins. If this 
chemical is pre-
dicted correctly 
(e.g., as sensi-
tiser) by a method 
being validated, 
then the method 
can be regarded 
as applicable to chemicals with similar properties, and 
therefore there would be no need to test other chemicals 
that have similar properties but a different structure, 
in that same method. Thus the Chemistry Framework 
is essentially applying the principles of grouping and 
read-across, not to predict the toxicological properties 
of a chemical, but instead to define the (chemical) appli-
cability of a method.
Alternative methods in biomedical research: second 
call for tender reviewing methods in 5 new areas 
EURL ECVAM has launched a second call for tender to review 
alternative methods and models being used for research in 
the areas of cardiovascular diseases, breast cancer, immu-
nogenicity testing for advanced therapy medicinal products, 
Box 2.5
autoimmune diseases and immune oncology models. This new 
set of studies is aimed to continue the collection of successful 
non-animal procedures and techniques (e.g., in vitro, in silico) in 
five new areas of biomedical research, to broaden the knowl-
edge on the possible benefits from the significant technological 
advances made in recent years in novel non-animal methods 
development, providing mechanistic information and modelling 
human-specific processes or tissues.
The call will cover comprehensive information on the status 
and applications of innovative and alternative methods in bio-
medical research, on the basis of extensive reviews of scientific 
literature and related information sources.
The outcome of the study, together with the data obtained 
from the previous review (see section 2.7 in Zuang et al., 2017), 
will be valuable to advance uptake, implementation and pro-
motion of non-animal methodologies in biomedical sciences. 
This second review is expected to be completed during 2020 
and the information gathered will be made publicly available.
The chemistry framework 
will facilitate the 
comparison of two methods 
that have been validated 
with different validation sets 
of chemicals
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It is intended that the framework facilitates, for example, 
the comparison of two methods that have been validated 
with different validation sets of chemicals. It should also 
enable the definition of generic validation sets, consist-
ing of a list of properties and effects that a method must 
be capable of identifying to be considered scientifically 
valid. A manuscript describing the basis of the chemistry 
framework is in preparation.
2.10 Integration of Data across Toxicity 
Endpoints to Explore New Ways for 
Carcinogenicity Testing
Knowledge about underlying and recently identified 
mechanisms involved in the development and promotion 
of cancer, as well as tools to analyse them (mecha-
nism-based tests, epigenetics, -omics) have considerable 
potential to advance safety assessment. 
For this reason, a methodology to guide the evaluation 
of carcinogenic hazard of chemicals is being developed 
in order to facilitate the uptake and the integration of 
new mechanistic data by combining information across 
different toxicity endpoints rather than considering them 
individually. Such an approach is also expected to help 
with the identification of potential information gaps and, 
at the same time, avoid redundant animal testing. A 
poster describing ongoing work at EURL ECVAM was pre-
sented at the European Association on Cancer Research 
Conference EACR25 in July 2018 (Madia et al., 2018).
A paper on the rationale behind this integrated approach 
and its potential application to other systemic toxicity 
endpoints is under finalisation.
READ MORE
m 25th Biennial Congress of the European Association for 
Cancer Research (EACR25): www.eacr25.org
2.11 Preclinical Assessment for Advanced 
Therapy Medicinal Products
New scientific progress in cellular and molecular bio-
technology has led to the development of Advanced 
Therapies Medicinal Products (ATMPs), such as gene 
therapy, somatic cell therapy, and tissue engineering. 
They offer the promise of providing innovative treat-
ments for patients, particularly in disease areas where 
conventional approaches are inadequate (Milone & 
Bhoji, 2018). As a consequence, the field of new drug 
development is moving its focus from well-defined 
small-molecule compounds towards ATMPs. However, 
the risk associated with their administration without 
an appropriate safety and efficacy assessment and the 
subsequent detrimental consequences for patients have 
been reported  (Cuende et al., 2014; Zheng et al., 2018). 
Because of the novelty, complexity and technical specific-
ity of ATMPs, specially tailored and harmonised guidance 
is needed to evaluate their safety and efficacy, which 
addresses both commercial product manufacturers and 
hospitals. Thus there is a growing need to understand 
what the challenges associated with the progress of 
ATMPs through 
the medicines 
life-cycle are. 
Based on the 
internal scientific 
expertise, as well 
as on the collab-
oration with the 
wider scientific 
and regulatory 
c o m m u n i t i e s , 
EURL ECVAM 
is exploring opportunities to contribute to the harmo-
nisation of requirements for the safety (and efficacy) 
assessment of ATMPs. Through surveying various stake-
holders, gaps and opportunities have been identified that 
will be the subject of further investigation.
2.12 Relationship between Children's 
Health and Exposure to Environmental 
Chemicals
EURL ECVAM recently met with the Norway Institute for 
Public Health (NIPH) to discuss the topic of Children's 
health and exposure to environmental chemicals (see 
fig. 2.4) where consideration was given to integration of 
multiple sources of information including mechanistic 
knowledge, biomonitoring data, epidemiological studies, 
in silico as well as in 
vitro data to support 
decision making. As a 
result of this collab-
oration, a review on 
early life exposure to 
air pollution particu-
late matter as a risk 
factor for attention 
deficit and hyperac-
tivity disorder (ADHD) 
has been published 
(Myhre et al., 2018). Chemicals that are known to trigger 
specific developmental neurotoxic (DNT) effects belong 
to a variety of chemical classes including industrial 
chemicals, persistent organic pollutants (POPs), metals 
and pesticides. Effects resulting from the combined 
Advanced therapies 
medicinal products 
(ATMPs) offer the promise 
of providing innovative 
treatments for patients, 
particularly in disease 
areas where conventional 
approaches are inadequate
NIPH and EURL ECVAM 
have initiated studies 
where mixtures of DNT 
chemicals are being 
evaluated using in 
vitro assays anchored 
to common key events 
identified in AOPs
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exposure to these chemicals across different regulatory 
domains are not currently considered. NIPH and EURL 
ECVAM have initiated studies where mixtures of DNT 
chemicals which were found in human samples (e.g., 
breast milk or children's blood) and belong to heteroge-
neous classes of chemicals are being evaluated using in 
vitro assays anchored to common key events identified 
in AOPs where impairment of learning and memory in 
children was defined as the adverse outcome.
READ MORE
m Norwegian Institute of Public Health (NIPH): www.fhi.no/en
Figure 2.4  Workshop on Children's health and exposure to environmental chemicals organised between EURL ECVAM and the 
Norway Institute for Public Health (NIPH) at the JRC Ispra in June 2018.
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A new pre-submission (TR MARCoNI) and three new 
full submissions (GARD, Bioelution and RTgill-W1) were 
received by EURL ECVAM since the last EURL ECVAM 
status report published in November 2017 (see section 
3 in Zuang et al., 2017). The assessments of the new 
pre-submission and of the full submission of the GARD 
were concluded this year, while the assessment of the 
two other new full submissions will progress into 2019. 
The assessment of the γH2AX/pH3 pre-submission (see 
section 3.1) and of the SENS-IS full submission (see 
section 3.3) were also concluded.
The assessment of the γH2AX/pH3 pre-submission was 
completed in February 2018 and the test submitter was 
informed that EURL ECVAM does not intend to progress 
the submission further at the present time (see section 
3.1). The assessment of the TR MARCoNI pre-submission 
was completed in March 2018 and the test submitter 
was invited to provide a full submission (see section 3.2).
The assessment of the full submission of the SENS-IS 
assay was finalised with some shortcomings being iden-
tified. The test submitter was invited to address those 
and submit a revised full submission (see section 3.3).
The assessment of the GARD full submission was put on
hold pending outcomes of discussions that are on-going 
at the OECD (ESAC, see section 3.4).
Full submissions of the Bioelution (see section 3.5) and 
RTgill-W1 cell line (see section 3.6) assays were received 
in 2018 and their assessments by EURL ECVAM will prog-
ress into 2019.
Following a preliminary EURL ECVAM assessment and 
PARERE consultation on the pre-submissions, the test 
submitters of the Toxtracker® and of the EDITOX assays 
were invited in 2017 to provide a full submission (see 
sections 3.2 and 3.4 in Zuang et al., 2017) but no full 
submissions were received for these two assays in 2018.
Finally, EURL ECVAM updated its Test Pre-submission 
Form and its Test Submission Template in 2018 with 
the intention of making them more straightforward 
to complete and to request additional information on 
the use of animal derived serum and animal derived 
antibodies, including their replacement by suitable 
non-animal alternatives.
READ MORE
m TSAR: Tracking System for Alternative methods towards 
Regulatory acceptance: tsar.jrc.ec.europa.eu
m EURL ECVAM test method submission: europa.
eu/!ww88Mh
Test Method Submissions
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TEST METHOD SUBMISSIONS
3.1 γH2AX/pH3 Assay
In August 2017, EURL ECVAM received a pre-submission 
for the assessment of a method based on γH2AX/pH3 
biomarkers for the prediction of genotoxic potential of 
a range of substances. The combination of two particu-
lar biomarkers is proposed to detect early events in the 
DNA damage response and to discriminate structural 
and numerical chromosome damage. Increased levels of 
γH2AX phosphorylation at serine 139 measure the recruit-
ment of DNA repair machinery to DNA double strand 
breaks. The induction of Histone 3 (pH3) is proposed by 
the test submitter as an indicator of mitotic index and cell 
proliferation status. Specifically, aneugenic chemicals are 
considered to increase the mitotic index, thus pH3 tends to 
be reduced by cytotoxic conditions, including cytotoxicity 
associated with many DNA-reactive chemicals.
The submitter claimed that the integration of informa-
tion derived from the detection of the two biomarkers 
was more predictive of genotoxicity than the common 
Micronucleus in vitro 
and Ames tests. For 
this reason, the test 
method was pro-
posed to be used as 
screening and early 
selection test of 
candidate molecules 
before entry into 
drug development, 
or as a follow-up of 
positive results within 
the current available 
regulatory battery of in vitro genotoxicity assays, to 
provide insight into the mechanism of action and help 
read across approaches. 
EURL ECVAM acknowledged that the types of assays/
biomarkers described within the pre-submission have the 
potential to address the MoA of genotoxicity and may 
be relevant in a regulatory context. However, based on 
the information provided, the test method's definition, as 
well as its protocol and prediction model characterisation 
did not meet EURL ECVAM's criteria to allow a proper 
assessment of the test method. The test submitter was 
informed in February 2018 that EURL ECVAM does not 
intend to progress the submission further.
READ MORE
m γH2AX/pH3 Assay: tsar.jrc.ec.europa.eu/test-method/
tm2017-01
3.2 TR MARCoNI
In October 2017, EURL ECVAM received a pre-submission 
of an in vitro Thyroid receptor microarray assay for real-
time Nuclear Receptor-coregulator interaction. This test 
method quantitatively measures the interaction profile 
of a compound-activated thyroid receptor with a range of 
nuclear receptor co-regulators. Nuclear receptor co-reg-
ulator recruitment 
is a key biologi-
cal step between 
receptor binding 
and transactivation, 
and currently there 
are no available 
tests covering this 
specific interaction. 
The information 
provided in the test 
pre-submission was 
considered sufficient 
to understand the principle of the test method, and its 
biological and general mechanistic relevance. The TR MAR-
CoNI method could be integrated in a testing strategy 
and combined with additional methods suitable to capture 
different modes of action of thyroid hormone disruptors. 
In March 2018, EURL ECVAM completed the assess-
ment of the TR MARCoNI pre-submission, and invited 
the test submitter to progress the test method to a full 
submission, taking into account some issues raised by 
EURL ECVAM. In particular, it will be relevant to know 
the following: whether the TR MARCoNI method can 
detect thyroid disruptors that are not detected by other 
methods (e.g., receptor binding, transactivation or pro-
liferation); the reproducibility of the method; (potential) 
issues with Intellectual Property Rights; and additional 
information on compounds that have tested positive in 
this specific method.
READ MORE
m TR MARCoNI: tsar.jrc.ec.europa.eu/test-method/tm2017-02
3.3 SENS-IS
EURL ECVAM has finalised the evaluation of all the 
information received in the SENS-IS test method sub-
mission (toxicogenomic analysis on 3D reconstituted 
epidermis for measuring skin sensitisation potency; 
see section 3.3 in Zuang et al., 2017). The evaluation 
highlighted some shortcomings that impeded EURL 
ECVAM from reaching a conclusion on the validity of the 
test method. The test submitter was invited to address 
all the identified issues, eventually with a revised 
The TR MARCoNI method 
could be integrated in 
a testing strategy and 
combined with additional 
methods suitable to 
capture different modes 
of action of thyroid 
hormone disruptors
The combination of two 
particular biomarkers 
is proposed to detect 
early events in the 
DNA damage response 
and to discriminate 
structural and numerical 
chromosome damage
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submission, so as to allow EURL ECVAM to complete 
its assessment and to consider if the test method can 
be progressed to peer-review by the ECVAM Scientific 
Advisory Committee (ESAC). 
An additional consideration is the fact that SENS-IS 
is protected by a patent with a very wide coverage, 
which is likely to make it very difficult for third parties 
to develop and validate similar methods on the basis 
of performance standards. However, this is currently a 
requirement at OECD level for the adoption of methods 
based on Intellectual 
Property Rights (IPR) 
as Test Guidelines 
in order to avoid 
commercial monop-
olies (OECD, 2005). 
Although it is rec-
ognised that IPR are 
necessary to stimu-
late and protect innovation, there is also the need for the 
OECD Test Guidelines Programme to define principles 
and acceptable best practice for uptake of methods pro-
tected by patent and subject to licensing for commercial 
application. The JRC is currently involved in an expert 
group set up by the OECD to discuss this matter, but 
the deliberations are still on-going (see section 5.3.16).
READ MORE
m SENS-IS: tsar.jrc.ec.europa.eu/test-method/tm2011-11
3.4 GARD
The SenzaGen-led validation of the Genomic Allergen 
Rapid Detection (GARD) skin test for sensitisation hazard 
assessment was finalised (see section 4.5 in Zuang et 
al., 2017) and the information package was submitted to 
EURL ECVAM in January 2018. Knowing that additional 
work was conducted to generate information on the 
GARD potency, EURL ECVAM communicated to Senza-
Gen AB that the evaluation of the GARD could only be 
initiated once all the information was made available. 
EURL ECVAM received the submission on the validation 
of the GARD potency in July 2018.
There are a number of challenging scientific, technical 
and legal aspects that require particular attention before 
proper evaluation of GARD can commence. These are as 
follows: a suitable agreement needs to be put in place 
and appropriate arrangements made to provide EURL 
ECVAM access to the web-based GARD Data Analysis 
Application (GDAA) software hosting the data analysis 
and the Support Vector Machine-based prediction model, 
and its source codes; it is unclear if a web-based pre-
diction software (to process a user's experimental data) 
that is under the control of the method provider would be 
acceptable to regulatory authorities and implementable 
under Good Laboratory Practice (GLP); and finally, similar 
to SENS-IS, elements of the GARD method are protected 
by patent which may impede the development and val-
idation of similar methods. 
Most of the issues described above require resolution 
at the level of the OECD and the JRC (EURL ECVAM) is 
actively involved in the relevant discussions and expert 
groups. In addition, 
good progress is 
being made within 
the OECD project 
to develop a set 
of three Defined 
Approaches for 
skin sensitisation 
into a new Test 
Guideline, two of 
which address 
p o t e n c y - b a s e d 
classification (see section 5.3.8). EURL ECVAM will wait 
for the eventual outcome of the discussions at the OECD 
before taking a decision on whether to commence eval-
uation of the GARD.
READ MORE
m GARD: tsar.jrc.ec.europa.eu/test-method/tm2011-09
3.5 Bioelution Assay
As reported in the EURL ECVAM status report 2017 (see 
section 3.1 in Zuang et al., 2017) the bioelution test 
method is an in vitro extraction method that provides 
the fraction of a substance that dissolves under sur-
rogate physiological conditions (i.e., simulated gastric 
fluid) and is potentially available for absorption into 
systemic circulation (bioaccessible concentration). The 
test method was proposed by the European non-fer-
rous metal association (Eurometaux) to support read 
across and grouping under REACH for systemic end-
points and to assign CLP classifications. In the context 
of hazard classification, the test method has been 
proposed as a refinement to the current approach to 
alloy classification. 
The pre-submission underwent PARERE consultation 
and, in general, a positive feedback was received from 
the experts with regard to the potential use of the 
test method in a regulatory context. The regulatory 
Good progress is being 
made within the OECD 
project to develop a set of 
three Defined Approaches 
for skin sensitisation into 
a new Guideline, two of 
which address potency-
based classification
EURL ECVAM has 
finalised the evaluation 
of all the information 
received in the 
SENS-IS test method 
submission
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 application of the bioelution test method has also been 
discussed in other fora (i.e., ECHA, CARACAL) as reported 
by Zuang et al. (2017). Based on all the information 
retrieved, the pre-submission was positively evaluated in 
2017, and the test submitter was invited to proceed with 
a full submission. As 
a follow-up, a full 
test submission was 
received in February 
2018 together with 
clarifications on the 
questions that were 
raised in the pre-sub-
mission assessment 
report. During the 
reviewing process of 
the full submission, several issues were identified and 
the test submitter was invited to address them. The 
evaluation process will be finalised once the additional 
information will be provided.
READ MORE
m Bioelution Assay: tsar.jrc.ec.europa.eu/test-method/
tm2016-02
3.6 RTgill-W1 Cell Line Assay
The RTgill-W1 (rainbow trout gill cell line) cytotoxicity 
assay was initially submitted to EURL ECVAM in early 
2014 (see section 3.1 in Zuang et al., 2015). The assay has 
been developed within the CEllSens project (Tanneberger 
et al., 2013) and a ring trial evaluating the transferability 
and within-labora-
tory reproducibility 
of the test method 
has been organ-
ised by the Swiss 
Federal Institute 
of Aquatic Science 
and Technology 
(EAWAG) within the 
Cefic LRI project. 
Recently, Natsch 
et al., (2018) further demonstrated the suitability of the 
RTgill-W1 cell line for fish acute toxicity predictions of 
fragrance chemicals.
EURL ECVAM received a full submission of this assay in 
September 2018 and is currently evaluating it.
READ MORE
m RTgill-W1: tsar.jrc.ec.europa.eu/test-method/tm2014-01
m ECO8.3-NC3Rs-EAWAG: Round-robin test of the RTgill-W1 
cell line assay to study its robustness in establishment 
and inter-laboratory comparability: cefic-lri.org/projects/
eco8-3-nc3rs-eawag-round-robin-test-of-the-rtgill-w1-cell-
line-assay-to-study-its-robustness-in-establishment-and-
inter-laboratory-comparability
In the context of hazard 
classification, the 
bioelution assay method 
has been proposed as 
a refinement to the 
current approach to 
alloy classification
Recently, Natsch et 
al., (2018) further 
demonstrated the 
suitability of the RTgill-W1 
cell line for fish acute 
toxicity predictions of 
fragrance chemicals

27
27
4 Validation of Alternative 
Methods and Approaches
©
 F
la
tic
on
.c
om
 28
4.1 Endocrine Disruption - AR-CALUX Test 
Method
The AR-CALUX method is a reporter-based assay where 
an increase or decrease in expression of luminescence 
is measured in osteosarcoma cells, stably transfected 
with a human androgen receptor, when presented with 
chemicals that have (anti)androgenic potential.
The method was submitted by the Dutch company Bio-
Detection Systems (BDS) to EURL ECVAM for a validation 
study. This study is carried out with three participating 
laboratories of EURL ECVAM's network of specialised 
laboratories, the EU Network of Laboratories for the Val-
idation of Alternative Methods (EU-NETVAL, see section 
4.8). EURL ECVAM has obtained complete data sets for 
assessing transferability, reproducibility (within-labora-
tory and between-laboratory) and predictive capacity. 
The validation report and its review by ESAC is foreseen 
for 2019, to be followed by the submission of a draft 
test guideline to OECD.
EURL ECVAM has the lead in developing an OECD Per-
formance Based Test Guideline (PBTG) for Androgen 
Receptor Transactivation Assays (ARTAs) and related Per-
formance Standards, if applicable. This TG will be based 
on ARTAs either already validated (the AR STTA using the 
AR-EcoScreen cell line, led by Japan and issued as TG 
458, see annex 2) or in the process of a validation (the 
ARTA using the 22Rv1/MMTVGR- cell line, led by Korea, 
see annex 2) and the EURL ECVAM ongoing validation 
study of the in vitro method AR-CALUX.
4.2 Thyroid Hormone Disruption
EURL ECVAM is coordinating a validation study of a 
set of mechanistically informative alternative methods 
related to the detection of thyroid hormone disruption, 
in collaboration with EU-NETVAL and the developers of 
such methods.
In 2017, EURL ECVAM launched a call to EU-NETVAL 
members for participation in the validation study. A 
total of 17 alternative methods have been identified by 
EURL ECVAM as candidates taking primarily into account 
the information reported in an OECD scoping document 
on in vitro and ex vivo methods for the identification 
of modulators of thyroid hormone signalling (OECD, 
2014a), but also an OECD Detailed Review Paper (OECD, 
2006), and feedback received at various meetings [(e.g., 
the EU-NETVAL meeting of 2016,  the meeting of the 
OECD Validation Management Group-Non-Animal of 
2016, and the DG ENV/ANSES Thyroid Disruptor work-
shop (DG ENV, 2017)]. The methods cover the main 
possibilities of interaction with the thyroid signalling 
pathway (see also annex 2), i.e., (1) Central regulation 
Validation of Alternative
Methods and Approaches
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VALIDAT ION OF ALTERNATIVE METHODS AND APPROACHES
[synthesis/release of hypothalamic thyroid releasing 
hormone (TRH), its delivery and action on pituitary 
thyrotrophs, and the synthesis/release of thyroid 
stimulating hormone (TSH)], (2) Thyroid Hormone (TH) 
synthesis [thyroperoxidase (TPO) activity, activation 
of the sodium iodide symporter (NIS)], (3) Secretion 
and transport in serum of THs [Transthyretin (TTR) and 
Thyroxine binding globulin (TBG)] (4) Metabolism and 
excretion of THs (deiodinase-1 activity, glucuronidation, 
sulphation), (5) Local cellular concentrations [TH mem-
brane (MCT8) transporters], and (6) Cellular responses 
[activation of the TH nuclear receptors (TRalpha and 
beta transactivation)]. Furthermore, the validation 
study will also consider (7) Relevant short term in vitro 
methods integrating multiple Modes of Action (MoA, 
through the measurement of the intrafollicular T4-con-
tent in zebrafish embryos) and (8) Integrative cellular in 
vitro methods (cellular proliferation and differentiation 
regulated by the activation of the TH nuclear receptors; 
see annex 2).
This validation study consists of two parts: part one 
defines the methods and assesses their transferability 
and reliability, and part two is focused on the overall rel-
evance of the combination of methods. After the launch 
of the call, four-
teen EU-NETVAL 
facilities have been 
assigned to work 
on the 17 meth-
ods described in 
the call. The work 
done in the context 
of this validation 
study will comply 
with the recently 
published OECD 
Guidance on Good 
In Vitro Method 
Practices, GIVMP (OECD, 2018a;  see section 5.3.7 and 
box 5.3). For methods based on the use of cell lines, EURL 
ECVAM is currently assessing both the authentication 
and the absence of contamination of methods, which is 
a fundamental prerequisite before transfer of materials 
to the EU-NETVAL partners and the beginning of the 
validation activities.
For each of the methods, outline protocols are being 
drafted including definition of the test systems used and 
also the control and reference items. EURL ECVAM is also 
putting in place the necessary legal instruments, such 
as e.g. collaboration agreements and material transfer 
agreements, so that any existing intellectual property 
rights are properly managed in the validation study. 
Those methods which perform best will be selected for 
further assessment in support of EU and OECD strategies 
to address the potential risks to human health and the 
environment posed by thyroid disruptors.
READ MORE
m EURL ECVAM call to EU-NETVAL members for participa-
tion in the validation study for the detection of thyroid 
disruptors - News item: europa.eu/!Nv43dW
m Meeting of the EU Network of Laboratories for the 
Validation of Alternative Methods (EU-NETVAL) - News 
item: europa.eu/!Tm94Qu
4.3 Vaccine Quality Control – EDQM 
Biological Standardisation Programme
Most of the validation studies on alternative methods 
for vaccine quality control are carried out within the 
framework of the Biological Standardisation Programme 
(BSP) of the European Directorate for the Quality of Med-
icines & HealthCare (EDQM; Council of Europe) and are 
co-sponsored by the European Commission.
Several validation studies are currently ongoing which 
assess alternative methods for the safety and potency 
testing of human and veterinary vaccines, e.g., a serolog-
ical assay for the potency testing of whole-cell pertussis 
vaccines; the BINACLE assay for in vitro detection of 
toxicity in tetanus vaccines, and, in collaboration with 
the European Partnership on Alternative Approaches to 
Animal Testing (EPAA), BSP130 Phase III Validation of 
in vitro methods for the testing of Clostridium septicum 
vaccine (see section 5.7.4) and BSP148 Validation of a 
rabies in vitro potency assay (see section 5.7.5). Lang 
et al., (2018) summarises the work carried out by the 
European Pharmacopoeia and progress achieved with 
regard to the implementation of the 3Rs in European 
Pharmacopoeia monographs.
READ MORE
m EDQM Biological Standardisation Programme (BSP): www.
edqm.eu/en/work-programme-bsp
4.4 Genotoxicity Testing - Micronucleus 
Test and Comet Assay in Reconstructed 
Skin Models
During the 2017 International Workshop on Genotoxicity 
Testing (IWGT), one workgroup conducted a status review 
of available genotoxicity data generated in liver, lung and 
skin 3D tissue models. These models offer a more ‘in 
vivo-like’ behaviour for key parameters like cell viability, 
Those methods which 
perform best will be 
selected for further 
assessment in support of 
EU and OECD strategies 
to address the potential 
risks to human health and 
the environment posed by 
thyroid disruptors
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proliferation, differentiation, morphology, gene and pro-
tein expression, and function. Therefore, they can provide 
a valuable complement to the classical ‘2D’ cell culture 
based assays. These novel 3D tissue-based genotoxicity 
assays, can be used as second tier assays to follow up on 
positive results from standard in vitro assays. However, 
it is important that for each tissue model, the full range 
of genotoxic damage (leading to mutagenicity, clasto-
genicity, and aneugenicity) can be detected.
The workgroup found that many more data were availa-
ble for the 3D skin model assay (which has been in use 
for over ten years) than for the 3D liver and lung models. 
Review of the 3D liver spheroids focused on micronu-
cleus (MN) data, and it was suggested that an assay 
covering DNA damage leading to gene mutations (such 
as the comet assay) 
should be developed for 
the liver spheroids. After 
review of data from the 
3D lung tissue (all from 
the comet assay), it was 
acknowledged that the 
3D lung comet assay 
would detect chemicals 
that induce DNA damage leading to gene mutation and 
chromosomal damage, and the development of 3D lung 
assays that can detect aneugenicity is strongly encour-
aged. The limited proliferation of the lung cells makes the 
micronucleus (MN) assay currently problematic and needs 
therefore more investigation. Further development of 3D 
liver and lung-based genotoxicity assays was encouraged 
since they could be a complement to the 3D skin based 
assays, each allowing exposure-specific assessment.
The validation work on the 3D skin comet and Recon-
structed Skin Micronucleus (RSMN) assays, coordinated 
by Cosmetics Europe, has been finalised and the relative 
manuscripts are in preparation. The combination of the 
two methods (using 56 chemicals) was shown to be highly 
predictive. The IWGT workgroup believes that the 3D skin 
comet and RSMN assays are now sufficiently validated to 
move towards the development of individual OECD Test 
Guidelines.  Further discussion on the way forward to 
accelerate the implementation of these assays in regu-
latory decision making will take place in a workshop that 
will be organised by Cosmetics Europe in November 2018.
READ MORE
m International Workshop on Genotoxicity Testing (IWGT): 
www.iwgt2017.org
4.5 Genotoxicity Testing - Hen's Egg Test 
for Micronucleus Induction (HET-MN) 
The hen's egg test for micronucleus induction (HET-MN) 
may represent a good supplement to the genotoxicity 
assays in 3D skin models because it uses the complex 
model of the incubated hen's egg, which mimics sys-
temic exposure. It has been proposed to be used as a 
follow-up to positive results in the two-test in vitro geno-
toxicity battery, as proposed by the Scientific Committee 
on Consumer Safety (SCCS) for the testing of cosmetic 
ingredients (SCCS, 2018).
3D tissue models can 
provide a valuable 
complement to the 
classical ‘2D’ cell 
culture based assays
Figure 4.1  Number of survey respondents per country.
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VALIDAT ION OF ALTERNATIVE METHODS AND APPROACHES
A validation study is currently under finalisation by a 
German consortium (Greywe et al., 2012). The experi-
mental work was carried out in three laboratories with 
testing of more than 30 chemicals (Riesinger et al., in 
preparation; Maul et al., in preparation).
4.6 EURL ECVAM Survey on Issues 
Influencing End-user Confidence in 
Complex in vitro Models 
During May 2018, EURL ECVAM conducted a survey to 
collect scientific opinions on how to assess the relevance 
and fitness-for-purpose of complex in vitro models such 
as organ-on-chip devices. This is to understand how to 
best facilitate their uptake and application in a variety 
of areas, such as for risk assessment and research. As 
this new generation of models and methods matures, it 
is important to facilitate their translation from research 
and development into useful application by considering 
the scientific and technical issues that influence end-
user confidence and uptake.
The purpose of this survey was to get a better under-
standing of the current level of uptake and satisfaction 
regarding complex in vitro models, and the current think-
ing around how best to establish their validity for use in 
research and testing. The survey sought the opinion of 
all those interested in complex in vitro models and their 
potential applications irrespective of how familiar one 
may be with the sub-
ject area. For a better 
interpretation of the 
data, the questions 
took into account the 
different levels of 
expertise and inter-
ests of the responders 
to assess their views 
on the credibility and 
relevance of these 
models. Responses from 646 people worldwide (see fig. 
4.1) from academia (54%), industry (23%), public service 
(17%) and others (6%) were received.
The first results of the survey were presented at the 
20th International Congress on In Vitro Toxicology (ESTIV 
2018; see box 4.1) which took place in Berlin in October 
2018. The whole set of findings will be made publicly 
available once the responses have been fully analysed. 
The intention is to combine the results with information 
gathered from other sources to eventually inform vali-
dation strategies and technology-transfer initiatives for 
expediting the uptake and use of complex in vitro models 
EURL ECVAM survey on issues influencing end-user 
confidence in complex in vitro models
Complex in vitro models such as 3D cell cultures, bioprinted 
tissues, bioreactor cultures or microphysiological systems 
(e.g., organ-on-chip devices) aim to represent higher-level 
anatomical and physiological aspects of human biology in 
practical experimental setups. Methods based on complex in 
vitro models have the potential to not only provide an attrac-
tive alternative to animal models, but also offer the promise 
of advancing scientific methodologies underpinning research, 
development and testing in a variety of sectors.
At the 20th International Congress on In Vitro Toxicology (ESTIV 
2018), held from 15 to 18 October 2018 in Berlin, EURL ECVAM 
released the first results of a major internal survey launched 
in May 2018 on complex in vitro models, which include 3D 
cell cultures, bioprinted tissues, and microphysiological (organ-
on-chip) systems. The survey provided valuable insight into 
what developers and end-users are thinking regarding the 
validation of such models to ensure their successful translation 
into useful application. A total of 646 responses were received 
Box 4.1
from 36 countries, 76% of those surveyed believe that it is 
possible to establish the validity of complex in vitro models 
without knowing their specific application. Among those, 60% 
of respondents believe that validation is useful to increase 
acceptance and uptake.
The first results of the 
survey were presented 
at the 20th International 
Congress on In Vitro 
Toxicology (ESTIV 2018) 
which took place in 
Berlin in October 2018
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and methods in a variety of fields such as chemical risk 
assessment and biomedical research.
READ MORE
m Survey on issues influencing end-user confidence in 
complex in vitro models for use in research and testing: 
europa.eu/!Nm89my
m  20th International Congress on In Vitro Toxicology 
(ESTIV2018): www.estiv2018.com
4.7 EURL ECVAM Scientific Advisory 
Committee Peer Reviews
4.7.1 Renewal of ESAC 
EURL ECVAM renewed its Scientific Advisory Commit-
tee (ESAC) in 2018 (see  fig. 4.2). Renewed every three 
years, ESAC is composed of external scientists who 
are appointed on 
the basis of their 
scientific exper-
tise and who act 
independently in 
the public inter-
est. ESAC advises 
EURL ECVAM on 
scientific and technical issues related to the protection of 
animals used for scientific purposes. Nine experts were 
formally appointed on 16 April 2018 as the new core 
members of the ESAC. More details on the new ESAC 
including its membership, Terms of Reference and Rules 
of Procedure can be found on the Register of Commis-
sion Expert groups. The new ESAC will meet in plenary 
at the JRC in Ispra, Italy, on 4 to 5 December 2018 and 
on 3 to 5 June 2019.
READ MORE
m EURL ECVAM Scientific Advisory Committee (ESAC): 
europa.eu/!gp34jf
m ESAC in the Register of Commission Expert groups: 
europa.eu/!qm67uC
4.7.2 Upcoming ESAC Reviews 
In 2018, the ESAC has been mandated to review the 
scientific validity of antibodies and non-antibody affinity 
reagents produced using animal-free technologies (see 
section 4.7.2.1). ESAC is expected to discuss and endorse 
its Opinion on this topic during the plenary meeting 
scheduled for 4 to 5 December 2018.
Preparations are currently underway to mandate ESAC 
to review and deliver an opinion on the scientific validity 
of the AR-CALUX test method for detection of andro-
genic activity of chemicals in 2019 (see section 4.1). The 
Opinion on the AR-CALUX is expected to be discussed 
Figure 4.2  Core members of the new ESAC, European Commission staff and members of the International Cooperation on 
Alternative Test Methods (ICATM) from Brazil and Korea. 
ESAC is composed of 
external scientists who are 
appointed on the basis of 
their scientific expertise 
and act independently
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and endorsed by the ESAC during its plenary meeting 
scheduled for 3 to 5 June 2019.
Conditional on a positive evaluation by EURL ECVAM 
of the current full test method submissions on the 
bioelution assay for testing of metals, inorganic metal 
compounds and complex metal-containing materials 
in synthetic gastric fluid (see section 3.5) and on the 
RTgill-W1 cell line assay to predict acute fish toxicity of 
chemicals (see section 3.6), these methods may also be 
considered for ESAC peer review in 2019.
4.7.2.1 Scientific Validity of Antibodies and 
Non-antibody Affinity Reagents Produced Using 
Animal-free Technologies
Affinity reagents are binding molecules that have a high 
specificity for their unique target (antigen). They are 
crucial for research, diagnostics, therapeutic and regu-
latory applications. Based on their recognition properties 
and binding specificity, protein-based antibodies are 
currently still the most important tools for the specific 
detection of proteins or other molecules. However, with 
developments in protein and genetic engineering, new 
alternative binders are being introduced, such as aptam-
ers, affimers, DARPINs, etc. These alternative binders 
can be based on peptides, proteins, ribonucleic acids, or 
single-stranded DNA. Although these new molecules are 
already being applied in diagnostics, antibodies are still 
the molecules of choice for many applications. 
In many cases, antibody production is still relying on 
animal-based methods. More recently developed ani-
mal-free technologies involve the use of large collections 
of recombinant forms of miniaturised antibodies such 
as single-chain variable fragment (scFv) and frag-
ment antigen binding (Fab), or antibody analogues. 
These approaches require the ability to present large 
binder libraries 
on the surface of 
various available 
display systems 
(e.g., phage display), 
which permit the 
selection of pep-
tides or proteins 
with high affinity 
and specificity for 
virtually any target. 
In line with the legal 
requirements of EU 
Directive on the protection of animals used for scien-
tific purposes (2010/63/EU), animals should not be used 
in procedures, where a non-animal alternative exists, 
which provide the same or higher level of information 
as obtained from animal procedures. 
In April 2018, EURL ECVAM mandated ESAC to review 
the available evidence and deliver an opinion on the 
scientific validity of antibodies and non-antibody affin-
ity reagents produced using animal-free technologies 
for use in research, regulatory testing and diagnostics. 
Figure 4.3  The ESAC Working Group on Affinity Reagents at the JRC Ispra.
In line with EU Directive 
2010/63 animals 
should not be used in 
procedures, where a 
non-animal alternative 
exists, which provide the 
same or higher level of 
information as obtained 
from animal procedures
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Taking into consideration the available evidence, the 
ESAC will provide an opinion on the suitability of existing 
animal-free technologies to produce affinity reagents 
with equal or better quality (purity, activity, specificity, 
affinity, stability) than that offered by antibodies pro-
duced using the conventional animal-based methods. 
In addition, ESAC will explore the scientific benefits of 
using animal-free affinity reagents and assess whether 
there are any production and/or application scenarios for 
which these are not fit-for-purpose and animal-derived 
antibodies are still indispensable. In case exceptions are 
identified, a strategy to tackle them should be proposed.
An ESAC Working Group was created to conduct the 
detailed review. Two core ESAC members agreed to 
participate in the Working Group and six new ad-hoc 
ESAC members were selected from the DG RTD Experts 
Management Internal (EMI) database on the basis of 
their expertise on the subject matter, and were formally 
appointed on 19 October 2018 to participate in the 
Working Group. More details on the current ESAC mem-
bership can be found on the Register of Commission 
Expert groups.
The ESAC Working Group met at the JRC in Ispra, Italy, 
on 8 to 9 November 2018 (see fig. 4.3) to advance the 
detailed review and draft a Working Group Report and an 
ESAC Opinion for discussion at the ESAC plenary meeting 
scheduled for 4 to 5 December 2018.
READ MORE
m ESAC in the Register of Commission Expert groups: 
europa.eu/!qm67uC
4.8 Update on EU-NETVAL
The first EU-NETVAL validation project involves three test 
facilities from Sweden, UK and France. Using the in vitro 
AR-CALUX method, experimental data is being generated 
to support the development of an OECD Test Guideline 
and associated performance standards  (if applicable) for 
Androgen Receptor Transactivation Assays (ARTA) for the 
detection of compounds with (anti)androgenic potential 
(see section 4.1).
During this validation, procedures were developed to 
ensure efficient communication and transfer of the 
method to the selected EU-NETVAL facilities and to per-
form the in vitro method under GLP conditions, since this 
is a requirement for TGs to satisfy the terms for Mutual 
Acceptance of Data by Member Countries.
In June 2017, EURL ECVAM launched a validation 
study to assess 17 in vitro methods for the detection 
of thyroid disruptors (see section 4.2 and annex 2). 
EU-NETVAL test facilities will interact with the in vitro 
method developers during the initial phase of the vali-
dation study for defining and establishing the methods 
in a way that they can be used in a GLP environment. 
This will be followed by an assessment of their reliability 
and the generation of reference data that can be used 
Figure 4.4  Meeting of the EU Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL) held in October 
2017 at the JRC Ispra.
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to support an analysis of their optimal combination in 
an eventual test battery.
The 17 methods were selected based on an OECD review 
paper (OECD, 2014a), and with input from previous 
meetings and workshops (see section 5.1). The methods 
which perform well may be selected for overall relevance 
a s s e s s m e n t 
(when used in 
comb ina t i on ) , 
with a set of 
selected refer-
ence chemicals, 
in view of their 
eventual use 
in a regulatory 
context. In vitro 
method develop-
ers and experts 
who have shown interest, or have in-depth knowledge 
on in vitro method best scientific and quality practices, 
are involved. The validation study will comply with the 
recently published OECD Guidance on Good In Vitro 
Method Practices (GIVIMP) that was led by EURL ECVAM 
(see section 5.3.7 and box 5.3).
An EU-NETVAL meeting took place on 10 to 11 Octo-
ber 2017 at the JRC, Ispra (see fig. 4.4) to facilitate 
the sharing of expertise and practical knowledge for 
the advancement of in vitro methods in animal-free 
safety assessments. Invited experts and in vitro method 
developers gathered with EU-NETVAL members to share 
experiences and knowledge on specific in vitro methods 
for the detection of thyroid hormone disrupting chem-
icals. This will support the newly launched validation 
study on in vitro methods for detecting thyroid disruptors 
described above (see section 4.2). Experts were invited to 
host sessions addressing the practical management of 
test items and test systems, as well as exchanging infor-
mation on the process of in-house validation (GIVIMP; 
OECD, 2018a) and on the use of non-TG methods such 
as the miniaturised Ames assay. These face-to-face 
knowledge sharing opportunities are essential for pro-
moting the use of in vitro methods.
Invited experts and in vitro 
method developers gathered 
with EU-NETVAL members 
to share experiences and 
knowledge on specific 
in vitro methods for the 
detection of thyroid hormone 
disrupting chemicals
European Network of Laboratories for the Valida-
tion of Alternative Methods (EU-NETVAL)
The European Network of Laboratories for the Validation of 
Alternative Methods (EU-NETVAL) was set up by EURL ECVAM 
in response to the provision of Directive 2010/63/EU on the 
protection of animals used for scientific purposes, which 
requests that EU Member States assist the European Com-
mission in the validation of alternative methods. EU-NETVAL is 
a large network of highly qualified test facilities across Europe, 
coordinated by EURL ECVAM to support the in vitro method 
validation process. 
EU-NETVAL covers a wide range of expertise and competences 
and includes laboratories experienced in advanced in vitro pro-
cedures, biological test systems and measurement techniques 
which are considered important to address specific aims and 
objectives identified in EURL ECVAM's strategies to achieve 
impact in the 3Rs for regulatory safety assessment. Currently, 
there are 37 members (including the European Commission's 
own in vitro GLP test facility) of EU-NETVAL representing fif-
teen countries in the network. Facilities are selected, using 
pre-defined eligibility criteria, to carry out tasks detailed in the 
terms of reference, endorsed by the National Contact Points of 
Directive 2010/63/EU.
Box 4.2
With the EU-NETVAL activities and applying the modular 
approach to validation (Hartung et al., 2004), EURL ECVAM 
demonstrates that validation is a flexible scientific process 
aiming to establish confidence that the methods are fit for a 
particular purpose.
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As a follow-up to the practical training sessions at the 2016 
EU-NETVAL meeting, which included a session on in vitro 
methods for assessing the skin sensitisation potential of 
chemicals [DPRA (OECD, 2015), KeratinoSensTM/LuSens 
(OECD, 2018b) and h-CLAT (OECD, 2018c) OECD TG 
methods)], EU-NETVAL members reported on their own 
experiences of using these methods. Feedback from 
the users of these methods is important for assessing 
the uptake of alternatives and for addressing potential 
issues for future users.
READ MORE
m EU Network of Laboratories for the Validation of 
Alternative Methods (EU-NETVAL): europa.eu/!jD93bV
m Meeting of the EU Network of Laboratories for the 
Validation of Alternative Methods (EU-NETVAL) – News 
item: europa.eu/!Qn48GP
4.9 Meeting of the Preliminary Assessment 
of Regulatory Relevance (PARERE) Network 
and the ECVAM Stakeholder Forum (ESTAF)
EURL ECVAM hosted the annual meeting of the Prelim-
inary Assessment of Regulatory Relevance (PARERE) 
network followed by a joint meeting of PARERE and the 
ECVAM Stakeholder Forum (ESTAF) on 27 to 29 Novem-
ber 2017 (see fig. 4.5).
The trans-sectorial PARERE network provides advice to 
EURL ECVAM on the regulatory relevance and suitability 
of alternative approaches proposed for validation, whilst 
both PARERE and ESTAF networks contribute to EURL 
ECVAM strategies and recommendations as part of the 
validation process.
The first part of the PARERE meeting provided updates 
on test submissions related to the Bioelution (see sec-
tion 3.5), the ToxTracker and the EDITOX methods (see 
section 3) on which PARERE had been consulted. It also 
included a session on toxicokinetic data in regulatory 
frameworks where the EU regulatory agencies EFSA, 
EMA and ECHA provided their perspectives on the use 
and integration of toxicokinetic data in regulatory safety 
decisions. EURL ECVAM presented its activities in the 
toxicokinetics area which was followed by a Q&A session 
on Absorption, Distribution, Metabolism and Excretion 
(ADME) and later, by a written consultation of PARERE 
on these projects. The regulatory value of all of these 
projects was acknowledged, as were the commonalities 
in their applications (e.g., providing ways of performing 
interspecies extrapolation and assessing human rele-
vance of animal data).
In the morning of 28 November, the more advanced 
case studies of the EU-ToxRisk project (see section 2.1) 
were presented, as well as the outcome of the PARERE 
Figure 4.5  Participants in the joint meeting of the Preliminary Assessment of Regulatory Relevance (PARERE) network and 
ECVAM Stakeholder Forum (ESTAF) at the JRC Ispra in November 2017.
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consultation on the preliminary regulatory relevance of 
these case studies. The PARERE members appreciated 
that EU-ToxRisk had taken up the comments from the 
first meeting in 2016 and that the case study descrip-
tions improved significantly since then. Furthermore, it 
was recognised that EU-ToxRisk had made huge progress 
over the last year.  More information on the outcome of 
the PARERE meeting of 2017 can be found at: https://
europa.eu/!mk78yT.
In addition to providing updates and highlights from EURL 
ECVAM, the joint meeting with both PARERE and ESTAF 
representatives focused on exploring the status of Three 
Rs relevant knowledge sources and sharing practices. 
Building on the outcomes of the study on the Three Rs 
knowledge sharing (Holley et al., 2016), the participants in 
the joint meeting took part in a workshop to identify good 
practices and explore opportunities in three specific areas: 
Research; Education and training; and Regulatory Testing.
Motivations and goals of basic researchers in pursuing 
the Three Rs may differ significantly from other areas. 
However, this may represent an opportunity to stimulate 
an open and frank discussion between experts in in vivo 
and alternative methods. The need for filling existing gaps 
and engaging aca-
demic researchers 
are clearly beneficial 
and would provide 
more opportuni-
ties for knowledge 
exchanges. EURL 
ECVAM has already 
followed up on this 
by organising a workshop with different actors in the 
field of biomedical sciences (see section 6.2.1).
It is evident that education and training are funda-
mental to driving progress in the development and 
uptake of the Three Rs. However, the current provision 
of resources in the Member States is not well defined 
and shows apparent differences in the level of coverage 
and content. Nevertheless, there are many opportunities 
to improve the delivery and access to education and 
training that are relevant to the Three Rs. As a starting 
point, a review of education and training resources has 
There are many 
opportunities to improve 
the delivery and access 
to education and training 
that are relevant to the 
Three Rs
Preliminary Assessment of Regulatory Relevance 
(PARERE) network and ECVAM Stakeholder Forum 
(ESTAF)
The Preliminary Assessment of Regulatory Relevance (PARERE) 
network was established by EURL ECVAM further to a provision 
of Directive 2010/63/EU that requires that Member States 
nominate a single point of contact to provide advice on the 
regulatory relevance and suitability of alternative approaches 
proposed for validation. This trans-sectorial network is com-
posed of regulators nominated by the EU Member States, 
representatives from EU regulatory agencies such as the 
European Medicines Agency (EMA), the European Chemicals 
Agency (ECHA) and the European Food Safety Authority (EFSA), 
and relevant Commission services. In order to expedite the 
process of regulatory acceptance of alternative methods, it 
was considered that regulators operating within all sectors of 
relevance to alternative methods should be involved as early 
as possible in providing a preliminary view on the potential 
regulatory relevance of methods and approaches submitted 
to EURL ECVAM for validation or peer review or evaluation. 
PARERE has some additional tasks which are described on the 
EURL ECVAM website: europa.eu/!gF94hp. PARERE members 
are consulted on several occasions over the year, either on 
the regulatory relevance of individual methods or approaches 
Box 4.3
that are submitted to EURL ECVAM or on other topics such 
as e.g. EURL ECVAM strategy documents in different areas, 
EURL ECVAM Recommendations, EURL ECVAM's projects at 
the OECD and case studies being developed within research 
projects funded by the EU Framework Programme for Research 
and Innovation, Horizon 2020. 
The ECVAM Stakeholder Forum (ESTAF) comprises stakeholder 
organisations from academia, industry and civil society (e.g., 
animal welfare groups), and the OECD. It was established to 
strengthen participatory approaches and to support commu-
nication and cooperation with the stakeholder community. The 
forum provides input in a number of areas of EURL ECVAM's 
work including strategies to implement the Three Rs and EURL 
ECVAM Recommendations that are typically issued on con-
clusion of a validation study. Due to the valuable scientific, 
technical and societal expertise of its various stakeholders, 
the ESTAF represents a precious network for sharing Three Rs 
knowledge, encouraging dialogue and exchanging information 
on topics related to alternative methods and approaches.
An open invitation for stakeholder organisations with an 
interest in joining the forum is available on the EURL ECVAM 
website: europa.eu/!JG48wW
been undertaken by EURL ECVAM in order to map the 
available provision of resources with Three Rs relevance 
(see section 6.3.1). Knowledge sharing in the area of reg-
ulatory testing already takes place, but there needs to be 
a better coordination and communication. For example, 
new developments in technology and scientific knowl-
edge gaps represent a significant barrier in the use and 
uptake of the Three Rs. As a result there is insufficient 
application or even reflection on the appropriate use of 
alternative approaches within the regulatory context 
of diverse sectors. More details of the joint meeting 
of PARERE and ESTAF are available at https://europa.
eu/!wr94Rm..
The next PARERE meeting will take place on 27 to 28 
November 2018 and will include updates from the 
PARERE network and a discussion on critical elements 
within test submissions as well as relevant work within 
some of the OECD working groups. On the second day, 
a workshop on the Adverse Outcome Pathways (AOP) 
framework will introduce the scope and the content of the 
OECD AOP framework and will discuss how this frame-
work could be moved forward with the PARERE network. 
The next joint meeting of PARERE and ESTAF will take 
place on 28 to 29 November 2018. It will focus on a 
workshop to discuss the validation of alternative meth-
ods, this time from a regulatory and industry perspective, 
and to gather opinions on key questions and ways for-
ward. Similar questions had been discussed during the 
workshop of the International Cooperation on Alternative 
Test Methods (ICATM) involving regulators from the dif-
ferent countries of the ICATM partners (see section 7.1).
READ MORE
m Preliminary Assessment of Regulatory Relevance (PARERE): 
europa.eu/!gF94hp
m ECVAM Stakeholder Forum (ESTAF): europa.eu/!wU38uj
m EURL ECVAM's stakeholder forum and regulatory advisors 
share opinions on better knowledge sharing - News item: 
europa.eu/!dN98Pw
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5.1 Activities Related to the Identification 
of Endocrine Disruptors
In support of the EU Community Strategy for Endocrine 
Disruptors and the OECD programme on testing and 
assessment of endocrine disruptors, the JRC through 
EURL ECVAM has been supporting the European Commis-
sion's Directorate Generals for Environment, and Health 
and Food Safety on several activities aimed at improving 
ED detection (see also box 5.1).
READ MORE
m DG SANTE - Endocrine Disruptors: europa.eu/!bV43dk
5.1.1 Revision of the Community Strategy
In 1999, the European Commission published a Com-
munity Strategy for Endocrine Disruptors (COM(1999) 
706) (EC, 1999) with the objectives of identifying the 
problem of endocrine disruption, its causes and conse-
quences, and to identify appropriate policy action on the 
basis of the precautionary principle, in order to respond 
quickly and effectively to the problem, thereby allevi-
ating public concern. A new Communication 'Towards 
a more comprehensive European Union framework on 
endocrine disruptors' has recently been published (EC, 
2018), which takes stock of the actions undertaken in 
the EU so far and outlines areas where further action is 
needed with a view to minimising exposure to endocrine 
disruptors and promoting the substitution of endocrine 
disrupting chemicals with less harmful chemicals. The 
proposals of the Commission, following up on the key 
strands of the 1999 Strategy, revolve around three prin-
ciples: 1) addressing the gaps in knowledge by taking 
forward the science; 2) linking science and regulation: 
ensuring an effective EU legal framework; 3) deepening 
international cooperation.
READ MORE
m Endocrine disruptors: A strategy for the future that pro-
tects EU citizens and the environment – Press release: 
europa.eu/!mR37Ug
5.1.2 Guidance Document on the Identification 
of Endocrine Disruptors in the Context of the 
EU Regulations on Biocides and Plant Protection 
Products
Scientific criteria for the determination of endocrine dis-
rupting properties for the Biocides [(EU) 2017/2100] and 
Pesticides [(EU) 2018/605] Regulations, were recently 
Promoting the Regulatory
Acceptance and International Adoption 
of Alternative Methods and Approaches
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adopted which will be applicable from June 2018 and 
November 2018, respectively. EURL ECVAM has been 
supporting the Commission on scientific aspects of the 
process for criteria development, including the drafting 
of a Guidance Document (GD) accompanying these crite-
ria, in support of the relevant agencies, EFSA and ECHA.
This GD assists applicants and assessors of competent 
regulatory authorities on how to apply these criteria 
(ECHA and EFSA, 2018). The GD describes how to 
gather, evaluate and consider all relevant information 
for the assessment, conduct a mode of action analy-
sis, and apply 
a weight of 
e v i d e n c e 
a p p r o a c h , 
in order to 
e s t a b l i s h 
whether the 
ED criteria 
are fulfilled. 
The GD has 
been based 
upon the suite 
of in vitro and 
in vivo test guidelines currently available, including in 
silico tools, as described by the recently updated OECD's 
Conceptual Framework for the Testing and Assessment 
of Endocrine Disruptors and accompanying guidance 
(OECD, 2018d; see section 5.3.13). The assessment 
strategy pursued in the guidance requires the gener-
ation of supplementary data only when necessary to 
avoid further animal testing.
READ MORE
m ECHA - Guidance on identifying endocrine disruptors
 published: echa.europa.eu/it/-/
guidance-on-identifying-endocrine-disruptors-published
m EFSA - Guidance on identifying endocrine disruptors 
published: www.efsa.europa.eu/en/press/news/180607
5.2 Activities in the OECD Working Party 
on Hazard Assessment 
5.2.1 OECD Integrated Approaches to Testing and 
Assessment Case Studies Project
The IATA Case Studies Project under the OECD Working 
Party on Hazard Assessment (WPHA) aims to support 
efforts of the OECD Member Countries to increase the 
use of alternative methods within IATA. The project is 
investigating the practical applicability of IATA by dis-
cussing case studies, based on a draft template (OECD, 
2014b,c), to create a common understanding of using 
the approaches. Findings and conclusions are summa-
rised in considerations documents, which highlight the 
major issues discussed and lessons learned from the 
IATA approaches of the case studies, to contribute to the 
development of further guidance and respective tools. 
Activities on the development and validation 
of assays for the identification of endocrine 
disruptors
The adoption of the ECHA-EFSA GD will allow the implemen-
tation of scientific criteria for the determination of endocrine 
disrupting properties for the Biocides [(EU) 2017/2100] and 
Pesticides [(EU) 2018/605] Regulations (see section 5.1.2). 
However, there is still much work to be done in the develop-
ment and validation of assays for the detection of endocrine 
disruptors. In particular, EURL ECVAM has embarked upon a 
project with its network of validation laboratories (EU-NETVAL) 
to characterise the performance of 17 alternative methods 
that investigate interference with different aspects of thyroid 
physiology (either by interference with synthesis, action or 
clearance; see section 4.2) and is offering support to a number 
of H2020 funded projects focussed on development and val-
idation of novel methods for screening and testing for EDs 
which are about to start (see section 2.3).
Box 5.1
The GD describes how to 
gather, evaluate and consider 
all relevant information for 
the assessment, conduct 
a mode of action analysis, 
and apply a weight of 
evidence approach, in order 
to establish whether the ED 
criteria are fulfilled
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The first and second cycle comprised case studies 
focused on grouping and read-across for different 
hazard endpoints (OECD, 2016a-d;  OECD, 2017a,b), one 
specifically supported by toxicogenomics data (OECD, 
2017c), a pesticide cumulative risk assessment and 
assessment of lifestage susceptibility (OECD, 2017d), 
as well as the JRC/BIAC chemical safety assessment 
workflow based on exposure considerations and focus-
ing on non-animal methods, integrating multiple data 
streams for safety assessment decisions (OECD, 2017e) 
and based on the SEURAT-1 cross-cluster ab initio case 
study (Berggren et al., 2017). 
The third cycle started in 2017 and reviewed an 
IATA workflow using interchemical and intrachemical 
comparison of data from traditional and alternative 
approaches (OECD, 2018e), the prioritisation of chem-
icals using an IATA-based Ecological Risk Classification 
(OECD, 2018f), a read-across case study with metabo-
lism playing a key role in toxicity (OECD, 2018g) and a 
JRC case study on grouping and read-across for nanoma-
terials - genotoxicity 
of nano-TiO2 (OECD, 
2018h), based on the 
Nanocomput project 
(Worth et al., 2017a). 
The aim of this case 
study was to deter-
mine the genotoxic 
hazard potential of 
two nano-TiO2 target 
substances by read-
ing across in vitro 
comet assay results. 
It is illustrating the 
applicability of the workflow for grouping and read-
across proposed in the REACH guidance update for 
nanomaterials (ECHA, 2017a) and identifying sources 
of uncertainty, exploring the extent to which ECHA's 
Read-Across Assessment Framework (RAAF) (ECHA, 
2017b) captures the different sources of uncertainty 
for nanoforms, pointing out nanospecificities to be con-
sidered. Furthermore, the relevance of cheminformatics 
methods in grouping of nanoforms was explored. The 
four case studies of the 2017 cycle mentioned above 
and its considerations document (OECD, 2018i), updat-
ing the learnings from the previous cycles (OECD, 
2016e; OECD, 2017f) with the new experience and 
issues identified for further discussion, were endorsed 
at the WPHA meeting in June 2018 and have been pub-
lished on the OECD website. Uncertainty assessment 
was one focus of the discussions.
The fourth cycle is reviewing a case study on read-across 
for testicular toxicity of ethylene glycol methyl ether 
(EGME)-related chemicals, including considerations of 
metabolism and AOP information, as well as a Defined 
Approach for identifying estrogen receptor (ER) active 
chemicals, consisting of an integrated battery of in vitro 
high throughput screening (HTS) assays and a compu-
tational model of ER pathway activity.
READ MORE
m Integrated Approaches to Testing and Assessment (IATA) 
- Case studies project: www.oecd.org/chemicalsafety/
risk-assessment/iata-integrated-approaches-to-test-
ing-and-assessment.htm 
5.2.2 Information Exchange Seminar for IATA-
related Projects 
A half-day “Information Exchange Seminar for IATA 
Related Projects” was held on 14 November 2017 as 
a webconference. Members from past or ongoing OECD 
IATA-related projects were invited to participate to 
exchange information and experience in IATA related 
activities and identify possible synergies.
An overview of OECD IATA related definitions and of 11 
OECD IATA-related projects were presented. EURL ECVAM 
contributed with presentations on the guidance docu-
ments on Defined Approaches (OECD, 2016f,g) and on the 
project to establish a guideline for defined approaches 
relating to skin sensitisation. Furthermore, EURL ECVAM 
gave an overview of currently available guidance docu-
ments and templates related to IATA and IATA components 
in view of noting gaps or possible overlaps, with specific 
notice of the consideration of assessment and reporting 
of uncertainties in the guidance documents.
READ MORE
m Webinar: Information exchange seminar for IATA related 
projects – November 2017: youtu.be/PXZHJzDGljo
5.2.3 Mapping of Guidance Documents Related to 
IATA and IATA Components 
The scoping exercise of mapping IATA-related guidance 
carried out by EURL ECVAM showed that the number 
of documents from different sources, directly or indi-
rectly related to guidance on IATA, is proliferating but 
fragmented and sometimes duplicated across countries, 
sectors and topic areas. These results and previous dis-
cussions in the IATA Case Studies Project Group gave rise 
to a project under the WPHA, led by EC (through JRC-
EURL ECVAM) in a project team with Canada, Germany 
The IATA Case Studies 
Project under the OECD 
Working Party on Hazard 
Assessment (WPHA) 
aims to support efforts 
of the OECD Member 
Countries to increase 
the use of alternative 
methods within IATA
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and the Netherlands. The aim of the project is to compile 
a comprehensive overview document on the concepts 
and available guidance for IATA and their components as 
well as for connected cross-cutting topics such as data 
quality and uncertainties.
5.2.4 Chemical Mixtures and Combined 
Exposure
Every day we are exposed to low levels of hundreds of 
different manmade chemicals present for example in 
our food, consumer products and the air we breathe. Our 
environment is also exposed to a near-infinite number 
of chemical mixtures derived from numerous sources. 
However, current safety assessment practice is primarily 
based on understanding the potential risk posed by single 
substances rather than their "real life" combinations, thus 
potential combination effects might be overlooked.
Combined exposure to multiple chemicals can lead to 
adverse effects on human health or the ecosystem, 
even if single substances in the mixtures are below 
their individual safety thresholds. While manufactured 
products such as pesticide formulations or cosmetic 
products are covered in current chemical legislation, 
unintentional mixtures which are coincidentally formed 
such as mixtures of contaminants e.g., in indoor air, are 
not consistently addressed. Their composition is often 
unknown and changes over time, making them difficult to 
regulate. The assess-
ment of unintentional 
mixtures is therefore 
usually limited to spe-
cific legislative sectors 
only, such as pesticide 
residues in food. EURL 
ECVAM is investigat-
ing recent progress in 
considering combined 
exposures to multi-
ple chemicals to help 
translate best science into best assessment practice. The 
latest policy brief (Bopp et al., 2018b), puts together 
issues around the topic, including the specific challenges 
that will further inform discussions of the working group 
of Commission services and EU agencies on the combi-
nation effects of chemicals.
Chemical mixtures: how to address the safety of 
combined exposures to multiple chemicals for 
people and the environment
Different methods are already being used to predict or assess 
mixture toxicity. Chemical mixtures are assessed either by 
testing the whole mixture (e.g., in effect-based monitoring of 
surface water) or by predicting the combined risk based on 
concentration and effect information of the individual com-
ponents in the mixture (e.g., in the assessment of dioxins and 
dioxin-like compounds in food and feed).
With a view to harmonising assessment methodology, interna-
tional bodies, such as the World Health Organisation (WHO) and 
the Organisation for Economic Cooperation and Development 
(OECD) have developed guidance on the assessment of risks 
from combined exposure to multiple chemicals.  However, there 
are still many gaps concerning availability and interpretation of 
data, and there is no harmonised assessment approach across 
different sectors of legislation.
EURL ECVAM has been analysing the available methodologies 
for chemicals testing. Due to the large number of chemical 
combinations, it is practically unfeasible to test all possible 
mixtures experimentally, in particular in animal studies for 
Box 5.2
ethical and practical reasons. Therefore smart strategies are 
needed to address the data gaps and to assess the potential 
hazards using new tools that rely less on in vivo testing and 
incorporate instead alternative experimental and computa-
tional tools. Their main strengths lie in their integrated use in 
smart combinations, allowing a better, mechanistically based 
prediction of mixture effects.
EURL ECVAM is 
investigating recent 
progress in considering 
combined exposures 
to multiple chemicals 
to help translate best 
science into best 
assessment practice
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EURL ECVAM is performing research on the use of 
alternative (non-animal) methods and new strategies 
to assess the combination effects of chemicals. Having 
reviewed current EU regulatory requirements and mix-
ture assessment practices (Bopp et al., 2015, 2016; 
Kienzler et al., 2014, 2016), it is currently exploring 
links between mixtures and possible subsequent dis-
eases, interaction effects of chemicals, as well as the 
use of biomonitoring data in exposure assessment. EURL 
ECVAM also recently reviewed the role and availability of 
Physiologically Based Kinetic (PBK) models in addressing 
chemical mixtures (Desalegn et al., 2018).
EURL ECVAM collaborates with five European research 
consortia focusing on chemical mixture assessment for 
the environment (SOLUTIONS), human health (Euro-
Mix, HBM4EU), endocrine disruption (EDC-MixRisk) and 
alternatives to animal testing (EU-ToxRisk) (Bopp et al., 
2018a; see section 2.2). As international harmonisation 
is essential in this context, EURL ECVAM actively supports 
the OECD project on combined exposure (led by the OECD 
Working Party on Hazard Assessment in collaboration 
with the Working Party on Exposure Assessment) and 
supports the development of consistent assessment 
approaches for combined exposure to chemical mixtures 
at international level. The draft guidance on "Consider-
ations for Assessing the Risks of Combined Exposures 
to Multiple Chemicals" was endorsed in October 2018.
READ MORE
m SOLUTIONS: www.solutions-project.eu
m EuroMix: www.euromixproject.eu
m HBM4EU: www.hbm4eu.eu
m EDC-MixRisk: edcmixrisk.ki.se
m EU-ToxRisk: www.eu-toxrisk.eu
5.2.5 Guidance Document on Physiologically 
Based Mathematical Models 
New approach methodologies (NAM) combining in vitro 
data, in silico data and physiologically based kinetic 
(PBK) modelling have the potential to play a significant 
role in reducing animal testing. It is necessary to investi-
gate the strengths, uncertainties, and limitations of PBK 
models developed using NAM data, for establishing a 
higher degree of confidence in the regulatory application 
of such models (Paini et al., in press). With this in mind, 
the EC (through EURL ECVAM) and the US Environmental 
Protection Agency (EPA) are co-leading an expert working 
group at the OECD to develop a guidance document on 
the characterisation, validation and reporting of physi-
ologically based models that are based on data derived 
from non-animal methods to facilitate regulatory 
applications. A reporting template was developed to 
capture and highlight the uncertainties in the several 
steps of develop-
ment and application 
of PBK models. In 
addition, following 
this template, a few 
well-documented 
case studies were 
discussed at a face-
to-face meeting of 
the working group in 
Paris in September 
2018. It is expected 
that these case 
studies will inform and illustrate the guidance which 
should be finalised in 2019.
5.3 Activities in the OECD Test Guidelines 
Programme
5.3.1 Summary of the Outcome of the 30th 
Meeting of the Working Group of National 
Coordinators of the OECD Test Guidelines 
Programme
At the 30th meeting of the Working Group of National 
Coordinators of the OECD Test Guidelines Programme 
(WNT) held at the OECD headquarters in Boulogne, Paris 
on 24 to 27 April 2018 (see fig. 5.1), eight Test Guide-
lines were approved of which two were new TGs and six 
were updated TGs.
The new and updated TGs included:
• New Test Guideline 319A on the "Determination of 
in vitro intrinsic clearance using cryopreserved rain-
bow trout hepatocytes" (co-led by the EC through 
JRC-EURL ECVAM, and the US; see section 5.3.3 and 
annexes 1 and 2).
• New Test Guideline 319B on the "Determination of 
in vitro intrinsic clearance using rainbow trout liver 
S9 sub-cellular fraction" (co-led by the EC through 
JRC-EURL ECVAM, and the US; see section 5.3.3 and 
annexes 1 and 2).
• Updated Test Guideline 438 (and updated Guidance 
Document 160, see below) on the Isolated Chicken 
Eye Test Method for identifying  i) chemicals inducing 
serious eye damage and ii) chemicals not requiring 
classification for eye irritation or serious eye damage, 
including histopathological examination as additional 
endpoint to identify UN GHS cat.1 non-extreme 
pH (2<pH<11.5) detergents and surfactants and 
modified decision criteria for chemicals requiring 
classification for eye hazard (taking into consideration 
New approach 
methodologies (NAM) 
combining in vitro 
data, in silico data and 
physiologically based 
kinetic (PBK) modelling 
have the potential to 
play a significant role in 
reducing animal testing
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the variability of the Draize eye test; see annexes 1 
and 2).
• Updated Test Guideline 492 on Reconstructed human 
Cornea-like Epithelium (RhCE) test methods for iden-
tifying chemicals not requiring classification and 
labelling for eye irritation or serious eye damage with 
the inclusion of the Labcyte CORNEA MODEL 24 EIT 
test method (see annexes 1 and 2). 
• Updated Test Guideline 442D on in vitro skin sensitisa-
tion addressing key event 2 on keratinocyte activation 
with the inclusion of the LuSens test method, and the 
Keratinosens test method using animal-free serum 
(see annexes 1 and 2).
• Updated test Guideline 442B on the Local Lymph 
Node Assay (LLNA) including the BrdU FCM method 
(see annex 2).
• Updated Test Guideline 408 on 90 day Oral Repeated 
Dose Toxicity Study including endocrine-related end-
points (see section 5.3.15).
• Updated Test Guideline 414 on Prenatal Development 
Toxicity Study including endocrine-related endpoints 
(see section 5.3.15).
Three new Guidance Documents and four updated ones 
were approved as well and included:
• Updated Guidance Document 23 on Aqueous-phase 
Aquatic Toxicity Testing of Difficult Test Chemicals 
[US, EC (through EURL ECVAM) and ICAPO-led].
• New Guidance Document 280 on Determination of in 
vitro intrinsic clearance using cryopreserved hepat-
ocytes (RT-HEP) or liver S9 sub-cellular fractions 
(RT-S9) from rainbow trout and extrapolation to in 
vivo intrinsic clearance [EC (through EURL ECVAM) 
and US-led].
• Updated Guidance Document 160 on the collection of 
eye tissues for histological evaluation and collection 
of data (see annex 2).
• Updated Guidance Document 39 on inhalation toxicity 
studies.
• Updated Guidance Document 150 on Evaluation of 
Chemicals for Endocrine Disruption using Standard-
ised Guidelines (EC through EURL ECVAM was member 
of the Steering Group, see section 5.3.13).
• New Guidance Document 286 on Good In Vitro 
Method Practice (JRC through EURL ECVAM-led, see 
section 5.3.7).
• New Guidance Document on Efficacy of Biocide 
Treated Articles.
In addition, modifications were also made to some exist-
ing Test Guidelines on chronic toxicities such as TGs 443, 
451, 452, 453 and GD 116 to include a sentence on 
adequacy of dose/concentration selection to fulfil reg-
ulatory needs. Fourteen new projects were adopted on 
the OECD Workplan. More information can be found on 
the OECD website of the TGP.
The following chapters mainly focus on TGs for which the 
EC (through JRC-EURL ECVAM) has the lead or co-lead. 
However, some projects with relevance to the alterna-
tive field led by other Member Countries are also briefly 
described. Beside those, EURL ECVAM participated in 
Figure 5.1  30th meeting of the Working Group of National Coordinators of the OECD Test Guidelines Programme (WNT) held 
at the OECD headquarters in Boulogne, Paris in April 2018.
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numerous OECD expert groups and validation manage-
ment groups and commented on several other draft TGs 
and GDs led by other OECD Member Countries. 
READ MORE
m OECD Guidelines for the testing of chemicals and 
related documents: www.oecd.org/chemicalsafety/testing/
oecd-guidelines-testing-chemicals-related-documents.htm
5.3.2 OECD Test Guidelines on Determination of 
in vitro Fish Intrinsic Hepatic Clearance 
The OECD project on the development of new OECD TGs 
on the determination of in vitro Fish Intrinsic Hepatic 
Clearance (under the lead of USA and the EC represented 
by JRC EURL ECVAM) aimed at standardising two in 
vitro methods using either rainbow trout S9 fraction 
(Johanning et al., 2012) or cryopreserved rainbow trout 
hepatocytes (Fay et al., 2015) to determine in vitro fish 
intrinsic hepatic clearance.
The project built on work carried out within the frame-
work of the HESI project "Bioaccumulation". HESI 
coordinated a multi-laboratory ring trial (2014-2016) 
to assess the reliability, transferability, and predictive 
value of the two in vitro methods (Nichols et al., 2018). 
The two OECD TGs, the associated guidance document 
and the ring trial report underwent OECD public consul-
tation in 2017. OECD WNT approved the documents at 
its 30th meeting in April 2018, and the documents are 
now available on the OECD website (OECD, 2018j-m). 
Moreover, EURL ECVAM supported this project by making 
available a fish in vitro biotransformation database cov-
ering intrinsic clearance data determined with in vitro 
methods (hepatocytes, S9, microsomes). The database 
is publicly available from the JRC Data Catalogue (Halder 
et al., 2018b; see section 6.1.4) and may help users of 
the new OECD TG 319a and 319b to determine whether 
their test chemicals fall within the applicability domain 
of the methods.
The associated OECD Guidance Document 280 (OECD, 
2018l) provides information on how to best perform the 
two in vitro methods. Moreover, it describes how the in 
vitro intrinsic clearance (indicating metabolism) can be 
extrapolated to a 
whole-body metab-
olism rate constant 
(see fig. 5.2). Inclu-
sion of measured 
biotransformation 
rates enhances the 
reliability of models 
to estimate the Bio-
concentration Factor 
(BCF), since the conventional log Kow-based QSARs or 
other models often neglect the contribution of biotrans-
formation and potential reduction of bioaccumulation 
(Laue et al., 2014; Nichols et al., 2013).
The bioconcentration potential of a chemical is impor-
tant information that is required in many pieces of 
chemical legislation. It is used for hazard classification 
and for the assessment of persistent, bioaccumulative 
and toxic (PBT) substances. The BCF is either predicted 
or measured (typically in fish, but if necessary, also in 
invertebrates). Depending on the regulatory framework, 
predicted BCFs based on in vitro data may be applied to 
screen chemicals for their bioaccumulative properties 
and to decide whether a chemical is bioaccumulative at 
The bioconcentration 
potential of a chemical 
is important information 
that is required in many 
pieces of chemical 
legislation 
Figure 5.2  How to use in vitro determined hepatic clearance to predict BCF values.
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the screening level; to assess the bioaccumulation poten-
tial as part of a weight of evidence approach or read 
across, or, to decide whether a full in vivo fish study is 
warranted. Predicted BCFs based on in vitro data may not 
replace in vivo fish bioaccumulation tests, however, they 
may be an alternative if in vivo testing is technically not 
feasible, or if the corresponding regulatory framework 
does not allow vertebrate testing. 
READ MORE
m EURL ECVAM Fish In Vitro Intrinsic Clearance Database:
 data.jrc.ec.europa.eu/dataset/
jrc-eurl-ecvam-fish-in-vitro-intr-clear-db
5.3.3 OECD Guidance Document 23 on 
Aqueous-phase Aquatic Toxicity Testing of 
Difficult Test Chemicals
This project initiated by the International Council on 
Animal Protection in OECD Programmes (ICAPO) and 
co-led by the EC (JRC-EURL ECVAM), USA and ICAPO is 
divided into two parts. Part 1, the update of GD 23, was 
successfully concluded in 2018 and the revised GD 23 is 
available on the OECD website (OECD, 2018n).
GD 23 supplements OECD test guidelines used for 
regulatory purposes. The revision reflects the experi-
ence gained in handling difficult-to-test chemicals in 
aquatic exposures as well as progress made in devel-
oping methods for testing these chemicals since GD 
23's first publication in 2000. Specific focus was on the 
expansion of the guidance on testing of poorly water 
soluble test chemicals, 
i.e., attention was paid 
to updating exposure 
methods that do not 
employ a solvent in 
order to eliminate the 
need for a solvent con-
trol, and thus, reducing 
the number of animals 
used in aquatic toxic-
ity tests. Moreover, GD 
23 now includes more 
detailed guidance 
for substances of unknown or variable composition, 
complex reaction products, and biological materials 
(UVCBs). The updated GD 23 will help government 
agencies, industry, and contract research organisations 
conduct valid and reliable aquatic toxicity studies on 
difficult-to-test chemicals while minimising both the 
number of animals used and the need to repeat studies.
Part 2 of the project is ongoing and aims at determining 
whether it is possible to use only one control, the solvent 
control, when solvents are used in aquatic toxicity tests 
on fish. A retrospective review of existing data generated 
according to OECD test guidelines in the presence of a 
solvent will be used to determine if the use of only one 
control would impact the outcome of the study. 
5.3.4 Guidance Document on IATA for Fish 
Acute Toxicity Testing
The project aims at developing an IATA for fish acute 
toxicity testing. As a first step the focus was on updating 
OECD GD 126, the threshold approach for acute fish tox-
icity (OECD, 2010), and integrate the fish embryo acute 
toxicity test (OECD, 2013b) into the step-wise approach 
for determining acute fish toxicity. The project started 
in 2015 under the lead of Austria and ICAPO and the 
development of the guidance document is ongoing.
5.3.5 Revision of OECD Test Guideline 203
OECD TG 203 fish acute toxicity test (OECD, 1992) deter-
mines the concentration of a chemical at which 50% of 
the fish die (LC50) and is one of the few guidelines still 
using death as an endpoint. The project (led by Swit-
zerland and UK) aims at including the use of non-lethal 
endpoints to reduce the suffering of the test fish. A new 
draft underwent WNT consultation during 2018 and is 
available on the OECD website.
READ MORE
m Draft Revised Test Guideline 203 - Fish Acute Toxicity 
Test: www.oecd.org/chemicalsafety/testing/Draft%20
Update%20TG%20203_July%202018-for%20public%20
comments.pdf
5.3.6 OECD Test Guideline on CYP induction
When in vitro methods are used for systemic toxicity 
testing, metabolically competent test systems need to 
be integrated, since toxicokinetic properties of most 
substances are dependent on metabolism. Elucidating 
metabolic competence allows better interpretation and 
comparability of in vitro methods. Cytochrome P450 
(CYP) induction, requiring de novo protein synthesis, is 
a sensitive biomarker for evaluating phenotypic hepatic 
metabolic competence. Regarding induction, there are 
two EURL ECVAM validated methods for measuring 
cytochrome P450 induction of CYP1A2, CYP2B6 and 
CYP3A4 isoforms.
The CYP induction methods are important as the metab-
olism of a test item may (i) be increased by the test 
item itself (auto-induction) or by another concurrently 
administrated/exposed substance (e.g., mixture), (ii) 
The updated GD 23 will 
help conduct valid and 
reliable aquatic toxicity 
studies on difficult-to-
test chemicals while 
minimising both the 
number of animals 
used and the need to 
repeat studies
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perturb the endogenous metabolism by induction or 
inhibition of enzymes involved in the process, or (iii) lead 
to toxicity by reactive metabolite formation. Mechanistic 
information on CYP induction should be considered in the 
context of IATA for adverse effects. 
EURL ECVAM is preparing a detailed manuscript that 
summarises the results of the validation study of two 
in vitro methods assessing the potential of a chemi-
cal to induce CYP1A2, CYP2B6, and CYP3A4 using 
cryopreserved primary human hepatocytes (PHH) and 
a cryopreserved human derived HepaRG cell line. The 
manuscript will recommend that: 
a) CYP induction should be measured in human derived 
metabolically competent test systems, 
b) HepaRG was comparable to PHH in predicting CYP 
induction, representing a substitute/complementary in 
vitro system for CYP induction studies, 
c) CYP induction should be measured at phenotypic level 
(i.e., activity), 
d) 2-fold induction is an acceptable threshold for posi-
tive identification of in vitro CYP inducers, 
e) a concentration-dependent response (i.e., at least 
two consecutive concentrations generating 2-fold 
induction response) should be observed to reduce the 
risk of false positives, and to classify a compound as 
an in vitro inducer. 
The manuscript will be shared with relevant OECD expert 
groups with a view to integrating the human CYP induction 
in vitro methods, and the generated metabolic activation 
and induction data, into testing strategies (Coecke et al., 
2006; Wilk-Zasadna et al., 2015; Hakkola et al., 2018). 
READ MORE
m CYP induction assay using the cryopreserved human 
hepatocytes: tsar.jrc.ec.europa.eu/test-method/tm2009-13
m CYP induction assay using the human cryopreserved 
HepaRG™ cell line: tsar.jrc.ec.europa.eu/test-method/
tm2009-14
5.3.7 OECD Guidance Document on Good 
In Vitro Practices for the Development and 
Implementation of In Vitro Methods for 
Regulatory Use in Human Safety Assessment 
(GIVIMP)
There is a strong belief that in vitro methods are fast 
becoming the key tool for a new way of doing toxicology. 
However, their potential will not be fully exploited if they 
are not developed and applied in a way that scientific 
integrity and quality is assured, as the data they produce 
will not be trusted by decision makers. New challenges 
arise with the development of high-throughput tech-
nologies, stem cells and new culture technologies 
(organotypical cell cultures, organ-on-chip technologies). 
Moreover, in vitro methods often require improvements 
in their design and implementation before they can be 
validated and evaluated regarding their reliability and 
relevance for a particular regulatory purpose.
The recently approved OECD Guidance Document on 
Good In Vitro Method Practices (GIVIMP; OECD, 2018a), 
led and coordinated by EURL ECVAM, aims to provide a 
framework of technical and quality practices for safe-
guarding that the in vitro method is of the highest 
possible scientific quality. Applying GIVIMP during the 
development of in 
vitro methods will 
help to improve the 
quality of submit-
ted methods and 
ultimately the effi-
ciency of validation 
studies. GIVIMP will 
not only support 
validation bodies 
but it is intended to 
support method 
developers and 
end-users working in academic, industry or government 
laboratories across all 36 OECD Member Countries and 
beyond. A large number of international experts, includ-
ing members of a dedicated OECD expert group and 
EU-NETVAL, contributed to the state-of-the-art knowl-
edge gathered within the guidance document. GIVIMP 
also benefitted from a number of written commenting 
rounds and two expert meetings before its final endorse-
ment by the OECD WNT in April 2018.
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to support method 
developers and end-users 
working in academic, 
industry or government 
laboratories across all 36 
OECD Member Countries 
and beyond
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GIVIMP consists of ten chapters addressing key aspects 
throughout the in vitro method lifecycle from develop-
ment to regulatory use: (1) Roles and responsibilities, 
(2) Quality considerations, (3) Facilities (4) Apparatus, 
material and reagents, (5) Test systems, (6) Test and 
reference/control items, (7) Standard operating pro-
cedures (SOPs), (8) Performance of the method, (9) 
Reporting of results, (10) Storage and retention of 
records and materials.
5.3.8 OECD Guideline on Defined Approaches 
relating to Skin Sensitisation
The need to replace regulatory animal assays for skin 
sensitisation with "Defined Approaches" (DAs) based on 
the integration of relevant information from a variety of 
non-animal sources (in vitro and in chemico methods, 
in silico predictions, physicochemical properties, read-
across results, and other inputs relevant to the skin 
sensitisation adverse outcome pathway (AOP) initiated 
by covalent binding to skin proteins) is being considered 
by the OECD (Casati et al., 2018). In 2017, the OECD 
included in its work program the proposal for a project 
on the development of a Guideline on DAs for skin sen-
sitisation put forward by the EC (through JRC's EURL 
ECVAM), US (NICEATM/EPA/CPSC) and Canada (Health 
Canada) with the support of other ICATM partners. A 
special meeting of the OECD WNT took place from 13 to 
15 December 2017 at the JRC (see fig. 5.3). On occasion 
of this meeting preliminary assessment criteria, as well 
as potential ways for analysing the in vivo (LLNA and 
human) data were proposed for discussion (see sec-
tion 5.3). An expert group charged with assisting in the 
development of the guideline and composed by more 
than 50 members representing ten countries was set 
up by the OECD.
In 2018, activities focused on the consolidation of the 
evaluation framework for DAs (see section 5.2.10 in 
Zuang et al., 2017) and application of the framework to 
initially review three of the simplest DAs (The Adverse 
Outcome Pathway-based "2 out of 3" integrated testing 
strategy from BASF, the sequential testing strategy (STS) 
and the inte-
grated testing 
strategy (ITS) 
for sensitising 
potency classifi-
cation both from 
Kao Corporation; 
see Annex I to 
OECD GD 256) 
(OECD, 2016h) 
that include val-
idated and OECD 
adopted in vitro 
methods and 
have simple rule-based data interpretation procedures 
(DIP). The review process, finalised by the experts in 
June 2018, showed the adequateness of the proposed 
evaluation framework and highlighted the importance of 
a number of activities already initiated by the leaders 
of the project in order to progress the development of a 
guideline on these DAs.
Figure 5.3  Special meeting of the OECD WNT on Defined Approaches for skin sensitisation at the JRC Ispra in December 2017.
The need to replace 
regulatory animal assays 
for skin sensitisation with 
"Defined Approaches" (DAs) 
based on the integration of 
relevant information from 
a variety of non-animal 
sources is being considered 
by the OECD
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International guidance on good practice for the 
development and application of in vitro methods 
(GIVIMP)
The Organisation for Economic Cooperation and Development 
(OECD) has published guidance on Good In Vitro Method Prac-
tices (GIVIMP) to ensure the reliability and integrity of in vitro 
data used for the safety assessment of chemicals.
The guidance document is intended to support method 
developers and end-users working in academic, industry or 
government laboratories across all 36 OECD Member Coun-
tries and beyond.
GIVIMP addresses key elements of good in vitro practice 
including:
• clear definition of roles and responsibilities,
• procedures for storing and handling cells and tissues,
• ways to prepare test items and avoid cross-contamination,
• defining and describing standard operating procedures 
and how to properly report results.
Modern in vitro methods are typically based on human cells 
or engineered tissues and are designed to identify potentially 
harmful effects of chemicals used in a variety of contexts 
including consumer goods, industrial processes and plant 
protection products. They are fast becoming key tools for 
a new way of doing toxicology without resorting to animal 
Box 5.3
testing. Test data derived from in vitro methods are increas-
ingly being used in combination with other information within 
Integrated Approaches to Testing and Assessment (IATA) to 
support safety decisions. However, good practices are essen-
tial to ensure that in vitro data can be trusted by industry 
end-users and regulatory authorities for the protection of 
workers, consumers and the environment.
Moreover, in vitro methods that undergo validation often 
require improvements in their design and implementation 
before they can be evaluated regarding their reliability and 
relevance for a particular regulatory purpose. Applying GIVIMP 
during the development of in vitro methods will help improve 
the quality of submitted methods and ultimately the effi-
ciency of validation studies.
The development of GIVIMP was coordinated by EURL ECVAM 
within the context of a project of the OECD Test Guidelines 
Programme. A large number of international experts, including 
members of a dedicated OECD expert group and the European 
Union Network of Validation Laboratories (EU-NETVAL; see 
section 4.8) contributed to the state-of-the-art knowledge 
gathered within the guidance document. GIVIMP also bene-
fitted from a number of written commenting rounds and two 
expert meetings before its final endorsement by the OECD's 
Working Party of National Coordinators of the test guidelines 
programme in April 2018.
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The main activities include but are not restricted to:
• The analysis of the variability of the reference in vivo 
data (LLNA and human data),
• The analysis of the impact of the variability of the 
individual information sources composing the DAs on 
the DAs' predictions,
• A consistent definition of the DAs' applicability 
domain,
• The evaluation of how the DAs designed for potency 
categorisation predict GHS potency classes (cat 1A 
and cat 1B).
The results of these activities are informing the devel-
opment of the draft guideline that was circulated for 
comments within the expert group and the WNT in 
Q4 of 2018. 
Consideration is also given to the evaluation and 
inclusion in the draft guideline of DAs involving more 
sophisticated DIPs based for example on the use of 
neural or Bayesian networks. A meeting of the expert 
group is scheduled on 6 to 7 December 2018 at the 
OECD to discuss outstanding issues in view of incorpo-
rating the expert recommendations in the draft guideline. 
The aim is to reach consensus within the expert group 
on a final guideline to be submitted for approval by the 
WNT in 2019. 
5.3.9 OECD Feasibility Study for Establishing Test 
Guidelines for In Vitro Human Hepatic Metabolic 
Clearance and Metabolite Formation 
An OECD proposal was submitted by the Netherlands in 
November 2017 on "A feasibility study for establishing 
Test Guidelines for in vitro human hepatic metabolic 
clearance and metabolite formation". The project was 
approved in April 2018 and will be run under the lead 
of the Netherlands.
Although EURL ECVAM discontinued the OECD project 
on a guidance document for human hepatic metabolic 
clearance methods (see section 5.2.11 in Zuang et al., 
2017), it will contribute relevant background information 
to this new project, such as the components to be con-
sidered when characterising in vitro hepatic metabolic 
clearance methods, especially when employed for regu-
latory decision making (Gouliarmou et al., 2018), as well 
as continue to participate in the OECD expert group on 
biotransformation assays.
5.3.10 OECD Developmental Neurotoxicity 
Project
Scientists in developmental neurotoxicity (DNT) from 
academia, regulatory bodies and industry, across the 
world, reached an overall consensus that current data 
requirements for in vivo DNT testing are not sufficient to 
adequately screen and characterise compounds poten-
tially hazardous for the developing brain. They proposed 
to apply human in vitro DNT testing which together with in 
silico approaches will in the future allow development of 
predictive models for human DNT effects. This consensus 
statement (Fritsche 
et al., 2018) and 18 
other papers outlin-
ing novel concepts 
(i.e., AOP, IATA, 
ontology-dr iven 
animal-free test-
ing) as well as a 
range of alternative 
approaches (i.e., in 
vitro, zebrafish, C. 
elegans, in silico, 
a systems biology 
approach), have 
recently been pub-
lished in a DNT special issue of Toxicology and Applied 
Pharmacology entitled Alternative Approaches to Devel-
opmental Neurotoxicity Evaluation under an editorial 
lead of EURL ECVAM and the Leibniz Research Institute 
for Environmental Medicine  in Düsseldorf (Germany; 
Fritsche & Bal-Price, 2018).
EURL ECVAM together with international partners (EFSA, 
OECD, US EPA, academia) is developing a strategy with a 
focus on a battery of in vitro methods, preferably derived 
from human induced pluripotent stem cells (Bal-Price et 
al., 2018a). These methods permit evaluation of a chem-
ical impact on critical neurodevelopmental processes, 
mimicking different windows of human brain develop-
ment. Recently, readiness of these in vitro DNT assays for 
different regulatory purposes has been evaluated follow-
ing thirteen criteria established by DNT experts, including 
JRC-EURL ECVAM scientists (Bal-Price et al., 2018b). 
Available in vitro assays should be incorporated into IATA 
together with other sources of information (e.g., in silico 
methods, non-mammalian models as well as existing 
animal and human data). IATA development should 
be driven by a problem formulation and a battery of 
assays should be established based on 'fit-for-purpose' 
principles, delivering data for hazard identification/char-
acterisation or risk assessment. Such approach has been 
taken on board by the OECD project that aims to develop 
an OECD Guidance Document on in vitro methods for 
DNT testing. This project, co-led by EFSA, EC (through 
JRC-EURL ECVAM) and US EPA, was included in the OECD 
work programme in 2017 and a GD will be developed.
EURL ECVAM together 
with international 
partners (EFSA, OECD, 
US EPA, academia) is 
developing a strategy 
with a focus on a battery 
of in vitro methods, 
preferably derived 
from human induced 
pluripotent stem cells
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5.3.11 OECD Guidance Document on IATA for 
Non-genotoxic Carcinogens
Non-genotoxic carcinogens contribute to an increased 
cancer risk through a variety of mechanisms that are 
not yet directly included in international regulatory 
approaches. To address this need, an OECD expert work-
ing group was set up to develop an IATA on non-genotoxic 
carcinogens and to identify mechanistic assays which 
can be used to cover specific cellular and molecular 
events involved in the development of tumours (Jacobs 
et al., 2016). Among other activities, the working group 
has so far conducted an analysis of uncertainty in the 
rodent cancer bioassay (Paparella et al., 2017) and is 
expanding it to novel approaches. The main objective 
of this latter analysis is to transparently illustrate the 
complexity associated with the in vivo approach currently 
used and its actual performance in order to support the 
development of acceptance criteria for future novel 
approaches and IATA. 
One of the main achievements of this year was the 
agreement on a backbone structure of the IATA, which 
will serve to organise the available assays into levels 
of testing. So far, about 50 assays (mainly in vitro) 
have been collected. The level of readiness of these 
assays will be evaluated by the working group following 
Improving chemical testing approaches for devel-
opmental neurotoxicity assessment
Currently there is only very limited information on poten-
tial developmental neurotoxicity (DNT) effects of the many 
thousands of chemicals that we come into contact with in 
our daily lives. Experts on DNT from the JRC, US EPA, OECD 
and academia reached a consensus that this issue cannot be 
overcome with current regulatory testing approaches which 
are based solely on conventional animal tests. This is because 
animal models for DNT poorly reflect key features of human 
biology and disease and are typically very expensive and time 
consuming to conduct. Children are particularly vulnerable to 
DNT related health effects. Recent studies have clearly shown 
an increase in the prevalence of conditions such as autism, 
Box 5.4
learning disabilities, attention deficit and hyperactivity. While 
these disorders are due to a combination of multiple causes 
including inherited predisposition, environmental stressors and 
factors linked to socioeconomic status, both laboratory and 
human studies indicate that exposure to hazardous chemicals 
can contribute significantly to DNT related effects.
Recently, scientists from the EURL ECVAM and the Norwegian 
Institute for Public Health came together for a workshop to 
discuss the Children's health and exposure to environmental 
chemicals (see section 2.12). A particular focus was on the inte-
gration of multiple sources of information for DNT assessment 
derived from biomonitoring campaigns, epidemiological stud-
ies, computational models and in vitro methods. EURL ECVAM 
scientists propose to use mechanistic knowledge described 
in Adverse Outcome Pathways (AOPs) to rationally combine 
diverse but complementary data in the context of Integrated 
Approaches to Testing and Assessment (IATA).
Such IATA will address various regulatory needs including 
chemical screening and prioritisation, hazard identification 
and characterisation and the safety assessment of combined 
exposure to multiple chemicals (i.e., the 'mixtures' challenge). 
It is strongly believed that an application of currently available 
human-relevant in vitro models derived from induced pluri-
potent stem cells combined with other proposed non-animal 
approaches will permit development of predictive models for 
DNT effects for better protection of pregnant women, infants 
and children exposed to environmental chemicals.
Thus EURL ECVAM has been working with the DNT community 
to define a set of criteria that can be applied to judge the 
readiness of currently available in vitro methods for regulatory 
application (see section 5.3.10 and annex 2).
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well defined and agreed assessment criteria. A prelim-
inary analysis has identified assay gaps in the area of 
immunotoxicity/immunosuppression, however a further 
in-depth analysis will need to be conducted to identify 
further gaps in the database. 
5.3.12 OECD Detailed Review Paper on the 
Miniaturised Ames Test 
An OECD expert working group on the development of 
the miniaturised Ames test was established in November 
2016 with the aim to conduct a retrospective analysis of 
data obtained from the different miniaturised versions of 
the Ames test, and a comparative evaluation with Ames 
results from the classic test method. The ultimate aim 
is to draft a Detailed Review Paper (DRP) for an eventual 
incorporation of these methods into an updated version 
of the Ames test in OECD TG 471. Several miniaturised 
versions of the Ames test are used routinely as early 
screening methods in product development. The added 
value for the miniaturised versions of the test is mainly 
based on significant reduction of test material, on reduc-
tion of costs, and on the possibility for simultaneous 
analyses of a large number of samples. The inclusion of 
these versions of the Ames test in an updated version 
of the TG would allow more regulatory acceptance and 
integration of the test in genotoxicity testing.
Based on a decision from the kick-off meeting held in 
February 2017, the expert working group first launched 
an exploratory survey (May 2017) in order to obtain 
better insights in the use of the miniaturised Ames 
tests, the amount of 
data available for the 
different tests, and the 
extent to which these 
data can ultimately be 
shared. The results of the 
exploratory survey have 
served the call for actual 
data sharing that was 
opened in March 2018. 
In this context, EURL ECVAM extended the exploratory 
survey to its EU-NETVAL and followed up the request of 
data with the 37 Members of EU-NETVAL.
The expert working group worked on the definition of 
criteria for the evaluation of data (limit recommen-
dations, reproducibility, correspondence with standard 
Ames results, use of historical data, etc.) and conducted 
a preliminary review of data received and a check for 
completeness. So far, 18 companies have provided data 
for more than 200 unique substances, plus 150 coded 
compounds tested through various versions of the 
miniaturised Ames tests. Data analysis is foreseen to 
be completed by first quarter of 2019 in view of the DRP 
drafting which is running in parallel and in preparation of 
the request (SPSF) for eventual OECD TG 471 revision. 
5.3.13 OECD Guidance Document 150 on 
Standardised Test Guidelines for Evaluating 
Chemicals for Endocrine Disruption
The OECD Guidance Document 150 on Standardised Test 
Guidelines for Evaluating Chemicals for Endocrine Dis-
ruption was first published in 2012. It provides guidance 
on the interpretation 
of assays with 
respect to indications 
of endocrine disrup-
tion in order to 
support regulatory 
decision-making on 
the hazard of spe-
cific chemicals and 
toxicologically-rele-
vant metabolites. In 
particular, it provides 
guidance on how to interpret the outcome of individual 
tests and how to strengthen the weight of the evidence 
on whether or not a substance may be an ED.
Within this GD, the Conceptual Framework for Testing 
and Assessment of Endocrine Disrupting Chemicals 
lists the OECD TGs and standardised test methods 
available, under development or proposed, that can 
be used to evaluate chemicals for endocrine disrup-
tion. New methods that have been developed and 
validated or updated since 2012 have been added 
to the GD. Moreover it is now considering endocrine 
modalities beyond estrogens, androgens, thyroid and 
steroidogenesis, namely juvenile hormone, ecdysone 
©
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Several miniaturised 
versions of the 
Ames test are used 
routinely as early 
screening methods in 
product development
OECD GD 150 provides 
guidance on how to 
interpret the outcome 
of individual tests and 
how to strengthen the 
weight of the evidence 
on whether or not a 
substance may be an ED
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or retinoid modalities. Finally, the revised GD includes 
considerations on cross-species extrapolations, multiple 
modes of endocrine action, use of weight of evidence 
and adverse outcome approaches, and presents regula-
tory experience of assessment of endocrine disrupting 
chemicals from various regions of the world.
The revised version of the GD 150 has been adopted 
by the WNT in April 2018 and published (OECD, 2018d).
5.3.14 Detailed Review Paper on the Retinoid 
System 
Under the co-lead of EC and Sweden, a DRP on the reti-
noid system is being drafted. The focus on the retinoid 
system responds to the need to extend our knowledge on 
endocrine disruption beyond the estrogen, androgen, and 
thyroid hormone signalling pathways. The document will 
describe the general background of the retinoid system, 
including cross-species comparisons, and focuses on 
the role of retinoids within various organs or systems. It 
will also include some information on tests and markers 
relevant to retinoid disruption with potential relevance 
for regulatory testing.
5.3.15 Update of OECD TG 408 on the Repeated 
Dose 90-day Oral Toxicity Study and TG 414 on 
the Prenatal Developmental Toxicity Study
In 2018, two OECD in vivo Test Guidelines have been 
updated to include endpoints relevant to endocrine disrup-
tion. This activity embraces the 3Rs since more information 
can be obtained from the same number of animals.
The repeated dose 90–day oral toxicity study in rodents 
(TG 408) has been updated to include: the measurement 
of thyroxine (T4), triiodothyronine (T3), thyroid stimulat-
ing hormone (TSH) and thyroid gland weight. In addition, 
the measurement of serum total cholesterol, low-density 
lipoproteins (LDL) and high-density lipoproteins (HDL) 
are also now required, as these parameters are directly 
controlled by thyroid hormone action and contribute 
(with other thyroid endpoints) to evidence of thyroid 
effects. Optional endpoints include other hormone meas-
urements and assessments of sperm parameters.
The prenatal developmental toxicity study (TG 414) was 
updated by inclusion of the measurement of anogenital 
distance in all foetuses, and, in dams, the measurements 
of thyroid hormones levels (T3, T4 and TSH), thyroid 
weight and histopathology, and (optionally) measure-
ments of other hormones if relevant. It should be noted 
that the newly added requirements are rat-specific (thus 
do not apply to rabbits).
5.3.16 Development of an OECD Guidance 
Document on Good Licensing Practices for 
Intellectual Property Elements in OECD Test 
Guidelines
A new project proposal for the development of a guid-
ance document describing principles on good practices 
for the availability and distribution of protected elements 
in OECD TGs was approved at the 30th WNT meeting 
in 2018. It follows up on the recommendation of an 
OECD expert workshop on IPR held in September 2017 
(OECD, 2018o), that more guidance, transparency and 
communication are needed for protected elements in 
new technologies included in OECD TGs.
The document explains the process and documentation 
needed by the TG Programme at various steps of TG 
development. More-
over, it includes the 
principles and con-
ditions for accepting 
protected elements in 
TGs, and lays out the 
conditions to meet for 
the distribution and 
availability of the pro-
tected elements, and 
for the development of 
similar methods based on Performance Standards. The 
draft GD underwent a first commenting round by the 
WNT in October 2018.
READ MORE
m Intellectual Property elements in OECD Test Guidelines: 
www.oecd.org/chemicalsafety/testing/intellectual-proper-
ty-in-oecd-test-guidelines.htm
5.3.17 OECD Harmonised Templates
The OECD Harmonised Templates (OHTs) for reporting 
chemical test summaries are standard data formats 
which are publicly available. They are designed to report 
information used for the risk assessment of chemicals, 
mainly studies done to determine the chemical proper-
ties or effects on human health and the environment, 
and also (since 2016) to describe their use and related 
exposure to workers, consumers and the environment. 
The 2017/2018 OECD revision of the OHTs included a 
series of updates, technical improvements and comple-
tions identified by OECD and template users over the 
past years. The changes contributed to harmonising 
the elements considered, the closed vocabulary and 
the terminology used in the OHTs. The template format 
More guidance, 
transparency and 
communication are 
needed for protected 
elements in new 
technologies included 
in OECD TGs
55
 
PROMOTING THE REGULATORY ACCEPTANCE AND INTERNATIONAL ADOPTION OF ALTERNATIVE METHODS AND APPROACHES
was simplified, and new templates made available 
including the one on intermediate effects (OHT 201), 
which was developed by 
the JRC-EURL ECVAM, by 
applying its in-house knowl-
edge (predictive toxicology, 
toxicity pathways and assay 
validation), and involving 
ECHA as well as external 
stakeholders. This OHT on 
‘Intermediate effects’ allows 
reporting of non-apical 
observations during in vitro 
testing, e.g., intermediate 
effects at molecular, sub-
cellular, cell, tissue or organ 
level which can be relevant 
when studying the hazard posed by a compound (and 
possibly inform the adverse outcome pathways).
The JRC-EURL ECVAM is currently collaborating with the 
OECD and ECHA to endorse the use of OHT 201 for all 
in vitro test results, in particular those that are currently 
stored in less suitable "apical" (in vivo test–oriented) 
templates. This will make access and retrieval of in 
vitro test results easier for the AOP community and is 
intended to bridge the gap between chemical-agnos-
tic AOPs and real-life manifestations of the adversity 
described with them. Release of an updated OHT 201 is 
expected for 2019.
READ MORE
m OECD Harmonised Template 201: www.oecd.org/ehs/
templates/harmonised-templates-intermediate-effects.htm
5.3.18 eChemPortal
The OECD eChemPortal provides free public access to 
information on chemical properties and direct links to 
collections of information prepared for governmental 
chemical review programmes at national, regional, and 
international levels. Access to information on existing 
chemicals, new industrial chemicals, pesticides and 
biocides is provided. eChemPortal also makes avail-
able national/regional classification results according 
to national/regional hazard classification schemes or 
according to the Globally Harmonised System of Clas-
sification and Labelling of chemicals (GHS). In addition, 
eChemPortal provides also exposure and use informa-
tion on chemicals.
The JRC-EURL ECVAM is a member of the Steering Group 
for the management and further development of the 
eChemPortal, and as such provides expertise in both the 
subject matter (e.g., chemical risk assessment and study 
results) and the Information and Communications Tech-
nology (ICT) aspect.
In 2018, a series of technological improvements behind 
the scenes were decided and implemented (most impor-
tantly, a better and faster search), and the establishment 
of a Joint IUCLID Dissemination Portal was initiated, 
which will make it easier for JRC IUCLID-based DBs to 
become eChemPortal participants. IUCLID stands for 
International Uniform Chemical Information Database 
and is a software application to capture, store, maintain 
and exchange data on intrinsic and hazard properties 
of chemical substances. Distributed free of charge, the 
software is useful in particular to chemical industry com-
panies and to government authorities, e.g., IUCLID is the 
key tool for chemical industry to fulfil data submission 
obligations under REACH.
READ MORE
m eChemPortal: www.echemportal.org
m IUCLID: iuclid6.echa.europa.eu
5.4 Activities in the Extended Advisory Group 
on Molecular Screening and Toxicogenomics
 
5.4.1 Update on the AOP-Knowledge Base
AOPs are the central element of a toxicological knowl-
edge framework being built to support chemical risk 
assessment based on mechanistic reasoning. To enable 
the scientific community to share, develop and discuss 
their AOP-related knowledge in one central location, the 
OECD has, in parallel to the instigation of the overall AOP 
initiative, started the AOP-Knowledge Base (KB) project 
(see fig. 5.4). Within this project EURL ECVAM contributes 
to ICT design and analysis know-how, and co-manages 
the project together with the US EPA. AOP-KB consists 
of two modules, each tailored to specific needs; a third 
module titled e.AOP.Portal is the uniform search interface 
to retrieve AOPs from the other two; the data interchange 
format to be used between the AOP-KB modules, named 
AOP-XML, was developed by EURL ECVAM.
The first AOP-KB module available to the public 
was the AOP-KB Wiki, a system that organises, via 
The 2017/2018 
OECD revision 
of the OHTs 
included a series of 
updates, technical 
improvements 
and completions 
identified by OECD 
and template users 
over the past years
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crowd-sourcing, the available knowledge and pub-
lished research into a verbal description of individual 
pathways, via a user friendly wiki interface. Con-
trolled-vocabulary drop-down lists from which to select 
methods, actions, biological objects, life stages, species, 
etc., related to the AOP had already simplified the entry 
of standardised information.
The introduction of ontologies to further harmonise 
the naming of AOP objects was implemented as a next 
step in the AOP-KB 
Wiki. While the AOP-
Wiki had always 
combined both 
free text fields and 
closed vocabulary 
to describe mecha-
nistically linked Key 
Events (KEs) and 
their Relationships 
(KERs), a new version 
of the Wiki (version 2.0) came with a full implementation 
of the ontology concept. The ontology-based annotations 
to AOP-KB objects are aimed to facilitate and improve 
the systematic re-use of KEs by minimising redundancy 
and also allowing for more flexibility in naming the KEs 
according to their AOP-specific context. Ontologies as 
computer readable descriptions of the biological com-
ponents will drive the possibility to find connections and 
make inferences between KEs at different levels of gran-
ularity, thereby facilitating the automatic development 
of AOP networks. Overall, the introduction of a controlled 
terminology in the AOP-Wiki represents a significant 
advancement for the progress and optimisation of the 
AOPs and it will ultimately be beneficial also for other 
modules of the AOP-KB.
The introduction of the AOP concept into the area of 
chemical risk assessment is a major milestone towards 
the goal of identifying, assessing and ultimately accept-
ing alternatives to animal tests for regulatory purposes. 
Without the AOP-KB tool, the AOP concept would remain 
a theoretical idea without any real-life impact. By facili-
tating the collection and also discussion of AOP-related 
information, the AOP-KB anchors this novel concept 
firmly in the scientific and regulatory environments, 
which is a prerequisite for a world with less animal 
testing. The new concept of IATA profits from the AOP 
Figure 5.4  The Adverse Outcome Pathway Knowledge Base (AOP-KB).
Overall, the introduction 
of a controlled 
terminology in the 
AOP-Wiki represents a 
significant advancement 
for the progress and 
optimisation of the AOPs
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concept, as it informs scientists and regulators about the 
biology behind a chemical's mode of action which needs 
to be modelled in in vitro and in silico methods.
While the current version of AOP-KB is fully functional 
and well maintained, in 2018, the decision was taken 
to redesign the knowledge base with a view to better 
accommodating knowledge users (as opposed to knowl-
edge providers) needs and to thereby further promoting 
the AOP framework as such. Release of an updated 
AOP-KB 2.0 is expected in the coming years.
READ MORE
m e.AOP.Portal: aopkb.oecd.org
m AOP Wiki: aopwiki.org
m Adverse Outcome Pathway Knowledge Base (AOP-KB): 
aopkb.oecd.org/index.html
5.4.2 Development of Adverse Outcome 
Pathways Relevant to Neurotoxicity
EURL ECVAM was involved in the development of an 
AOP entitled "Inhibition of the mitochondrial complex I 
of nigra-striatal neurons leads to parkinsonian motor 
deficits" in collaboration with EFSA which has been 
endorsed by WNT/WPHA and published by OECD (Bal-
Price et al., 2018c).
An AOP related to the disruption of the synthesis of 
thyroid hormone entitled "Inhibition of Na+/I- sym-
porter (NIS) leads to learning and memory impairment" 
passed an external OECD reviewing process and soon 
it will be forwarded to the OECD's WNT/WPHA for a 
final endorsement. 
AOP 13 entitled "Chronic binding of antagonist to 
N-methyl-D-aspartate receptors (NMDARs) during 
brain development induces impairment of learning and 
memory abilities" already endorsed by OECD in 2017 
has been published in an open access format in Tox-
icology and Applied Pharmacology DNT special issue 
(Sachana et al., 2018). This AOP has been used as the 
backbone of a project of the University of Lausanne 
(Department of Physiology) where quantitative meas-
urements of Key Events Relationships identified in this 
AOP will be performed using brain aggregates derived 
from Human induced Pluripotent Stem Cells (hiPSCs, a 
project supported by Cefic). Most of the current AOPs 
are comprised of qualitative pathway descriptions, and 
further experimental work is required to develop the 
response-response relationships between key events in 
quantitative terms. These AOPs follow publicly availa-
ble conventions adopted in the OECD AOP development 
programme to permit tailored application of AOPs for a 
range of different regulatory purposes.
READ MORE
m AOP 3 - Mitochondrial dysfunction and Neurotoxicity: 
aopwiki.org/aops/3
m AOP 54 - NIS inhibition and learning and memory impair-
ment: aopwiki.org/aops/54
m AOP 13 - Binding of antagonist to NMDARs impairs cog-
nition: aopwiki.org/wiki/index.php/Aop:13
5.4.3 Transcriptomics Reporting Framework 
The lack of standardised reporting frameworks was 
recognised among the obstacles that limit the reg-
ulatory uptake of 'omics data (Buesen et al., 2017). 
For this reason, under the auspices of the Extended 
Advisory Group on Molecular Screening and Toxicog-
enomics (EAGMST), a project was initiated, which 
aims to develop frameworks for the standardisation 
of reporting of 'omics data generation, and analysis, 
to ensure that all information required to understand, 
interpret and reproduce an 'omics experiment and its 
results are available. The project will initially focus on 
the development of a guidance document for reporting 
of transcriptomics data. Similar activities for metabo-
lomics and proteomics will follow.
A working group is already working on the transcrip-
tomics reporting framework (TRF) which will have a 
modular structure. It will include an introductory and an 
experimental module that will be independent of the 
'omics platform 
used. These will be 
followed by 'omics' 
platform-depend-
ent modules on 
the description of 
sample process-
ing procedures, 
methods used to 
collect raw data 
and methods used 
to generate processed data and identify differentially 
expressed genes. Modules for more complex downstream 
analyses will also be drafted.
For the experimental module, the working group, chaired 
by EURL ECVAM, will pay particular attention to align it 
with other existing OECD documents. Finally, a round-
robin case study will be conducted to evaluate the utility 
of the TRF in fostering reproducibility of 'omics data 
analyses by different research groups.
Under the auspices of the 
EAGMST, a project was 
initiated, which aims to 
develop frameworks for 
the standardisation of 
reporting of 'omics data 
generation, and analysis
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5.5 VICH Guideline on Vaccines: 
Harmonisation of Criteria for Waiving of 
Laboratory Animal Batch Safety Testing of 
Vaccines for Veterinary Use 
The requirements on batch safety testing differ between 
the various geographic regions. For example, general 
safety tests for batch release of human and veterinary 
vaccines are no longer required in Europe and were 
deleted from European Pharmacopoeia monographs 
several years ago (abnormal toxicity test; Schwanig et 
al., 1997) or recently (target animal batch safety test; 
EDQM, 2012). Since these tests may still be required 
outside of Europe, European manufacturers may need to 
carry out these tests when exporting to third countries.
For many years, EURL ECVAM has been working on 
behalf of EMA with experts of the International Coop-
eration on Harmonisation of Technical Requirements 
for Registration of Veterinary Medicinal Products (VICH) 
on the development of 
VICH guidelines on har-
monisation of criteria to 
waive the target animal 
/laboratory batch safety 
testing for vaccines for 
veterinary use (see sec-
tion 5.4 in Zuang et al., 
2017). Since May 2018, 
two VICH guidelines are 
in force that establish 
criteria for waiving the target animal batch safety test 
for inactivated (VICH GL50(R); VICH, 2017a) and live vac-
cines (VICH GL55; VICH, 2017b). A third guideline is under 
development aiming at the harmonisation of criteria to 
waive the general batch safety test in laboratory animals 
(e.g., abnormal toxicity test) for veterinary vaccines.
READ MORE
m Two new guidelines for the reduction of animal tests 
for quality control of veterinary vaccines – News item: 
europa.eu/!CN98kT
5.6 Promoting Regulatory Acceptance in 
the Frame of EMA: J3Rs Working Group
The Joint Committee for Medicinal Products for Veterinary 
Use (CVMP)/Committee for Medicinal Products for Human 
Use (CHMP) Working Group on the Application of the 3Rs 
in Regulatory Testing of Medicinal Products (J3Rs WG) 
provides advice to the CVMP and the CHMP on all matters 
concerning the use of animals in regulatory testing of 
medicines with particular focus on the application of the 
3Rs principles. J3Rs WG, formerly established by EMA in 
2016 as successor of the JEG 3Rs, consists of a core group 
of European experts from each of the existing CVMP and 
CHMP Working Parties for which animal testing is relevant, 
experts on 3Rs 
and representa-
tives from EDQM 
and the European 
Commission (e.g., 
EURL ECVAM). In 
this context, EMA 
has created a new 
section on its web-
site on the ethical 
use of animals in 
the testing of med-
icines which describes the various activities and provides 
links to collaborators and stakeholders.
The first biennial report of the J3Rs WG was published 
in 2018 (EMA, 2018a). It summarises the mandate of 
J3Rs, the workplan for 2018-2019 and refers to new 
publications, e.g., a guidance aiming at vaccine quality 
control methods and use of data generated in collabo-
rative trials for product-specific validation (EMA, 2017) 
or two reflection papers providing overviews of the 
current regulatory testing requirements for medicinal 
products for veterinary/human use and opportunities 
for implementation of the 3Rs (EMA, 2018b,c). In June 
2018, J3Rs WG organised training on 3Rs for assessors 
of veterinary vaccines within the framework of the EU 
Network Training Centre (EU NTC), which is an initiative 
set up by the Heads of Medicines Agencies (HMA) in the 
EU Member States and EMA. The training was hosted by 
the Danish Medicines Agency.
READ MORE
m Ethical use of animals in medicine testing: www.ema.
europa.eu/human-regulatory/research-development/
ethical-use-animals-medicine-testing
m EU Network Training Centre (EU-NTC): www.hma.eu/otsg.
html
5.7 Activities of EPAA to Promote the 
Regulatory Acceptance of Alternative 
Methods 
The European Partnership for Alternative Approaches to 
Animal Testing (EPAA) is a public-private collaboration 
between the European Commission, European trade 
associations and companies from seven business sectors. 
The partners are committed to pooling knowledge and 
resources to accelerate the development, validation and 
acceptance of alternative approaches to animal use in 
Since May 2018, two 
VICH guidelines are in 
force that establish 
criteria for waiving 
the target animal 
batch safety test for 
inactivated and live 
vaccines
EMA has created a new 
section on its website on 
the ethical use of animals 
in the testing of medicines 
which describes the various 
activities and provides 
links to collaborators and 
stakeholders
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regulatory testing. The overall aim is the replacement, 
reduction and refinement (3Rs) of animal use in regula-
tory testing. JRC, represented by EURL ECVAM, is one of 
the Commission services that are members of the EPAA.
In recent years, EPAA focussed mainly on the promotion 
of regulatory issues and user acceptance. In this context, 
EPAA runs a number of projects that are described in the 
sections below. The partnership also engages in training 
and dissemination activities (see section 6.5). An overview 
of the EPAA activities in 2017 is given in the EPAA Annual 
Reports that are publicly available online, the most recent 
one covering the year 2017.
A former EPAA activity regarding the consistency 
approach for various vaccines set the ground for the 
current Horizon 2020 project "VAC2VAC - Vaccine batch 
to vaccine batch comparison by consistency testing" 
(see section 2.5).
READ MORE
m EPAA, European Partnership for Alternative Approaches 
to Animal Testing: europa.eu/!rq76qf
m EPAA Annual Report 2017: europa.eu/!tk44bD
5.7.1 Optimised Evaluation of Skin Sensitisation 
3D skin tissue models provide a more realistic rep-
resentation of the skin structure and organisation 
compared to 2D cell cultures and they have the potential 
to overcome some of the drawbacks of the aqueous 
medium-based cell culture models, for example those 
associated with the testing of hydrophobic and other 
"difficult to test" substances.
In December 2015, the EPAA skin sensitisation team 
launched a collaborative project aimed at gaining a 
better understanding on the performance of three meth-
ods based on 3D skin models (Reconstructed human 
Epidermis (RhE) IL-18 test method, SensCeeTox and 
SENS-IS) for predicting skin sensitisation hazard and 
potency categorisation by testing a set of 12 difficult 
substances, selected for their relevance to industry. In 
2018, the testing was finalised and the results were pre-
sented at the EUROTOX 2018 congress. A peer-reviewed 
publication report-
ing the outcome 
of the study is in 
preparation. Moreo-
ver, the team aims 
at continuing the 
series of workshops 
in partnership with 
Cefic LRI and Cos-
metics Europe to 
share experience 
on the latest avail-
able methods and 
approaches, and their applicability or limitations in meet-
ing regulatory safety requirements for skin sensitisation. 
The organisation of a new workshop to be held in the 
first half of 2019 at the ECHA premises has started.
READ MORE
m 54th Congress of the European Societies of Toxicology 
(EUROTOX 2018): www.eurotox-congress.com/2018
5.7.2 Waiving of the Two-year Carcinogenicity 
Studies
A new project co-chaired by scientists from the Dutch 
National Institute for Public Health and the Environment 
(RIVM), industry and EURL ECVAM was initiated last year. 
It represents a follow-up of the previous carcinogenic-
ity project for pharmaceuticals. The latter showed that 
taking into account the results of the three to six month 
rat studies and the pharmacological properties of a phar-
maceutical substance may lead to a reliable prediction 
of a carcinogen without the need for two-year carcino-
genicity studies (van der Laan et al., 2016). The present 
project aims at assessing whether the same approach 
can also be applied to agrochemicals, namely to provide 
evidence that data from 3-month repeated dose toxicity 
studies together with mechanistic-based parameters can 
be leveraged to predict human relevant carcinogenic 
potential of agrochemicals with reduced or no need 
for a two-year carcinogenicity study.  Literature search 
for more than 400 agrochemicals is being conducted 
which should result in an overview of the main Modes 
of Actions (MOAs) involved in carcinogenesis triggered 
by these chemicals. In collaboration with industrial part-
ners the proposed novel approach will be evaluated with 
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a couple of case studies. The results will be discussed 
and shared with experts from industry, academia and 
regulatory agencies during a dedicated workshop.
5.7.3 Acute Toxicity 
As described in the previous EURL ECVAM status report 
(see section 5.6.3 in Zuang et al., 2017), a data mining 
exercise is carried out as part of the EPAA acute toxicity 
project, which aims to identify clinical signs predictive 
of mortality at higher dose levels. The ultimate goal is 
to propose an animal-free decision framework for acute 
systemic toxicity testing. Nevertheless, in those cases 
where animal usage cannot be avoided, the intention is 
to recommend the replacement of death as an endpoint 
by clinical signs predictive of mortality.
The project, initiated in 2015, is done in close collabo-
ration with the UK National Centre for the Replacement, 
Refinement and Reduction of Animals in Research 
(NC3Rs) and the UK Chemicals Regulation Directorate 
(CRD). A large number of studies have been coded and 
analysed against the acceptability criteria. Only a few 
meet the criteria, making the final set of studies insuf-
ficient to support a robust statistical analysis. The team 
is currently discussing possible solutions to complete 
successfully the project.
5.7.4 Clostridial Vaccine Project
The EPAA clostridial vaccines group evaluated Vero cell 
based assays to replace the Minimum Lethal Dose and 
Total Combining Power assays required for in-process 
control of Clostridium septicum vaccines. The collabora-
tive study was carried out in collaboration with the EDQM 
BSP and the outcome 
of study BSP130 was 
discussed with the 
study participants 
at a workshop in 
September 2015 
(Sinitskaya et al., 
2016). The results 
show that the in vitro 
assays are repeata-
ble and reproducible and that there is excellent overall 
concordance with the mouse tests. However, in order to 
fully exploit the advantage of the Vero cell assays, some 
further work is needed.
A follow-up study (BSP130 III) with 14 participants was 
performed during 2016-2017 aiming at the further 
optimisation of the Vero cell assays to increase their 
sensitivity and accuracy. The final report of the study 
should become available in 2018 and a dissemination 
workshop is planned for 2020. Adaptations of the Vero 
cell assays to other clostridial vaccines is evaluated in 
the VAC2VAC project (see section 2.5).
READ MORE
m EDQM Biological Standardisation programme (BSP): www.
edqm.eu/en/work-programme-bsp
5.7.5 Human Rabies Vaccine Project
The project aims at replacing the in vivo test carried out 
for batch potency testing of human rabies vaccines with 
an in vitro antigen quantitation test (e.g., an enzyme-
linked immunosorbent assay (ELISA) determing the 
glycoprotein-G content in rabies vaccines). Out of three 
different ELISAs used by manufacturers and control 
authorities, the most suitable ELISA has been identified 
(Morgeaux et al., 2017) and is now validated under the 
umbrella of EDQM BSP. The BSP148 project "Validation 
of a rabies in vitro potency assay" was launched in 2017 
and has attracted global interest during 2018. 
READ MORE
m EDQM Biological Standardisation programme (BSP): www.
edqm.eu/en/work-programme-bsp
5.7.6 Harmonisation on Biologicals
This EPAA project aims at progressing harmonisation of 
requirements for batch testing of vaccines and other 
biological products at a global level.  The project team 
is following up the recommendations of a workshop 
held in 2015 (Schutte et al., 2017) in collaboration 
with workshop participants and relevant stakeholders. 
For example, requests for revision on removal of the 
abnormal toxicity test from 49 monographs have been 
drafted by the Paul-Ehrlich Institute in Germany and 
presented to the European Pharmacopoeia Commission 
via the German Pharmacopoeia. In November 2017, the 
European Pharmacopoeia Commission endorsed the 
deletion of the abnormal toxicity test and agreed to the 
revision of the monographs (EDQM, 2017). Revised mon-
ographs will come into force in 2019. In collaboration 
with DG Health and Food Safety (DG SANTE), the group 
approached the World Organisation for Animal Health 
and references to the VICH GL50 and 55 (see section 5.5) 
have been included into the "Manual of Diagnostic Tests 
and Vaccines for Terrestrial Animals 2018". 
At present, the group is evaluating the choice of meth-
ods for pyrogenicity testing, e.g., test in rabbits, bacterial 
endotoxin test or monocyte activation test, and what the 
barriers to the use of the in vitro methods are.
The results show that 
the in vitro assays 
are repeatable and 
reproducible and that 
there is excellent overall 
concordance with the 
mouse tests
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READ MORE
m Recommendations to delete or replace animal tests 
for quality control of biologicals - News item: europa.
eu/!nR76yy
m Manual of diagnostic tests and vaccines for ter-
restrial animals 2018: www.oie.int/standard-setting/
terrestrial-manual/access-online
5.8 UN subcommittee on Globally 
Harmonised System of Classification and 
Labelling of Chemicals (GHS)
5.8.1 Working Group on Introduction of 
Alternatives in the GHS Criteria
The UN sub-committee on GHS agreed to address the 
use of non-animal testing methods for classification of 
health hazards within its programme of work for the 
2017-2018 biennium, and therefore the informal work-
ing group “Use of non-animal testing methods for 
classification of health hazards” was established, cur-
rently including about 50 members. Under the lead of 
NL and UK, the working group has re-drafted the current 
GHS chapter on skin corrosion/irritation to include 
non-animal methods, i.e., internationally adopted in vitro 
OECD TG methods, as well as further elaborate the text 
on non-testing methods.
JRC through EURL ECVAM is contributing to the work of 
the group, and the aim is now to present a final revision 
of this chapter for adoption within this biennium. The 
plan is then to continue to look at serious eye damage/
irritation and skin sensitisation, for which EURL ECVAM 
is preparing the discussions with support of NL and UK, 
respectively. Thereafter, it will be necessary to tackle 
the systemic health effects, which will be both inter-
esting and challenging, as it might trigger the start to 
create a more efficient international system to evaluate 
chronic health hazards based on non-animal data and 
mechanistic knowledge.
5.8.2 United Nations Model Regulations for 
Transport of Dangerous Goods Subcommittee 
on Transport Packing Groups for Corrosion
At their summer 2018 session, the UN sub-committee 
on Transport of Dangerous Goods (TDG) discussed the 
proposal from the 
European Commis-
sion, presented by 
JRC EURL ECVAM, 
to update the text 
with regard to Test 
Guideline 431 "In 
vitro skin corrosion: 
R e c o n s t r u c t e d 
Human Epidermis 
(RhE) Test Method" 
(2016), to allow for 
sub-classification 
in packing group 1, and recommended precautionary 
classification in packing group 2, if not possible to dis-
tinguish between packing group 2 and 3. TG 431 allows 
for separation into all three packing groups, but when 
revised at the OECD, there were not enough chemicals 
identified to belong to packing group 3 to enable valida-
tion of this sub-category. 
The UN subcommittee is expected to adopt the revision 
related to TG 431 at their December 2018 meeting, and 
thereby allow that the vast majority of corrosive chem-
icals can be classified based on in vitro data to ensure 
safe transport of chemicals worldwide.
5.9 Activities within the International 
Cooperation on Cosmetics Regulation (ICCR)
5.9.1 ICCR Joint Regulators-Industry Working 
Group on "Integrated Strategies for Safety 
Assessments of Cosmetic Ingredients"
Animal testing for the safety assessment of cosmetic 
ingredients and products has been completely banned 
in the EU. The safety of cosmetics therefore needs to be 
The UN subcommittee 
is expected to adopt the 
revision related to TG 431 
and thereby allow that the 
vast majority of corrosive 
chemicals can be classified 
based on in vitro data to 
ensure safe transport of 
chemicals worldwide
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ensured by new methods and strategies. This is in line 
with a general shift in toxicology from testing in whole 
organisms as a “black box” towards understanding the 
mechanisms behind adverse effects, allowing for a more 
informed and targeted evaluation of chemicals. 
In Part 1 of a report (ICCR, 2017), the ad hoc ICCR Joint 
Regulators-Industry Working Group (JWG) on "Integrated 
Strategies for Safety Assessments of Cosmetic Ingredi-
ents" had outlined overarching principles that underpin 
the integration of novel methods and data for the safety 
assessment of cosmetic ingredients, or ‘next generation’ 
risk assessment, which have also been published in a jour-
nal Special Issue on “In Silico Approaches for the Safety 
Assessment of Cosmetic-Related Substances” (Dent et 
al., 2018). The four main principles for an integrated 
strategy for risk assessment 
of cosmetics ingredients set 
human-relevant risk assess-
ment and prevention of 
harm as overall goals, while 
basing the assessment on a 
mechanistic hypothesis and 
considering the exposure 
scenario. The other five 
principles describe how the 
assessments should be con-
ducted and documented.  EURL ECVAM has continued to 
contribute to the working group and writing of Part 2 of 
the report, which provides some additional guidance to 
safety assessors on the types of NAMs that may be used 
in a ‘next generation’ risk assessment. The report was 
adopted at the 12th ICCR Annual Meeting in Tokyo in July 
2018 (ICCR, in preparation). The scope of NAMs consid-
ered in the report includes for example computational 
modelling approaches, read-across and exposure-based 
waiving, in chemico methods, in vitro testing in cell lines 
or 3D culture systems, organ-on-chip, ‘omics or reporter 
gene assays. 
READ MORE
m International Cooperation on Cosmetics Regulation 
(ICCR): www.iccr-cosmetics.org
m  Report from the Commission to the European Parliament 
and the Council on the development, validation and legal 
acceptance of methods alternative to animal testing in 
the field of cosmetics (2015-2017), COM/2018/531 final: 
europa.eu/!CG77Vc
m Computational Toxicology Special Issue “In Silico 
Approaches for the Safety Assessment of Cosmetic-
Related Substances”: www.sciencedirect.com/journal/
computational-toxicology/special-issue/10P3BXBLJLK
5.9.2 ICCR Allergens II Joint Working Group
Both regulators and industry within ICCR agreed that 
the topic of allergens in the context of cosmetics 
remains of high importance. EURL ECVAM is supporting 
DG Internal Market, Industry, Entrepreneurship and SME 
(DG GROW) representation in the ICCR by contribut-
ing to the activities of the Allergens II Joint Working 
Group (JWG). The JWG is currently working on a report 
investigating how combination of non-animal methods 
recently adopted by OECD may be used within IATA to 
adequately substitute for animal tests in the evalua-
tion of skin sensitisation potential. Once finalised and 
agreed by the ICCR, the report will be made publicly 
available on the ICCR website.
5.10 Activities with EC Directorate General 
Communications Networks, Content and 
Technology
In November 2017, EURL ECVAM participated at the 
DG Communications Networks, Content and Technology 
(DG CNECT) meeting on "Health, demographic change 
and well-being Workshop "In-silico" health new pro-
jects and regulatory needs", held in Brussels, Belgium. 
During this meeting seven projects (granted under 
H2020-SC1-2016-2017 personalised medicine, type of 
action Research and Innovation action (RIA): SC1-PM-
16-2017 and SC1-PM-17-2017) were presented by the 
project coordinators. Out of these projects, EURL ECVAM 
was invited to two of the project kick-off meetings, and 
will follow these projects up to completion:
1. REPO-Trial: An in silico-based approach to improve the 
efficacy and precision of drug REPurpOsing TRIALs for a 
mechanism-based patient cohort with predominant cer-
ebro-cardiovascular phenotypes. (21-23/02/2018).
2. StrituVad: In Silico Trial for Tuberculosis Vaccine Devel-
opment (19-20/03/2018).
In connection to the topic of in silico medicine, EURL 
ECVAM was asked to contribute to a white paper on 
Computational Modelling and Simulation (CM&S) and 
medicinal products’ lifecycle that the Avicenna Alliance 
Consortium presented at the European Parliament in
Animal testing 
for the safety 
assessment of 
cosmetic ingredients 
and products has 
been completely 
banned in the EU
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International Cooperation on Cosmetics Regulation 
(ICCR)
The ICCR is a voluntary international group of cosmetics 
regulatory authorities from Brazil, Canada, the European 
Union, Japan, and the United States. This group of regula-
tory authorities meets on an annual basis to discuss common 
issues on cosmetics safety and regulation, and to enter into 
a constructive dialogue with their relevant cosmetics industry 
trade associations. The purpose of this multilateral framework 
is to maintain the highest level of global consumer protection, 
while minimizing barriers to international trade.  
Box 5.5
Brussels on 4 September 2018. This document aims at 
proposing cornerstones regulatory and ethical frame-
works for CM&S in the life cycle of a new medicine. 
READ MORE
m REPO-Trial: cordis.europa.eu/project/rcn/212939_it.html 
and repo-trial.eu
m StrituVad: cordis.europa.eu/project/rcn/212940_it.html
m International Avicenna Alliance Conference - 4 
September 2018: avicenna-alliance.com/news/news/
in-vivo-in-vitro-in-silico-why-computer-modelling-is-the-
next-evolution-of-the-healthcare-sector
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Information on Alternatives
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 6.1 EURL ECVAM Databases 
The dissemination of information about alternative 
approaches (e.g., in vitro techniques and in silico models) 
and of chemical datasets contributes to the advance-
ment and strengthening of the Three Rs knowledge. In 
this context, publicly accessible information systems 
not only can facilitate the engagement of the scien-
tific community through the sharing and exploitation of 
existing data and information, but they can also inform 
regulators and assist educational and training activities. 
The EURL ECVAM coordinated information systems and 
services serve this purpose and are described in the 
following sections. 
6.1.1 DB-ALM—EURL ECVAM’s Database 
Service on Alternative Methods to Animal 
Experimentation 
DB-ALM is an open-access public repository which 
provides information on the alternative (non-animal) 
methods in the field of biomedical sciences and toxicol-
ogy. DB-ALM aims at facilitating the sharing of detailed 
and structured descriptions of alternative methods used 
in research and for regulatory purposes. Two different 
types of method descriptions are available: 
• the method summary reviewing the objectives and 
applications of a method, the scientific rationale for 
its experimental design, its status of development and, 
when applicable, regulatory acceptance. The method 
summary format is compliant with the OECD Guidance 
Document No. 211 for Describing Non-Guideline In 
Vitro Test Methods (OECD, 2014d).
• the protocol providing a step-by-step documentation 
with technical details and supporting materials to 
enable the implementation of a method in a laboratory.
DB-ALM currently contains 180 method summaries 
and 167 protocols downloadable as PDF documents. 
The DB-ALM repository can be searched both via free 
text and by advanced search, which allows the con-
struction of structured queries with keywords used for 
content annotation.
Initiatives to further facilitate access to the information 
about alternative methods are underway such as open-
ing access to the DB-ALM content without the need to 
log in. In addition, an active link has been implemented 
to interlink DB-ALM with another EURL ECVAM hosted 
system, TSAR (see section 6.1.2). 
Dissemination of Information on 
Alternatives
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READ MORE
m DB-ALM: ecvam-dbalm.jrc.ec.europa.eu
6.1.2 TSAR – Tracking System for Alternative 
Methods towards Regulatory Acceptance
TSAR allows to track in a transparent manner the pro-
gress of an alternative method, from the early phases 
of the validation process to its eventual inclusion into 
the regulatory framework (e.g., EU legislation, OECD Test 
Guidelines or Guidance documents, European Pharma-
copoeia, International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceu-
ticals for Human Use (ICH), International Cooperation on 
Harmonisation of Technical Requirements for Registra-
tion of Veterinary Medicinal Products (VICH), International 
Organisation for Standardisation (ISO) etc.).
TSAR, which is developed and hosted by EURL ECVAM, 
aims at disseminating information on methods that 
are considered by all the member organisations of the 
International Cooperation on Alternative Test Methods 
(ICATM) representing the EU, Canada, USA, South Korea, 
Brazil, China and Japan. 
TSAR provides an overview of the status of a method, 
from being proposed for validation until the eventual 
regulatory acceptance. This overview is performed with 
the support of a colour-coding visualisation that shows 
whether the different steps of the process - submission, 
validation, peer-review, 
recommendations and 
regulatory acceptance 
- are ongoing or com-
pleted. For each TSAR 
record, relevant infor-
mation, documents 
or links associated 
to each step are also 
provided. During the 
reporting period, a 
direct link to DB-ALM 
protocols has been 
introduced, where applicable, thus providing a more 
complete and easy-to-access documentation about the 
validated and regulatory accepted methods.
READ MORE
m TSAR: tsar.jrc.ec.europa.eu
6.1.3 JRC QSAR Model Database
The JRC Quantitative Structure Activity Relationship 
(QSAR) Model database is freely available to users and 
developers and aims to provide users with scientifically 
valid QSARs that can be used to support the risk assess-
ment of chemicals for regulatory purposes such as 
REACH. The database 
can be searched with 
free text, author names, 
chemical structures 
(including similarity to 
a specific structure), or 
title and QSARs can be 
freely downloaded. The 
developers of QSARs 
are welcome to submit 
their models to the 
JRC database using the QSAR Model Reporting Format 
(QMRF), which is an internationally agreed reporting 
format that facilitates the reporting of the five prin-
ciples of the OECD for the validation of QSARs (OECD, 
2007) and ensures harmonised reporting for all models. 
An editor for the compilation of QMRFs has been made 
available through the website.
During the reporting period of this Status Report, an 
entirely new JRC QSAR Model Database version has been 
released to enhance user interface and information dis-
play. The new database and QMRF also accept models 
for Nanomaterials. The database currently contains 
147 QSAR models grouped according to OECD defined 
endpoints and covering physicochemical properties, 
environmental fate parameters, toxicokinetics, ecotox-
icological and human health effects.
READ MORE
m QSAR Model Database: qsardb.jrc.ec.europa.eu/qmrf
m REACH Regulation: ec.europa.eu/environment/chemicals/
reach/reach_en.htm
6.1.4 Open Access Datasets 
In 2016, the JRC released its Data Catalogue which 
addresses, among others, the legal obligations from 
the European Commission's Reuse Decision (EC, 2011), 
which ensures that the European Commission as a 
producer and holder of public sector information sets 
an example by applying the same set of rules that it 
would like to be implemented at Member State level. 
TSAR allows to track in 
a transparent manner 
the progress of an 
alternative method, 
from the early phases 
of the validation 
process to its eventual 
inclusion into the 
regulatory framework 
The developers of 
QSARs are welcome 
to submit their 
models to the JRC 
database using the 
QSAR Model Reporting 
Format (QMRF)
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The JRC Data Catalogue therefore aims to complement 
the JRC Policy on Open Access to Scientific Publications 
and Supporting Guidance, and to promote open access 
to research data in the context of Horizon 2020.
The main purposes of the JRC Data Catalogue are to:
• Provide a central overview of data that is produced by 
the JRC (alone or in collaboration with third parties) 
and that can be shared with the public.
• Act as a single channel for automatically feeding the 
EU Open Data portal with relevant metadata to be 
published there.
• Contribute to the JRC's new role with respect to 
knowledge management.
In the reporting period, EURL ECVAM published five data-
sets/portals in the JRC Data Catalogue in its collection:
• ChemAgora (see section 6.1.4.1)
• EURL ECVAM Fish In Vitro Intrinsic Clearance Database 
(see section 2.7.4.1)
• EURL ECVAM Genotoxicity and Carcinogenicity Con-
solidated Database of Ames Positive Chemicals (see 
section section 6.1.4.2)
• Inventory of the 3Rs knowledge sources (see section 
6.1.4.3)
• Supplementary materials of the Nanocomput project 
(Worth et al., 2017b). 
READ MORE
m EURL ECVAM collection in the JRC Data Catalogue: data.
jrc.ec.europa.eu/collection/id-0088
m EU Open Data Portal: data.europa.eu/euodp/en/home
m ChemAgora: chemagora.jrc.ec.europa.eu/chemagora
m EURL ECVAM Fish In Vitro Intrinsic Clearance 
Database: data.jrc.ec.europa.eu/dataset/
jrc-eurl-ecvam-fish-in-vitro-intr-clear-db
m EURL ECVAM Genotoxicity and Carcinogenicity 
Consolidated Database of Ames Positive 
Chemicals: data.jrc.ec.europa.eu/dataset/
jrc-eurl-ecvam-genotoxicity-carcinogenicity-ames
m Inventory of the 3Rs knowledge sources: data.jrc.ec.eu-
ropa.eu/dataset/jrc-eurl-ecvam-eurl-ecvam-3rs
m Computational models for the safety assessment 
of nanomaterials: data.jrc.ec.europa.eu/dataset/
jrc-eurl-ecvam-nanocomput
6.1.4.1 ChemAgora
ChemAgora, the chemical information portal main-
tained by EURL ECVAM, facilitates the online retrieval of 
available information on a certain chemical substance. 
Chemicals can be searched by their name (or parts of it), 
CAS Registry Number, InChIKey or chemical structure in a 
series of public repositories. Making access to informa-
tion on chemical substances easier across heterogeneous 
platforms raises the public awareness about chemical 
knowledge. Stakeholders in the chemical community can 
take more informed decisions when being fully aware 
of the information available about a certain substance, 
and people using ChemAgora have a head start when 
it comes to finding out many details about a chemical.
In 2017, a similarity search option based on the ChEMBL 
Data Web Services (with the choice among 90%, 80% and 
70% Tanimoto 
similarity cut off) 
was added to the 
chemical struc-
ture editor page 
of the platform; 
in addition, fol-
lowing a request 
received from the 
National Center 
for Computational 
Toxicology of the US EPA, the EPA CompTox Chemistry 
Dashboard was added to the list of chemical resources 
searched by ChemAgora.
As a future improvement of the platform, the idea is 
under consideration to extend the search functionality 
adding the EC number used by ECHA. The ChemAgora 
search engine is currently used by the Information Plat-
form for Chemical Monitoring (IPCHeM) exploiting the 
conversion done by ChemAgora from the CAS Registry 
Number – the chemical identifier used by the IPCHEM 
portal – to the InChIKey identifier.
In the reporting period, the Journal of Chemical Informa-
tion and Modeling – a journal of the American Chemical 
Society – published a paper about ChemAgora (Zanzi & 
Wittwehr, 2017). The Chemical Abstract Service (CAS), 
which manages the de facto standard in chemical 
identification numbering, is a division of the American 
Chemical Society, and the publication there can be 
considered an acknowledgement of ChemAgora as a 
valuable resource (see box 6.1).
READ MORE
m ChemAgora: chemagora.jrc.ec.europa.eu/chemagora
m IPCHeM: ipchem.jrc.ec.europa.eu
m Chemical Abstracts Service (CAS): www.cas.org
ChemAgora, the chemical 
information portal 
maintained by EURL 
ECVAM, facilitates the 
online retrieval of available 
information on a certain 
chemical substance 
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6.1.4.2 EURL ECVAM Genotoxicity and 
Carcinogenicity Database of Ames Positive 
Chemicals 
The EURL ECVAM Genotoxicity and Carcinogenicity 
Consolidated Database of Ames positive chemicals is a 
structured and highly curated database compiling avail-
able genotoxicity and carcinogenicity data for 726 Ames 
positive chemicals originating from different sources 
(Corvi & Madia, 2018; Kirkland et al., 2014).
By using a harmonised format to gather the informa-
tion, this database is representing a powerful resource 
for data analysis that is meant to be used to guide a 
thorough evaluation of genotoxicity and carcinogenic-
ity: 1) as a resource for evaluating the predictivity of 
the Ames test for in vivo genotoxicity and carcino-
genicity when considered alone or in association with 
in vitro mammalian cell assays (gene mutation and 
clastogenicity/ aneugenicity) and for a better charac-
terisation of those cases where the Ames test leads 
to irrelevant ('false positive') results; but also, 2) as 
a platform for detailed structural characterisation of 
specific groups of compounds with or without car-
cinogenic or genotoxic activity. Inconsistencies (e.g., 
contradictory data derived from different sources) 
and poor data quality have been addressed through 
rigorous curation which included expert peer review.
Since its launch, the EURL ECVAM Genotoxicity and Car-
cinogenicity Database represents a reference database 
for both the regulatory and scientific communities as 
demonstrated by its contribution to a number of activ-
ities (see section 6.1.5 in Zuang et al., 2017). Recently, 
this dataset 
(9286 data 
points) was 
inco rpora ted 
into the new 
version of the 
QSAR Tool-
box that was 
released by 
OECD to support 
governments, 
chemical indus-
try and other 
stakeholders in filling gaps in (eco)toxicity data needed 
for assessing the hazards of chemicals. It also contrib-
uted to the recently published EFSA Scientific Opinion 
on "Reflection on interpretation of some aspects related 
to genotoxicity assessment" where it has been the basis 
to conduct an analysis of the sensitivity of unscheduled 
DNA synthesis in transgenic and comet genotoxicity 
assays to detect carcinogens (EFSA, 2017).
JRC portal ChemAgora simplifies access to 
chemical data
The JRC's ChemAgora web portal provides search capabilities 
to retrieve chemical data from a plethora of online resources 
enabling users to access both regulatory information on chem-
icals and public databases on chemical properties. ChemAgora 
is intended to support chemical risk assessment activities by 
assisting stakeholders to gain a quick overview of globally avail-
able data about chemicals they are interested in. This speeds 
up the process of data discovery and saves valuable resources.
ChemAgora, through an on-the-fly search, informs whether a 
chemical features in any of 17 external data sources or the 
OECD eChemPortal (featuring another 30 external sources), and 
provides clickable links leading to the third-party website pages 
containing the information. These third-party data sources con-
tain regulatory and scientific chemical information and typically 
use the CAS Registry Number (CASRN, a registered trademark 
of the American Chemical Society) as the substance identifier. 
Box 6.1
ChemAgora can also map InChIKeys to CASRNs, which bridges 
the gap between regulatory and scientific environments.
The ChemAgora portal has gained the recognition of the Amer-
ican Chemical Society (ACS) as highlighted in a recent ACS 
publication, "Journal of Chemical Modelling and Information" 
(Zanzi & Wittwehr, 2017).
The EURL ECVAM 
Genotoxicity and 
Carcinogenicity Consolidated 
Database of Ames 
positive chemicals is 
a database compiling 
available genotoxicity and 
carcinogenicity data for 726 
Ames positive chemicals 
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The database is a living project with possibilities of con-
tinuous update as new genotoxicity and carcinogenicity 
data are made available. The database is currently being 
extended to include additional curated data from more 
than 200 new chemicals with Ames negative results.
READ MORE
m EURL ECVAM Genotoxicity and Carcinogenicity 
Consolidated Database of Ames Positive 
Chemicals: data.jrc.ec.europa.eu/dataset/
jrc-eurl-ecvam-genotoxicity-carcinogenicity-ames
m QSAR Toolbox: www.oecd.org/chemicalsafety/risk-assess-
ment/oecd-qsar-toolbox.htm
6.1.4.3 Inventory of Three Rs Knowledge Sources
In response to the European Citizens' Initiative (ECI) 
"Stop Vivisection", in 2015, the European Commission 
identified four actions to accelerate the development 
and uptake of non-animal approaches (EC, 2015).
Action 1 of the European Commission's response aimed 
to conduct an assessment of current technologies, 
information sources and networks from all relevant 
sectors with potential impact on the advancement of 
the Three Rs. To support this action the JRC's EURL 
ECVAM had undertaken a review to map Three Rs 
knowledge, determine how knowledge is shared and 
to identify opportu-
nities to improve on 
the current situation. 
This review was 
performed by build-
ing an inventory of 
knowledge sources 
and carrying out a 
survey of the users 
of the knowledge 
sources. The out-
come of the review 
was summarised in 
a study by Holley et al., 2016 (see also section 5.2 
in Zuang et al., 2017), whilst in December 2017 the 
inventory comprising 800 knowledge sources relevant 
to the Three Rs was made publicly available (Holley et 
al., 2017). More details on the inventory of 3Rs knowl-
edge sources can be found in box 6.2.
The Three Rs knowledge sources inventory should be 
viewed as a snapshot of the status of knowledge sources 
available and as a starting point for further analysis of 
knowledge sharing strategies.
READ MORE
m ECI "Stop Vivisection": ec.europa.eu/citizens-initiative/
public/initiatives/successful/details/2012/000007
m Inventory of the Thee Rs knowledge sources: data.jrc.
ec.europa.eu/dataset/jrc-eurl-ecvam-eurl-ecvam-3rs
6.1.5 CheLIST 
A key requirement for the development, characterisation 
and eventual validation of alternative (non-animal) 
methods for use in biomedical research and regulatory 
safety assessment is the availability of suitable refer-
ence or benchmark chemicals for which reliable 
structural, physicochemical and biological property data 
are available. However, the type of information needed 
to select such reference chemicals is typically scattered 
across a plethora of heterogeneous databases, project 
websites and peer-reviewed literature. To tackle this 
issue, EURL ECVAM manages and publishes the "Chem-
ical Lists Information System" (CheLIST) that provides a 
means of identifying whether a chemical (or chemical 
group) has been tested in a major EU or international 
research project and whether the chemical appears on 
a specific regulatory inventory.
Information is provided on chemical identifiers (e.g., 
name, CAS number) and chemical structure, and the 
database can be searched according to these types of 
information. The various datasets and inventories can 
also be compared in order to identify overlaps in chem-
ical membership and to generate customised lists. All 
lists can be downloaded and the references provided 
for each list allow traceability back to the source. Using 
CheLIST, alternative methods can be developed faster 
as information about reference chemicals (for method 
validation) is available more easily.
In the reporting period CheLIST continued to grow, with 
EURL ECVAM monitoring the chemical programme land-
scape to identify more lists to add to CheLIST.
READ MORE
m CheLIST: chelist.jrc.ec.europa.eu
6.1.6 Endocrine Active Substances Information 
System (EASIS)
The revised 'Endocrine Active Substances Information 
System' (EASIS) uses the cloud based IUCLID 6 portal 
The Three Rs knowledge 
sources inventory 
should be viewed as a 
snapshot of the status 
of knowledge sources 
available and as a 
starting point for further 
analysis of knowledge 
sharing strategies
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from ECHA. The term "Endocrine Active Substance" (EAS) 
describes any chemical that can interact directly or 
indirectly with the endocrine system, and subsequently 
result in an effect on the endocrine system, target organs 
and tissues. Whether the effect is adverse (“disruptive”) 
or not, will depend on the type of effect, the dose and the 
background of the physiological situation (EFSA, 2010).
EASIS' web-based application is open to the public 
for query and review of results from scientific studies 
on chemicals related to endocrine activity or adverse 
effects (considered in relation to an endocrine disrupting 
mode of action). It deals generally with endocrine active 
substances, i.e., not only with endocrine disruptors. The 
starting point was a database created by Directorate 
General Environment (DG ENV) in 2006. The new appli-
cation, EASIS, was developed and the data from the DG 
ENV database were migrated into it. More data to cover 
the period after 2006 were added. There are currently 
data from 9246 
studies across 
541 compounds 
in EASIS, and 
the content is 
con t i nuous l y 
increased. The 
focus of the 
current update 
is on pathways 
and chemicals that are not well covered by other 
databases/sources. 
The data of the first web-based version of EASIS 
(launched in 2016) have been migrated from the 
Inventory of 3Rs Knowledge Sources published
A detailed inventory - compiled by JRC scientists - of 800 
knowledge sources relevant to the Replacement, Reduction and 
Refinement (Three Rs) of animal procedures used for scientific 
purposes is now available online (Holley et al., 2017). The JRC 
set out to assess the current situation regarding the sharing of 
knowledge relevant to the 3Rs with a mind to accelerate the 
development and uptake of non-animal approaches in research 
and testing. The findings of the report (Holley et al., 2016) 
show that although much 3Rs knowledge exists, its sharing, 
particularly between sectors and communities can be improved 
through better coordination, communication and outreach, and 
by more emphasis on targeted education and training initia-
tives. As part of this review, these knowledge sources have 
been described in a way which facilitates their curation and the 
subsequent analysis of potential knowledge gaps and means 
of sharing. The inventory covers different types of knowledge 
sources (e.g., organisations, events, expert groups, etc.) and 
identifies the ways in which these share information.
The knowledge sources considered for this inventory refer to 
any entity, tool or event that creates, collects, holds or dis-
seminates knowledge with potential 3Rs relevance for the 
knowledge source types. The information captured in the 
inventory cover different knowledge sources with 3Rs rele-
vance, including on-line information systems and specialised 
websites, experts groups, organisations, social media commu-
nities, professional associations and networks, conferences and 
workshops, industry initiatives and research programs.
Box 6.2
Knowledge is captured in many different forms, so in addition 
to the more typical explicit knowledge sources (e.g., on-line 
resources, publications and educational materials), other 
media used for knowledge dissemination and sharing, such 
as social media and scientific communities or 3Rs relevant 
research initiatives, which may contain more tacit knowledge, 
were also included. The data collection for the inventory took 
place over six months, from March to October 2016. There-
fore, the inventory should be considered as a representative 
selection of the most visible 3Rs knowledge sources during 
the time of compilation. The methodology for establishing 
the inventory and the subsequent analysis can be found in 
the JRC Report 'Accelerating progress in the Replacement, 
Reduction and Refinement of animal testing through better 
knowledge sharing' (Holley et al., 2016).
The data of the first web-
based version of EASIS 
(launched in 2016) have 
been migrated from the 
phased-out IUCLID 5 to the 
new IUCLID 6 format
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phased-out IUCLID 5 to the new IUCLID 6 format and 
new content is now being added directly in IUCLID 
format, which now also features a specific template 
for reporting in vitro observations. It is planned that the 
future evolution of EASIS will be in collaboration with 
ECHA to create an ECHA-JRC-OECD Joint Dissemination 
Portal (JDP) for non-REACH IUCLID data of which 'EASIS 
2.0' will be an integral part. 
READ MORE
m EASIS: ecs.echa.europa.eu/cloud/home.html
6.2 Knowledge Sharing Activities 
6.2.1 Bridging Across Methods in the 
Biosciences (BeAMS)
The biosciences are at a critical point of development, 
with new innovative technologies constantly emerging, 
making possible new methods and techniques. Currently, 
we see many emerging technologies for in vivo experi-
mental studies, in vitro and in silico studies. All of these 
technologies have their 
associated methods 
and techniques, which 
require high levels of 
specialisation and 
expertise on the part 
of researchers. Each 
innovation demands 
significant investment, 
both financial and in 
terms of researchers’ 
time and effort, in order to ensure that it reaches its full 
potential and yields useful scientific results. However, 
there is also a risk that each will evolve within silos with 
little connection between them, and that opportunities 
to fully exploit the potential of methods will be lost.
Bridging Across Methods in the bioSciences (BeAMS) 
is a JRC-EURL ECVAM initiative that aims to support 
Figure 6.1  Participants of the first BeAMS (Bridging Across Methods in the bioSciences) workshop, which was organised by 
JRC's EURL ECVAM in June 2018.
BridgE Across Methods 
in the bioSciences 
(BEAMS) is a EURL 
ECVAM initiative 
that aims to support 
greater connectivity 
between methods
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greater connectivity between methods. The focus is on 
how knowledge sharing can play a role and what form it 
should take. The BeAMS initiative started in June 2018 
with a workshop of renown actors in the field (see fig. 
6.1) and will lead to first tangible results in 2019, by 
exploring and identifying a science and innovation strat-
egy underpinning meaningful cross-disciplinarity.
6.2.2 Feasibility Study on Indicators of 
Alternative Methods or Approaches to Animal 
Experimentation
In December 2017, EURL ECVAM launched a feasi-
bility study on indicators of alternative methods and 
approaches to animal experimentation. The study is 
being carried out with the support of external experts 
and is aimed at investigating indicators to monitor the 
level of development and use of alternative non-animal 
methods in basic and applied life-science research, as 
well as for educational and regulatory testing purposes. 
This one-year project is organised in three main phases 
covering:
1) the identification of suitable indicators including their 
selection criteria.
2) the characterisation of a pool of indicators among 
those identified in phase one, covering all the relevant 
features and data to be collected.
3) a demonstration exercise based on the implementa-
tion of a subset of characterised indicators showing the 
feasibility of the methodological approach.
Overall, this feasibility study and its outcomes could 
help to identify impactful trends and further foster the 
development and uptake of alternative methods and 
approaches by ultimately supporting informed policy 
decisions related to the EU Directive on the protection 
of animals used for scientific purposes.
6.3 Education and Training Activities 
6.3.1 Review of 3Rs Education and Training 
Resources
Following a study (Holley et al., 2016) carried out by 
EURL ECVAM in 2016 to identify how 3Rs knowledge 
is shared (see section 6.1.4.3 and box 6.2), it was 
concluded that education and training is key to the suc-
cessful uptake of the principle in the use of animals for 
science and the development of alternative methods. 
In 2018, EURL ECVAM started preparation for projects 
that will map available resources and scope ways to 
develop guidance and tools for introducing 3Rs into the 
curricula of high schools, universities and continuing 
education (professional development) programmes.
Using external expertise both in the areas of education 
and training and 3Rs, EURL ECVAM is undertaking the 
following projects.
Firstly, a study to review available education and training 
resources to provide an overview of opportunities cur-
rently offered (see box 6.3). The objective is to identify 
courses, modules, teaching materials, guidance, and 
other resources to form a snapshot view of how, where 
and to whom the 3Rs principles and alternative to animal 
approaches are currently being taught. The resulting 
inventory and conclusions from the mapping exercise 
will provide a foundation for the other education and 
training projects.
With support from the European Parliament through a 
Pilot Project (where EP resources are allocated to test 
the feasibility of certain approaches in a policy area), 
EURL ECVAM will start work on developing strategies 
for successful introduction of 3Rs in curricula at high 
school, university and professional levels. Findings during 
this work will also help identify some optimal tools that 
will facilitate the introduction of 3Rs in the classroom or 
online. As part of this project, the tools will be built and 
distributed to educational bodies and course providers. 
Under the same EP 
Pilot Project, EURL 
ECVAM is collabo-
rating closely with 
DG Environment to 
engage experts to 
design and produce 
further eLearning 
tools. These mod-
ules will be freely 
available and will 
provide interactive instruction to students and profes-
sionals on tasks required under Directive 2010/63/EU on 
the protection of animals used for scientific purposes, 
enabling animal users to fully apply the 3Rs in their day-
to-day work and employ best practices when developing 
alternative methods or when searching for alternative 
methods and approaches.
Finally, using JRC in-house expertise a project will start 
this year to explore the possibilities of a 3Rs virtual 
reality training programme, bringing students as close 
as possible to real-life learning situations.
6.3.2 Training on Uncertainty Characterisation 
in 21st Century Toxicology 
Understanding, describing, communicating and, where 
possible, quantifying and reducing uncertainties is an 
EURL ECVAM will start 
work on developing 
strategies for successful 
introduction of 3Rs 
in curricula at high 
school, university and 
professional levels
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essential part of hazard and risk assessment, to allow 
informed decision-making and confidence in the results. 
Therefore, EURL ECVAM initiated and organised the Soci-
ety of Toxicology (SOT) Continuing Education Course 
"Uncertainty Characterisation in 21st Century Toxicol-
ogy: Current Practice and Practical Methods Supporting 
Regulatory Risk Assessment" together with a group of 
enthusiastic speakers at the 57th SOT Annual Meeting in 
March 2018. A focus of the course was the character-
isation of uncertainties for new approaches, since the 
incorporation of new toxicological methodologies into 
safety assessment are still being hampered by a lack of 
knowledge on how to describe and assess the associated 
different uncertainties. The presentations are available 
from the SOT website.
READ MORE
m Society of Toxicology (SOT): www.toxicology.org/index.asp
m SOT Continuing Education (CE) Programme at the 57th 
SOT Annual Meeting 2018: www.toxicology.org/events/am/
AM2018/continuing-education.asp 
m CEd-Tox: SOT Continuing Education Courses Online: www.
toxicology.org/education/ce/onlineCourses.asp 
6.3.3 Training Activities related to Adverse 
Outcome Pathways 
EURL ECVAM contributed with a lecture on the relation-
ship between AOPs and chemistry-based in silico models 
to predict toxicity (Cronin & Richarz, 2017) to the in3 
training workshop in Liverpool, UK in July 2018.
Mapping education and training on the 3Rs
EURL ECVAM has launched a study to review available edu-
cation and training resources that support the 3Rs approach: 
Replacement, Reduction and Refinement of animal proce-
dures used for scientific purposes. This ambitious global study 
aims to provide an initial overview of education and training 
opportunities being offered at high school, university and 
professional levels.
The objective is to identify courses, modules, teaching 
materials, guidance, and other resources to form a snap-
shot view of how, where and to whom the 3Rs principles 
Box 6.3
and alternative-to-animal approaches are currently being 
taught keeping in mind that many such initiatives might not 
be "3R labelled".
The review is expected to be completed during 2019 and the 
information gathered will be made publicly available. It is 
expected that the results obtained will help to identify oppor-
tunities, to boost 3Rs education and training and to target 
initiatives and investment to accelerate progress. The study 
is an important step in efforts to advance the development 
and uptake of 3Rs approaches in research and safety testing 
and is also a follow-up to Action 1 of the Commission's Com-
munication in response to the European Citizens' Initiative 
"Stop Vivisection".
In 2016 the JRC carried out a study to build an inventory of 
3Rs knowledge sources and to identify how 3Rs knowledge is 
shared (Holley et al., 2016; see also section 6.1.4.3 and box 
6.2). Findings demonstrated that although much 3Rs knowledge 
exists, its sharing can be improved especially between different 
fields of expertise through better coordination, communication 
and outreach, and by more emphasis on targeted education 
and training initiatives. This, together with the current study 
and survey establishes the follow-up to Action 1 of the Com-
mission's Communication in response to the European Citizens' 
Initiative "Stop Vivisection" (EC, 2015).©
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The in3 project on integrated in vitro & in silico tools 
is a Marie Skłodowska-Curie Action Innovative Training 
Network, investigating an integrated interdisciplinary 
approach to animal-free nanomaterial and chemical 
safety assessment. Furthermore, the EURL ECVAM activi-
ties in the field of Modes of Action, AOPs and integration 
of different data sources were presented. 
READ MORE
m in3: estiv.org/in3
6.3.4 Courses on Alternative Approaches in 
Modern Toxicology
In June 2018, EURL ECVAM gave a two-day course on 
"Alternative approaches to modern toxicology" for PhD 
students in life sciences at the University of Vienna 
upon invitation by the Head of the Department of Food 
Chemistry and Toxicology. This course aimed to create 
awareness on alternative methods for chemical risk 
assessment (toxicology/food safety) in theory and prac-
tice. The course was designed as a pilot project for the 
integration of alternative methods into the curriculum.
Presentations included toxicodynamics, AOPs and in vitro 
methods, introduction to risk and exposure assessment, 
biokinetics and exposure mathematical models. Exercises 
in break-out groups were related to AOP development to 
become familiar with the AOP Wiki and the principles of 
PBK models. A case study on 2,3,7,8-Tetrachlorodiben-
zo-p-dioxin (TCDD) and the Seveso Disaster underpinned 
the course and linked the various presentations and exer-
cises. Students were very interested and interactive and 
their feedback was excellent.
Following the longstanding tradition, EURL ECVAM also 
invited in 2018 the students from the Karolinska Insti-
tute, Master programme in toxicology, to a course on 
modern toxicological sciences (see fig. 6.2). Twenty-two 
students and four tutors participated in a one-day course 
including various interactive presentations, which all 
aimed at increasing their understanding of non-animal 
methods and their use in life sciences.
READ MORE
m "Alternative approaches to modern toxicology" 
course: chemie.univie.ac.at/news-events/news/detail/
news/27-28-juni-eu-jrc-lehrveranstaltung-alternative-ap-
proaches-to-modern-toxicology-jetzt-anmelde/?tx_news_
pi1%5Bcontroller%5D=News&tx_news_pi1%5Bac-
tion%5D=detail&-cHash=dd4b65bd6c0c51ad83b-
29bad54109862
m Master's Programme in Toxicology 
at the Karolinska Institute: ki.se/en/
utbildning/4tx15-masters-programme-in-toxicology
Figure 6.2  Students of the Master's Programme in Toxicology of the Karolinska Institute (Sweden) visiting the JRC Ispra in 
May 2018. 
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6.3.5 Traineeships at EURL ECVAM
Since 2016, the new JRC Traineeship Scheme offers 
a stimulating, multi-cultural and multi-disciplinary 
research environment for trainees. Several positions 
were opened at the EURL ECVAM Laboratories with a 
high turnover of well-performing students over the last 
two years (see fig. 6.3). The EURL ECVAM Traineeship 
projects are part of EURL ECVAM's work program, allow-
ing students to acquire or refine new techniques and 
publish their research results. 
READ MORE
m JRC Traineeship scheme: europa.eu/!yn83Xx
6.3.6 Education and Training on Biokinetics and 
Physiologically-Based Kinetic Modeling
The US Society of Toxicology (SOT) offers several Con-
tinuing Education Course (CEC) Programs that cover 
established knowledge in toxicology (see also section 
6.3.2). In 2018, EURL ECVAM co-chaired and participated 
to the course entitled "Physiologically-Based Pharma-
cokinetic Modeling to Support Modernised Chemical 
Safety Assessment" at the SOT2018.
PBK models have been applied to chemical risk assess-
ment for more than three decades, extrapolation of animal 
toxicity findings to humans has been the major applica-
tion. Under the proposed new toxicity testing paradigm, 
which relies on data from human-relevant in vitro toxicity 
assays interpreted through computational approaches, 
PBK models have been redefined as a critical translation 
tool for quantitative in vitro to in vivo extrapolation (IVIVE). 
The course was attended by 147 scientists and provided an 
opportunity to revisit the basic principles of PBK modeling 
with a special focus on supporting chemical risk assess-
ment under the new toxicity testing paradigm. In addition, 
the basics of model 
construction, recent 
advances in model 
parametr izat ion, 
including IVIVE, and 
evaluation of model 
performance and 
reliability along with 
use of available 
human data were 
presented and dis-
cussed with the participants. Finally, the focus was on 
the applications of the PBK models to support risk-based 
decisions in different tiers of risk assessment, and define 
and discuss challenges and future directions.
At the end of the day course, a hands-on demonstra-
tion was provided using a free online simulation tool 
(PLETHEM) to demonstrate the workflow of building and 
parameterizing a PBK model, simulating different human 
populations, and applying the model to translate concen-
tration-effect relationships from cell-based assays or in 
vivo studies to the dose-response relationship in target 
human populations to support chemical risk assessment.
In addition, EURL ECVAM was invited to participate to the 
SOT 2018 roundtable discussion "Can pharmacokinetic 
Figure 6.3  Some trainees during summer 2018.
Under the proposed new 
toxicity testing paradigm 
PBK models have been 
redefined as a critical 
translation tool for 
quantitative in vitro to in 
vivo extrapolation (IVIVE)
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modelling keep up with risk assessment in the 21st 
Century?" Discussion on the impact of the changing reg-
ulatory environment on the utility of PBK modeling in 
chemical risk assessment, including:
1) Adequacy of currently available PBK modeling plat-
forms for use in risk assessment.
2) Challenges associated with the movement toward 
high-throughput, animal-free toxicity testing.
3) Ways in which to foster increased acceptance of PBK 
modeling by regulatory scientists. The discussion was 
well perceived and attended by a large crowd of partic-
ipants from the SOT 2018. 
At the EUROTOX 2018, held in Brussels on 2 to 5 Sep-
tember 2018, EURL ECVAM staff chaired a CEC entitled: 
"Application of non-animal (toxico)kinetic data and tools 
in risk assessment from basic research to practice". 
With a similar aim as for the SOT 2018 CEC, a pres-
entation was given to 56 students on the basics, how 
to construct, develop, evaluate and apply PBK models 
for risk assessment purposes, with insight in biokinetic 
data generated using alternatives and how to find and 
use TK databases.
READ MORE
m SOT 57th Annual Meeting: www.toxicology.org/events/am/
AM2018/index.asp
m EUROTOX: www.eurotox.com
6.3.7 Course on Read-Across and In Silico Risk 
Assessment at Karolinska Institute
In November 2017, EURL ECVAM gave a two-day course 
on the use of read-across and in silico methodologies in 
risk assessment to second year students of the Master's 
programme in toxicology of the Karolinska Institute upon 
request of the director of the program. The first day of 
the course covered the theoretical part which included 
the basics of in silico tools and chemoinformatics, (Q)
SARs, and grouping and read-across, quantification of 
uncertainty in read-across. The second day was dedi-
cated to a hands-on exercise in which the students were 
introduced to the OECD QSAR Toolbox and given a series 
of read-across challenges to carry out. 
6.4 History of Alternative Methods in 
Toxicology Book 
EURL ECVAM staff have contributed to the editing and 
writing of a book entitled The History of Alternative Test 
Methods in Toxicology. The book was edited by Michael 
Balls (first Head of ECVAM; Nottingham University, UK), 
Robert Combes (Consultant, Norwich, UK) and Andrew 
Worth (EURL ECVAM) (Balls et al. (eds), 2018).
The book adopts a chronological approach to explore the 
history of alternative method development, validation, 
and use. Historical developments are described from a 
variety of perspectives – by country, region or organisa-
tion; technology type; and applications in the design or 
safety assessment of chemicals and products.
Contributions by EURL ECVAM staff include the following 
chapters:
• Types of Toxicity and Applications of Toxicity Testing
• Contributions to Alternatives from Italy and Spain
• The Role of ECVAM
• Involvement of the Organisation for Economic Coop-
eration and Development
• Alternative Approaches for the Assessment of Chem-
icals in Food
• Alternative Approaches for Carcinogenicity and Repro-
ductive Toxicity
• Dissemination of Information on Alternative Methods: 
Databases and Systems
• Integrated Approaches to Testing and Assessment
• The Validation of Alternative Test Methods
• Alternative Toxicity Test Methods: Lessons learned 
and yet to be learned
The History of Alternative Test Methods in Toxicology is 
published by Academic Press, Elsevier.
6.5 Dissemination Activities of EPAA
6.5.1 EPAA Partners Forum on Toxicokinetics 
and Read-Across 
In November 2017, the EPAA convened a Partners’ Forum 
on Toxicokinetics (TK) and Read-Across to provide an 
overview on research activities for developing in vitro 
TK methods and PBK models and for finding synergies 
to enhance use of TK data to strengthen read-across. 
©
 E
ls
ev
ie
r
 78
CHAPTER 6
Specific activities were identified to facilitate the use of 
in vitro and in silico TK data to support read-across: The 
collation of available tools indicating the parameters and 
applicability domains covered; endpoint-specific guid-
ance on TK parameters required for read-across; case 
studies exemplifying how TK data help support read-
across. Activities to enhance the scientific robustness of 
read-across include the further user-friendly combina-
tion of read-across 
tools and, formal 
guidance by the 
authorities speci-
fying the minimum 
information require-
ments to justify 
read-across for a 
given toxicity end-
point. The EPAA was 
invited to continue 
dissemination activ-
ities and to explore possibilities to create a database of 
TK tools that assist risk assessment. EURL ECVAM was 
invited to present the EURL ECVAM TK strategy document 
(Bessem et al., 2015) including updates in the field of 
hepatic clearance, cyp induction and PBK modeling. The 
recommendations that were drawn from this meeting 
were published in the peer reviewed journal Regulatory 
Toxicology and Phamacology (Laroche et al., 2018).
6.5.2 EPAA Awards
The EPAA Awards are granted to young scientists (3Rs 
Science Prize) or laboratory technicians and animal 
caretakers (3Rs Refinement Prize), respectively, whose 
work has brought an outstanding contribution to the 
development and implementation of alternatives to 
animal testing. Both, the Science and the Laboratory 
technician prize are awarded alternating every other 
year. To this end, each year a jury of representatives 
from the EPAA partners is established, among them a 
staff member of EURL ECVAM.
The 2017 Refinement Prize was awarded to Camilla 
Bengtsson and Marie Eriksson of the Swedish Toxicol-
ogy Sciences Research Center (Swetox) for their work 
entitled "Handling and training of mice and rats results 
in calmer animals during experimental procedures". They
have developed routines for training and handling mice 
and rats during the acclimatisation phase to make them 
more comfortable with the experimental procedures. 
The trained and handled animals show a substantial 
reduction of stress and can be dosed and blood sam-
pled without using devices to immobilise them during the 
experiment. This allows more accurate observations and 
an overall smoother execution of the testing.
Beginning of 2018, a new award programme was 
launched, the "EPAA 3Rs Student Grants", with the aim 
to foster participation of students and young scientists 
to high-profile scientific events in the area of 3Rs. Six 
awardees were financially supported to attend the 
2018 conferences of EUROTOX, ESTIV or EUSAAT. A 
staff member of EURL ECVAM was member of the 
selection panel.
6.5.3 Other Dissemination Activities
As an outcome of EPAA-internal working sessions held 
in 2016, a manuscript (Dal Negro et al., 2018) was pub-
lished in 2018 reviewing the challenges that different 
industry sectors face in the implementation of alterna-
tive methods. It was concluded that for all sectors the 
main constraints to the application of non-animal alter-
natives are the gaps still existing in scientific knowledge 
and technological limitations. 
The 13th EPAA Annual Conference, which took place on 
22 November 2017, focused on "Building synergies to 
accelerate development and acceptance of alternatives". 
A recording of the Conference and the Conference Report 
(EPAA, 2017) were published on the EPAA website. Under 
the sponsorship of EPAA and in collaboration with the 
Institute for In Vitro Sciences (IIVS), two training videos 
have been produced in recent years (see section 6.7.2 
in Zuang et al., 2017). Such videos are now available 
with Spanish subtitles (besides the English original and 
Portuguese and Chinese subtitled versions).
READ MORE
m EPAA: europa.eu/!rq76qf
m EPAA Annual Conference 2017: webcast.ec.europa.eu/
epaa-annual-conference-22-11-2017
m EPAA-IIVS Alternative methods video tutorials: europa.
eu/!bc39gg
The EPAA convened 
a Partners’ Forum on 
Toxicokinetics (TK) and 
Read-Across to provide 
an overview on research 
activities for developing 
in vitro TK methods and 
PBK models
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International Cooperation on 
Alternative Test Methods
7.1 International Cooperation on 
Alternative Test Methods 
Further to the successful ICATM workshop held at the 
JRC-EURL ECVAM on 4 to 6 October 2016, which led 
to concrete outcomes in the area of skin sensitisation 
(see section 7.1 in Zuang et al., 2017; Casati et al., 
2018), EURL ECVAM, together with its ICATM partners, 
hosted another ICATM workshop on 23 to 24 October 
2018, this time on the topic of "Validation of alternative 
methods towards internationally recognised standards 
for regulatory application" (see fig. 7.1). The workshop 
convened regulators from the EU, US, Canada, Japan, 
South Korea and Brazil. 
 
The ICATM workshop on validation primarily aimed to:
• Identify and discuss the current issues concerning the 
validation of alternative methods/approaches and 
possible solutions.
• Discuss lessons learnt from past and ongoing valida-
tion studies.
• Reflect on the Principles and Practice of validation 
in the context of non-guideline methods, non-testing 
methods, IATA/DAs, and tools and technology (e.g., 
microphysiological systems/organ-on-chip).
• Reflect on the elements necessary to establish cred-
ibility of a method.
• Discuss where validation as a process starts and 
where it ends.
• Discuss the possibility of and process for assessing 
(i) relevance without comparing to animal data (what 
does "biologically relevant" mean?) and (ii) reliability 
without conducting ring trials.
• Discuss the main reasons for conducting validation 
studies within ICATM. 
• Discuss if OECD Guidance Document 34 is still ade-
quate in the framework for validation in a regulatory 
context and what validation means in the context of 
an evolving Test Guidelines Programme at the OECD.
• Discuss how to evolve validation practice to increase 
efficiency, encourage more innovation and flexibility 
in study design and accommodate scientific progress.
• Explore how Standards could evolve as a tool to (i) 
facilitate the establishment of credibility of alter-
native methods/approaches and (ii) accelerate the 
acceptance of new approaches in a regulatory context.
An ICATM meeting, involving only ICATM partners, fol-
lowed the workshop to discuss and agree on actions 
to be undertaken by ICATM in the near future in the 
area of validation.
7.
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7.2 OECD - China Joint International 
Workshop on Genotoxicity 
The OECD, the China National Institute for Food and Drug 
Control, the China National Centre for Food Safety Risk 
Assessment together with the Guangdong Provincial 
Centre for Disease Control and prevention are co-organ-
ising a Joint International Workshop on the "Progress of 
Genotoxicity Methods and Regulatory Acceptance" was 
held in November 2018 in Guangzhou. The workshop 
is meant to promote exchange on understanding and 
regulatory acceptance of genotoxicity methods with 
the ultimate aim of possibly adopting in China existing 
OECD test guidelines and other international guidance 
available in the area. 
7.3 International Dialogue for the 
Evaluation of Allergens 
The International Dialogue for the Evaluation of Allergens 
(IDEA) project is designed to provide a broadly agreed and 
transparent framework for 
assessing fragrance sensi-
tisers globally. It provides 
the opportunity to build 
partnerships between the 
international fragrance 
industry and its stake-
holders to improve the 
risk assessment of those 
fragrance ingredients identified as allergens for better 
consumer protection.
IDEA is committed to the integration of non-animal data 
to replace the LLNA for risk assessment. This is a goal
shared by various stakeholders. EURL ECVAM is liaising 
with this IDEA project and participated in a dedicated work-
shop held on 16 to 17 May, 2018. Companies and 
stakeholders shared case studies explaining the application 
and current status of the approaches using only non-ani-
mal derived data for the determination of a non-expected 
sensitisation induction level (NESIL) to be used in quanti-
tative risk assessment (QRA). The main key outcome from 
the workshop was that a number of non-animal approaches 
are available that can predict sensitisation potency of 
fragrance substances for use in risk assessment. The entire 
set of presentations and key conclusions from the work-
shop can be accessed on the IDEA website.
READ MORE
m IDEA project: ideaproject.info
m IDEA Workshop on the replacement of animal test-
ing in QRA for skin sensitization: ideaproject.info/
eventsmanager/27/16/IDEA-Workshop-on-the-replacement-
of-animal-testing-in-QRA-for-skin-sensitization
Figure 7.1  Participants of the International Cooperation on Alternative Test Methods (ICATM) workshop on "Validation of alter-
native methods towards internationally recognised standards for regulatory application" held at the JRC Ispra in October 2018.
IDEA is committed 
to the integration of 
non-animal data to 
replace the LLNA for 
risk assessment
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7.4 Global Consortium on In Silico 
Toxicology Protocols 
Computational (“in silico”) methods include quantitative 
structure-activity relationship models (QSARs), struc-
tural alert profilers, read-across approaches inferring 
properties between similar chemicals, and receptor-li-
gand docking. They are widely used in applications such 
as drug development 
and screening of large 
lists of chemicals for 
potential toxicologi-
cal properties. They 
provide valuable 
information for the 
evaluation of chem-
icals, in particular in 
terms of mechanistic 
understanding of the links between chemical structure 
and biological activity. However, the acceptance of in 
silico model results in regulatory toxicology decision 
making is still limited. One reason for lack of accept-
ance is thought to be the absence of defined and 
harmonised procedures on how to apply the methods 
and interpret the results.
The aim of the In Silico Toxicology Protocol initiative, led 
by Leadscope, Inc., is therefore to develop principles for 
the consistent use and assessment of computational 
model results in chemical hazard evaluations. In par-
ticular, it is devising a structured process to generate, 
interpret, document, assess and communicate compu-
tational method results in a reproducible and consistent 
manner, in order to increase confidence in their use. 
EURL ECVAM is part of the international consortium 
formed by over 55 members from industry, regulatory 
or governmental agencies, academics, model develop-
ers and consultants across different sectors and regions 
(US, Canada, Japan, Europe), in view to achieve a broad 
consensus. The overall aim is to increase confidence in, 
and acceptance and uptake of, in silico methodologies 
for regulatory applications. 
The first publication of the consortium (Myatt et al., 2018) 
describes the general overarching framework of the In 
Silico Toxicology Protocols, integrating computational 
predictions alongside available experimental data for a 
defined set of adverse effects, which are then combined 
in an overall assessment. It includes considerations on 
the assessment of reliability and relevance, using a novel 
scoring scheme. The necessity of expert review steps is 
recognised, at the same time as the importance of a 
guided and transparent process for this evaluation and 
its documentation. Checklists for the In Silico Toxicology 
Protocol components, expert review and reporting ele-
ments are provided.
Work is ongoing to adapt the structured framework to 
specific toxicological endpoints, such as genotoxicity, skin 
sensitisation or acute toxicity. 
7.5 World Health Organisation Chemical 
Risk Assessment Network
The World Health Organisation (WHO) Chemical Risk 
Assessment Network (CRAN) within the International 
Programme on Chemical Safety (IPCS) is a collaborative 
initiative aiming at improving chemical risk assessment 
globally, through facilitating interaction and exchange 
of experience about risk assessment topics and activ-
ities between institutions engaged in chemical risk 
assessment activities around the world. It was estab-
lished at the end of 2013 and comprises institutions 
from over 45 countries, including government depart-
ments, academia, WHO Collaborating Centres and 
professional societies.
The WHO Network promotes the objectives of the 
Strategic Approach to International Chemicals Man-
agement (SAICM). It is coordinating projects that can 
be international, regional, multilateral or bilateral in 
scope, resulting for example in guidance documentation, 
training sessions or materials, tools or databases. An 
important focus is developing countries' perspectives on 
risk assessment. EURL ECVAM is contributing to the Net-
work, for example to the Network Coordination Groups 
on Mode of Action (MoA) and Combined Exposures and 
the development of guidance and tools on chemical risk 
assessment methodology. 
During the IUTOX Congress of Toxicology in Developing 
Countries (CTDC10) in April 2018 in Belgrade, Serbia, 30 
Network Participants from 15 Network institutions met for 
a WHO CRAN lunch time meeting with a focus on capacity 
building activities (see fig. 7.2). The WHO Chemicals Road 
Map to enhance health sector engagement in the SAICM 
The overall aim is to 
increase confidence 
in, and acceptance 
and uptake of, in silico 
methodologies for 
regulatory applications
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was introduced and the WHO CRAN Capacity Building 
Strategy for 2018-2020, linked to actions of the Road 
Map, was presented. The Strategy is aimed at increasing 
chemical risk assessment capacity in WHO Network par-
ticipants and thereby strengthens environmental health 
decision-making. Specifi-
cally, it aims at enhancing 
national institutional 
capacities to address 
health threats from 
chemicals and enhancing 
knowledge and methodol-
ogies for risk assessment. 
The strategic areas of the 
plan focus on assessing 
the capacity needs, iden-
tifying technical resources 
and developing human 
resources, identifying 
priorities for future training as well as promoting best 
chemical risk assessment practice. Furthermore, differ-
ent aspects and experience from Network institutions 
were discussed. The use of webinars for training was one 
specific topic. The WHO Secretariat will follow up on the 
ideas for capacity building activities to implement the 
different areas of the Network Strategy. 
7.6 Collaboration with the US Interagency 
Coordinating Committee on the Validation 
of Alternative Methods Working Groups
7.6.1 Read-Across Working Group
EURL ECVAM is participating as liaison of the Interna-
tional Cooperation on Alternative Test Methods (ICATM, 
see section 7.1) in the new ICCVAM Read-Across Working 
Group (RAWG) established in 2017. The RAWG aims at 
building capacity for ICCVAM members in the develop-
ment and application of read-across approaches for 
chemical safety assessment as well as harmonising 
these approaches between the agencies. The Working 
Group thus contributes to implementing the goals of 
the ICCVAM “Strategic Roadmap for Establishing New 
Approaches to Evaluate the Safety of Chemicals and 
Medical Products in the United States” (ICCVAM, 2018). 
READ MORE
m US Interagency Coordinating Committee on the 
Validation of Alternative Methods (ICCVAM): ntp.niehs.nih.
gov/pubhealth/evalatm/iccvam/index.html
7.6.2 In Vitro to In Vivo Extrapolation Working 
Group 
EURL ECVAM was invited to participate to the ICCVAM 
WG on in vitro to in vivo extrapolation (IVIVE). This WG is 
Figure 7.2  Network meeting at the Congress of Toxicology in Developing Countries (CTDC10) in April 2018.
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also represented by agency representatives of ICCVAM 
and ICATM members experts from outside of the federal 
government. The goal of this WG is to identify the state 
of the science on IVIVE 
for use in prioritisation 
and risk assessment 
purposes. Several tasks 
were identified, from 
literature search on cur-
rent IVIVE approaches 
up to determine best 
practise for IVIVE anal-
ysis. The WG is currently revising and harmonising the 
vocabulary and terminology with an effort to develop 
guidance on the application of IVIVE in risk assessment.
7.7 Health and Environmental Sciences 
Institute 
7.7.1 Update on the Genetic Toxicity Technical 
Committee 
The Health and Environmental Sciences Institute (HESI) 
Genetic Toxicology Technical Committee (GTTC) is 
focused on advancing the field of genetic toxicology 
and human risk assessment. Main objectives include 
the integration of genetic toxicology into risk assess-
ment and decision-making for protection of human 
health; the improvement of new and existing test guide-
lines, strategies, and interpretation of results; and 
investigation of non-traditional modalities, including 
novel entities and technologies.
During the annual meeting that took place in Arlington 
VA, US, in April 2018, the progress of various activities 
was presented by respective working groups. These were 
among others, an analysis of the most appropriate in vivo 
follow-up testing which include compared data for over 
90 chemicals from the transgenic rodent assay, the in 
vivo comet assay, and cancer data; an evaluation of the 
The goal of this WG 
is to identify the 
state of the science 
on IVIVE for use in 
prioritisation and risk 
assessment purposes
Predictive Computational Toxicology Approaches
The term computational (“in silico”) methods covers a wide range 
of approaches including:
• structural alert profilers
• quantitative structure-activity relationship models (QSARs)
• receptor-ligand docking
• read-across approaches inferring properties between sim-
ilar chemicals.
Computational models provide valuable information for the 
evaluation of chemicals, in particular in terms of mechanistic 
understanding of the links between chemical structure and 
biological activity. In silico methods are already widely used in 
applications such as drug development and screening of large 
lists of chemicals to predict potential toxicological properties, 
and also contributing to regulatory chemical safety assessment 
submissions in different ways .
In silico approaches were part of several EURL ECVAM activities 
described in this report:
• Chemistry framework: generic description of chemicals (see 
section 2.9)
• OECD project on a guideline on DAs for skin sensitisation 
prediction which may include the use of QSARs (see section 
5.3.8)
• Case study on grouping and read-across for nanomaterials: 
application of cheminformatics methods for grouping (see 
section 5.2.1 and Worth et al., 2017a)
• Report of the International Cooperation on Cosmetics Reg-
ulation (ICCR) Joint Regulators-Industry Working Group on 
"Integrated Strategies for Safety Assessments of Cosmetic 
Ingredients": in silico methods as one of the NAM described 
to be used in the ‘next generation’ risk assessment (see 
section 5.9.1)
• Global consortium developing In silico Toxicology Protocols: 
structured process to support confidence in, and uptake of, 
in silico approaches for regulatory applications (see section 
7.4 and Myatt et al., 2018)
• Guidance for the implementation of the hazard-based cri-
teria to identify endocrine-disrupting properties: in silico 
approaches included (see section 5.1.2)
• JRC QSAR Database and DB-ALM (see sections 6.1.3 and 
6.1.1; and Tsakovska et al., 2017 as examples for QSARs)
• ICCVAM Read-Across Working Group (see section 7.6.1)
• Training on AOPs and in silico models relationship (see 
section 6.3.3 and Cronin & Richarz, 2017)
• Course on read-across and in silico methods for risk assess-
ment (see section 6.3.7)
Box 7.1
85
 
INTERNATIONAL COOPERATION ON ALTERNATIVE TEST METHODS
Interagency Coordinating Committee on the Vali-
dation of Alternative Methods (ICCVAM)
The US Interagency Coordinating Committee on the Validation of 
Alternative Methods (ICCVAM) is an interagency committee of the 
US National Institute of Environmental Health Sciences (NIEHS), 
representing 16 US federal regulatory and research agencies that 
require, use, generate, or disseminate toxicological and safety 
testing information. ICCVAM is evaluating and promoting the 
development, regulatory acceptance, and use of new, revised, 
and alternative test methods, sharing experience among the US 
federal regulatory agencies.
Box 7.2
current testing paradigm for genotoxicity assessment of 
nanomaterials and recommendations for a tailored test 
battery and modification of tests as needed (Elespuru et 
al., 2018); a novel quantitative approach for analysing 
and interpreting genetic toxicity dose-response data 
with in vivo dose-response data being used to identify 
endpoint-specific critical 
effect size (CES) values 
that are suitable for 
routine determination of 
benchmark dose (BMD) 
values; an update of 
the clean sheet testing 
strategy activity (Dear-
field et al., 2017), where 
case studies are being 
prepared, under the dif-
ferent regulatory jurisdictions for publication to further 
illustrate the approach; an analysis of mode of action 
(MoA) and the development of AOPs related to specific 
genotoxic MoA pathways. In this context, methods to 
determine the mode of action of genotoxic agents are 
investigated, as well as the application of new technol-
ogies to establish the mode of action of genotoxicity for 
new chemical entities.
READ MORE
m Health and Environmental Sciences Institute (HESI) 
Genetic Toxicology Technical Committee (GTTC): hes-
iglobal.org/genetic-toxicology-gttc
7.7.2 Physiologically Based Pharmacokinetic 
Working Group
At the SOT 2017, the HESI Physiologically based Phar-
macokinetic (PBPK) WG was established, including 
international experts in PBK modeling. The goal is to 
facilitate the use of PBK modeling approaches in vari-
ous risk assessment applications by identifying specific 
needs. The first effort of this group was the establish-
ment of a harmonised template to report information, 
and provide recommendations to model reviewers to 
facilitate the uptake of PBK modeling approaches in 
regulatory risk assessment. The next effort will be to 
develop a framework and decision tree on PBK appli-
cations based on different degrees of data availability.
7.8 Other International Activities in the 
Area of Toxicokinetics 
In October 2017, EURL ECVAM participated at a Lor-
entz-Center international workshop on "Non-animal 
methods for Toxicokinetics". The goal of the workshop 
was to bring together experts and stakeholders from 
science, industry, and the regulatory area, including new 
generation toxicologists, to find ways to evolve the field 
of non-animal methods for toxicokinetics in toxicological 
research and regulatory safety evaluations. Based on 
pre-defined regulatory questions, a top four of essential 
human kinetic parameters were identified. These are 
(from high to low importance):
1) intrinsic hepatic clearance and identification of 
metabolites,
2) passive permeability (through intestine, lungs, other 
barriers),
3) tissue-partitioning and the fraction unbound in blood, 
and
4) transporter kinetics within different barriers (e.g., 
intestinal, kidney, blood/brain, placenta). These param-
eters have also been identified previously (Bessems et 
al., 2015; Paini et al., 2017a,b).
Regarding transporter kinetics within different barriers, 
EURL ECVAM launched in early 2018 an EU survey entitled 
"Membrane Trans-
porters in Chemical 
Safety Assessment" 
to gather the appli-
cability of available 
data and knowledge 
on membrane trans-
porters. The survey 
was designed with a 
specific interest to identify in vitro and in silico methods 
that are currently in use for transporter studies (Clerbaux 
The HESI Genetic 
Toxicology Technical 
Committee (GTTC) is 
focused on advancing 
the field of genetic 
toxicology and human 
risk assessment
EURL ECVAM launched 
in early 2018 an EU 
survey to gather the 
applicability of available 
data and knowledge on 
membrane transporters
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Figure 7.3  Geographical distribution of the Membrane Transporters in Chemical Safety Assessment questionnaire. The results 
are published in Clerbaux et al. (2018) and are available by individual country. They can be accessed at http://apps.klimeto.com/imt.
et al., 2018). Seventy-three respondents, from 21 coun-
tries, revealed that membrane transporters influencing 
chemical’s absorption, distribution, metabolism and 
excretion, are investigated by applying in vitro and in 
silico approaches during drug development and chem-
ical risk assessment in cosmetics and in food and feed 
safety. However, data from alternative approaches are 
not readily accepted by regulators. To gain trust and 
credibility, regulatory authorities require standardisation 
of methodologies and validation, against human data, 
when possible, as well as reproducibility and high quality 
in data generation (Clerbaux et al., 2018).
Along these lines, EURL ECVAM's next steps will be to 
review the role of membrane transporters for environ-
mental chemical risk assessment in collaboration with 
the US Food and Drug Administration (FDA) and with 
international experts in the field.
READ MORE
m Lorentz-Center: www.lorentzcenter.nl
m "Non-animal Methods for Toxicokinetics" Workshop: 
www.lorentzcenter.nl/lc/web/2017/943/info.
php3?wsid=943&venue=Oort
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8 Conclusions
Research and development activities continued during 
2018 in areas for which 3Rs solutions are more difficult 
to find. For regulatory toxicity testing, research projects 
focus on repeated dose and reproductive toxicity testing, 
on chemical mixtures and endocrine disruptors. These 
projects are either based on read-across case studies or 
aim at developing new in vitro methods and integrating 
in vitro methods and in silico computational technolo-
gies in integrated assessment and testing strategies to 
translate mechanistic understanding of toxicity into risk 
assessments. In the area of carcinogenicity, EURL ECVAM 
is currently exploring how mechanistic data across tox-
icity endpoints (based primarily on existing in vivo and 
in vitro OECD TGs) could be best combined, instead of 
taking them in isolation, to either waive redundant test-
ing or, ultimately, improve carcinogenicity testing.
The relationship between children's health and expo-
sure to environmental chemicals has been investigated 
by the integration of multiple information sources 
including mechanistic knowledge, biomonitoring data, 
epidemiological studies, in silico as well as in vitro data. 
Combined effects of chemicals known to trigger DNT are 
also currently being studied using mechanistically rele-
vant in vitro assays. For the quality control of vaccines, 
research projects aim to develop, optimise and evaluate 
non-animal methods for routine batch quality, safety and 
efficacy testing of vaccines.
Several R&D projects for fish toxicity and bioaccumula-
tion testing are currently ongoing. For acute fish toxicity 
testing, a fish cell line-based cytotoxicity assay has 
been developed and validated, AOPs for chronic fish 
toxicity testing are being developed and the application 
of threshold of toxicological concern in aquatic toxic-
ity assessment is being investigated. A tiered testing 
strategy based on in vitro approaches for fish bioac-
cumulation testing is under development as well as a 
toxicokinetic modelling framework for bioaccumulation 
assessment in mammals, combining in vitro and in vivo 
PBTK data, field collected bioaccumulation data, and 
quantitative structure-activity relationship models. 
Maintenance of normal thyroid function is essential for 
the psychological and physiological well-being and it 
is thus essential to be able to identify chemicals with 
potential thyroid disrupting properties with appropriate 
test methods. Therefore, EURL ECVAM initiated a vali-
dation study, together with EU-NETVAL, on 17 in vitro 
methods for the identification of thyroid hormone disrup-
tors. A multitude of in vitro tests are also currently being 
validated for DNT testing in the framework of an OECD 
Guidance Document on the use of an in vitro testing 
battery for DNT.
The well-advanced areas of topical toxicity, skin sen-
sitisation and genotoxicity were complemented with 
additional in vitro methods or combined (in silico and 
in vitro) approaches which have either already been 
adopted or are currently being reviewed and discussed 
in international fora. As member of the EPAA, EURL 
ECVAM collaborates with the Biological Standardisation 
Programme on several validation studies which assess 
alternative methods for the safety and potency testing 
of human and veterinary vaccines.
The more recent developments of complex in vitro models 
such as 3D cell cultures, bioprinted tissues, bioreactor cul-
tures and microphysiological systems (e.g., multi-organ 
on chip models), as well as the increasing integration of 
multiple data sources for safety testing, triggered some 
reflection on the current principles and practice of val-
idation, and on the elements that are needed to build 
user confidence in these new tools and approaches. EURL 
ECVAM engaged with its international partners (through 
ICATM), its network of regulators (PARERE) and its stake-
holder forum (ESTAF) to discuss that topic. 
8888
88
8
A multitude of projects which promote the regulatory 
acceptance and use of alternative approaches, as well 
as their wider international uptake, were either suc-
cessfully concluded or continued during 2018. For that 
purpose, EURL ECVAM is closely working with the other 
Commission services, the EU regulatory agencies and 
the EPAA at European level, as well as with international 
organisations such as the OECD, ICH, VICH, WHO, ICCR 
and the United Nations.
One major achievement was e.g. the publication of two 
VICH guidelines that establish criteria for waiving the 
target animal batch safety test for inactivated and live 
vaccines for veterinary use. These guidelines are in force 
since May 2018. The harmonisation of such criteria 
between different geographical regions in the world will 
avoid redundant and severe animal testing.
Regarding the activities at UN level, EURL ECVAM 
contributes to the drafting of the GHS chapter on skin 
corrosion/irritation to include non-animal methods, 
and leads the drafting of the chapters on serious eye 
damage/irritation and skin sensitisation within the 
informal working group “Use of non-animal testing 
methods for classification of health hazards” of the 
UN Subcommittee on GHS. This review of the GHS 
will include in vitro, in silico and in chemico methods, 
as well as grouping and read-across, as a basis for 
hazard assessment. The ultimate goal is not only to 
show how non-animal methods can be used to satisfy 
existing classification criteria (e.g., for eye irritation 
and skin sensitisation), but ultimately, how the criteria 
themselves could be adapted to non-animal data. 
Besides regulatory testing, EURL ECVAM intensified its 
activities in the area of basic, applied and translational 
research, as well as education and training, to efficiently 
support the implementation of Directive 2010/63/EU on 
the protection of animals used for scientific purposes 
also in those areas.
This included a study to review non-animal models and 
methods currently used to investigate respiratory tract 
diseases and neurodegenerative disorders; a knowledge 
sharing initiative on the testing procedures used within 
the different disciplines in biosciences; a feasibility study 
on indicators of alternative methods or approaches 
to animal experimentation; a review of current 3Rs 
education and training resources; the planning of a 
strategic introduction of 3Rs in curricula at high school, 
university and professional levels, and finally, the design 
of eLearning tools to be distributed to educational 
bodies and course providers. Information on alternatives 
continued to be disseminated through a variety of 
dedicated meetings, training efforts and specialised 
database services hosted by JRC-EURL ECVAM.
In conclusion therefore, considerable progress has been 
made on several fronts in the development, validation 
and acceptance of alternative approaches to animal 
testing. Moreover, the advancement of the Three Rs 
across multiple sectors is being expedited through 
efficient and effective collaboration between multiple 
stakeholders engaging at an international level in a 
variety of fora.
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Annexes
Annex 1 — Summary status of the adoption of Test Guidelines based on in 
vitro methods in the OECD TG programme (2011-2018)
Table 1 summarises the status of adoption of OECD test guidelines on in vitro methods from 2011 to 2018. It should be noted that beside TGs, also Guidance Documents and 
new projects on alternative methods were respectively adopted and included in the OECD Work programme during that period. For additional information, please consult the 
OECD website of the Test Guideline Programme: http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicalsandrelateddocuments.htm
Table 1. Status of adoption of OECD Test Guidelines based on in vitro methods 2011-2018.
Nr. Toxicity area Test method description Acceptance status
1 Skin corrosion Reconstructed human Epidermis (RhE) test 
methods, as included in OECD TG 431/EU TM 
B.40 bis.
Adopted as a new TG in 2004; updated version (sub-categorisation, inclusion of performance 
standards, inclusion of SkinEthic™ RHE and epiCS®) adopted in 2013. Revised version including 
sub-categorisation with the epiCS® test method adopted in 2014.
Updated in 2015 for the deletion of the performance standards (published separately in the Series 
on Testing and Assessment No. 219), inclusion of paragraphs referring to the IATA for Skin Corro-
sion and Irritation (OECD GD No. 203) and inclusion of the use of HPLC/UPLC-spectrophotometry 
as an alternative procedure to measure tissue viability (increasing the applicability domain of 
the test methods to coloured substances interfering with the measurement of MTT-formazan).
Updated in 2016 for improving the predictive capacity of the three validated in vitro skin corrosion 
test methods (EpiDermTM, SkinEthicTM and EpiCS®) for the correct prediction of Sub-Cat.1A.
2 Skin corrosion Transcutaneous Electrical Resistance (TER) test 
method, as included in OECD TG 430/EU TM 
B.40.
Adopted as a new TG in 2004; updated version (inclusion of performance standards) adopted 
in 2013.
Updated in 2015 for the deletion of the performance standards (published separately in the 
Series on Testing and Assessment No. 218) and the inclusion of paragraphs referring to the 
IATA for Skin Corrosion and Irritation (OECD GD No. 203).
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3 Skin corrosion In vitro Membrane Barrier Test Method for Skin 
Corrosion, as included in OECD TG 435/EU TM 
B.40.
Adopted as a new TG in 2006; Updated in 2015 for the inclusion of the Corrositex® prediction 
model, the deletion of the performance standards (to be published separately in the Series on 
Testing and Assessment), the inclusion of paragraphs referring to the IATA for Skin Corrosion 
and Irritation and the updating of the list of proficiency substances (OECD GD No. 203).
4 Skin irritation Reconstructed human Epidermis (RhE) test 
methods, as included in OECD TG 439/EU B.46.
Adopted as a new TG in 2010; updated version (inclusion of LabCyte EPI-model24 SIT) adopted 
in 2013.
Updated in 2015 for the deletion of the performance standards (published separately in 
the Series on Testing and Assessment No. 220), inclusion of paragraphs referring to the 
IATA for Skin Corrosion and Irritation (OECD GD No. 203) and inclusion of the use of HPLC/
UPLC-spectrophotometry as an alternative procedure to measure tissue viability (increasing 
the applicability domain of the test methods to coloured substances interfering with the 
measurement of MTT-formazan).
5 Serious eye damage/
eye irritation 
Fluorescein Leakage (FL) test method, as 
included in OECD TG 460.
Adopted as a new TG in 2012; updated version to include a new reference to OECD GD 236 
on an IATA for Serious Eye Damage and Eye Irritation adopted in 2017.
6 Serious eye damage/
eye irritation
Bovine Corneal Opacity and Permeability 
(BCOP) test method, as included in OECD TG 
437/EU TM B.47.
Adopted as a new TG in 2009; updated version (revision of positive controls, use to identify 
non-classified chemicals and several other revisions) adopted in 2013; updated version to 
include a new reference to OECD GD 236 on an IATA for Serious Eye Damage and Eye Irritation 
adopted in 2017.
7 Serious eye damage/
eye irritation
Isolated Chicken Eye (ICE) test method, as 
included in OECD TG 438/EU TM B.48.
Adopted as a new TG in 2009, updated version (use to identify non-classified chemicals and 
several other revisions) adopted in 2013; updated version to include a new reference to OECD 
GD 236 on an IATA for Serious Eye Damage and Eye Irritation adopted in 2017; updated 
versionto include histopathological examination as additional endpoint to identify UN GHS 
cat.1 non-extreme pH (2<pH<11.5) detergents and surfactants and modified decision criteria 
for chemicals requiring classification for eye hazard (taking into consideration the variability 
of the Draize eye test) adopted in 2018.
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8 Serious eye damage/
eye irritation
Cytosensor Microphysiometer (CM) test method. New draft TG first discussed at WNT in 2013 but not adopted, pending further clarification on 
its use to identify non-classified chemicals. The additional data requested by the WNT that 
should have been submitted by US to support the project were not received and thus the project 
has been discontinued because of lower priority for the EC (lead of project).
9 Serious eye damage/
eye irritation
Short Time Exposure (STE) test method for the 
detection of chemicals causing serious eye 
damage and chemicals not requiring classifi-
cation for serious eye damage or eye irritation, 
as included in OECD TG 491.
Adopted as a new TG in 2015; updated version to include a new reference to OECD GD 236 
on an IATA for Serious Eye Damage and Eye Irritation adopted in 2017.
10 Serious eye damage/
eye irritation
Reconstructed human Cornea-like Epithelium 
(RhCE) test methods for the detection of chem-
icals not requiring classification and labelling 
for eye irritation or serious eye damage, as 
included in OECD TG 492.
Adopted as a new TG in 2015; updated version to include SkinEthic™ HCE EIT and a new 
reference to OECD GD 236 on an IATA for Serious Eye Damage and Eye Irritation adopted in 
2017; updated version to include the Labcyte CORNEA-MODEL 24 EIT adopted in 2018.
11 Skin sensitisation In chemico skin sensitisation: Direct Peptide 
Reactivity Assay (DPRA), as included in OECD 
TG 442C.
Adopted as a new TG in 2015.
12 Skin sensitisation Key-event based Test Guideline 442D: In vitro 
skin sensitisation assays addressing the AOP 
key event on keratinocyte activation.
Adopted as a new TG in 2015; updated version to include the ARE-Nrf2 Luciferase KeratinoS-
ens™ test method using animal-free serum and the ARE-Nrf2 Luciferase LuSens test method 
adopted in 2018.
13 Skin sensitisation In Vitro Skin Sensitisation assays addressing 
the Key Event on activation of dendritic cells on 
the Adverse Outcome Pathway for Skin Sensiti-
sation, as included in OECD TG 442E.
Adopted as a new TG in 2016 as "In Vitro Skin Sensitisation: human Cell Line Activation Test 
(h-CLAT)"; updated version to include U-SENS™ and IL-8 Luc test methods adopted in 2017. 
The TG was revised to an "OECD Test Guideline for the Testing of Chemicals Based on Key 
events", grouping the three adopted test methods addressing key event 3 within the existing 
AOP into one single TG.
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14 Carcinogenicity In vitro Syrian Hamster Embryo (SHE) Cell 
Transformation Assay (CTA) as included in 
OECD GD No. 2141.
Adopted as a new GD in 2015.
15 Carcinogenicity In vitro Bhas 42 Cell Transformation Assay 
(CTA) as included in OECD GD no 2311.
Adoption as a new GD in 2016.
16 Genotoxicity In vitro Mammalian Chromosome Aberration 
Assay as included in OECD TG 473.
Updated OECD TG 473 (originally adopted in 1983) adopted in 2014. Updated in 2016 to 
reference the Guidance Document on genetic toxicology Test Guidelines.
17 Genotoxicity In vitro Mammalian Cell Micronucleus Assay as 
included in OECD TG 487.
Updated OECD TG 487 (originally adopted in 2010) adopted in 2014. Updated in 2016 to 
reference the Guidance Document on genetic toxicology Test Guidelines.
18 Genotoxicity In vitro Mammalian Cell Gene Mutation Test 
using Hprt and xprt genes as included in OECD 
TG 476.
OECD TG 476 (originally adopted in 1984) "In vitro Mammalian Cell Gene Mutation Test" has 
been split up into two TGs: 
1. The updated TG 476 now using the Hprt and xprt genes was adopted in 2015;
2. OECD TG 490 using thymidine kinase Gene was adopted in 2015.
Both TGs were updated in 2016 to reference the Guidance Document on genetic toxicology 
Test Guidelines and TG 490 was also corrected (see below).
19 Genotoxicity In vitro Mammalian Cell Gene Mutation Tests 
Using the Thymidine Kinase Gene as included 
in OECD TG 490.
Adopted as TG 490 in 2015 (see above). Updated in 2016 to reference the Guidance Document 
on genetic toxicology Test Guidelines and to correct a paragraph related to the maximum 
concentration that is based on cytotoxicity. 
20 Endocrine disruption H295R Steroidogenesis Assay. Adopted as TG 456 in 2011.
21 Endocrine disruption Estrogen receptor transactivation assay 
(BG1Luc ER TA; agonist and antagonist proto-
cols) as included in OECD TG 457.
Adopted in 2012.
OECD TG 457 was deleted in 2015. The method was included in OECD TG 455 in 2012 (agonist 
part) and 2015 (antagonist part) (see table entry below).
1 These test methods were initially proposed to be included in Test Guidelines. It was later decided to include them in Guidance Documents.
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22 Endocrine disruption Performance-Based Test Guideline for Stably 
Transfected Transactivation In vitro Assays to 
Detect Estrogen Receptor Agonists and Antag-
onists as included in OECD TG 455.
OECD 455 adopted in 2009 (STTA assay using the hERα-HeLa-9903 cell line); updated version 
(PBTG, inclusion of VM7Luc ER TA assay using the VM7Luc4E2 cell line) adopted in 2012; Second 
updated version, including  the antagonist part of both methods was adopted in 2015.
This update led to the deletion of OECD TG 457 in parallel as it is no longer needed (see above).
Third updated version to include the ER-CALUX method (using a U2OS cell line) was approved 
in 2016.
23 Endocrine disruption Performance-Based Test Guideline for Human 
Recombinant Estrogen Receptor (hrER) In vitro 
Assays to Detect Chemicals with ER Binding 
Affinity as included in OECD TG 493.
Adopted as new TG in 2015. It includes two reference test methods:
•  In Vitro Estrogen Receptor (ER) Binding Assay Using a Full Length Human Recombinant ERα;
• In Vitro Estrogen Receptor Binding Assay Using a Human Recombinant Ligand Binding Domain 
Protein
24 Endocrine disruption Stably Transfected Human Androgen Receptor 
Transcriptional Activation Assay for Detection 
of Androgenic Agonist and Antagonist Activity 
as included in OECD TG 458.
Adopted as new TG in 2016.
The method uses the AR-EcoScreen™ cell line.
25 Acute fish toxicity Fish Embryo Acute Toxicity (FET) Test2 as 
included in OECD TG 236.
Adopted in 2013..
26 Fish bioaccumulation Determination of in vitro intrinsic clearance 
using cryopreserved rainbow trout hepatocytes 
as included in OECD TG 319A.
Adopted in 2018.
In vitro derived clearance data can be used to improve the prediction of in silico methods to 
derive a bioconcentration factor as a means for bioaccumulation.
27 Fish bioaccumulation Determination of in vitro intrinsic clearance 
using rainbow trout liver S9 sub-cellular frac-
tion as included in OECD TG 319B.
Adopted in 2018
In vitro derived clearance data can be used to improve the prediction of in silico methods to 
derive a bioconcentration factor as a means for bioaccumulation.
2 The Fish Embryo Acute Toxicity Test is, strictly speaking, not an in vitro test, as it uses fish embryos which are not covered by Directive 2010/63/EU.
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Annex 2 — ICATM Alternative Test Methods Validation and Status of Regulatory 
Acceptance
Table 2. ICATM Alternative Test Methods Validation and Status of Regulatory Acceptance.
Method Current Status Lead 
Organisation
International Acceptance
Dermal Corrosion Test Methods
CORROSITEX Skin Corrosion 
Test
Completed OECD TG 435 (2006)
Updated version (including the Corrositex® prediction model, the deletion of the 
performance standards (to be published separately on the Series on Testing and 
Assessment), including paragraphs referring to the IATA for Skin Corrosion and Irri-
tation in OECD GD No. 203 and the updating of the list of proficiency substances) 
adopted in 2015.
EpiSkin™, EpiDerm™ SCT, 
SkinEthic™ RHE, epiCS® 
Skin Corrosion Tests
Completed OECD TG 431 (2004)
Updated version (sub-categorisation, inclusion of performance standards, inclusion of 
SkinEthic™ RHE and epiCS™) adopted in 2013. Revised version including the sub-cat-
egorization with the epiCS™ test method adopted in 2014.
Updated version [deleting the performance standards (published separately on the 
Series on Testing and Assessment No. 219), including paragraphs referring to the 
IATA for Skin Corrosion and Irritation in OECD GD No. 203 and including the use of 
HPLC/UPLC-spectrophotometry as an alternative procedure to measure tissue viability 
(increasing the applicability domain of the test methods to coloured substances 
interfering with the measurement of MTT-formazan)] adopted in 2015. Updated in 
2016 for improving the predictive capacity of the three validated in vitro skin corrosion 
test methods (EpiDermTM SCT, SkinEthicTM RHE and epiCS®) for the correct prediction 
of Sub-Cat.1A.
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Rat TER Skin Corrosion Test Completed OECD TG 430 (2004)
Updated version (inclusion of performance standards) adopted in 2013.
Updated version [deleting the performance standards (published separately on the 
Series on Testing and Assessment No. 218) and including paragraphs referring to the 
IATA for Skin Corrosion and Irritation in OECD GD No. 203] adopted in 2015.
In vitro Reconstructed 
human Epidermis (RhE) test 
methods:  LabCyte EPI-
MODEL24 SCT
JSAAE sponsored validation study 
was completed in early 2018. The 
peer review was completed in 
October 2018.
JaCVAM Included in the OECD TGP work plan in 2018.
Dermal Irritation Test Methods
In vitro Reconstructed 
human Epidermis (RhE) test 
methods: EpiSkin™, Epi-
Derm™ SIT, SkinEthic™ RHE 
and LabCyte EPI-MODEL24 
SIT 
Completed OECD TG 439 (2010)
Updated version (including the LabCyte EPI-MODEL24 SIT) adopted in 2013.
Updated version [deleting the performance standards (published separately on the 
Series on Testing and Assessment No. 220), including paragraphs referring to the 
IATA for Skin Corrosion and Irritation in OECD GD No. 203 and including the use of 
HPLC/UPLC-spectrophotometry as an alternative procedure to measure tissue viability 
(increasing the applicability domain of the test methods to coloured substances 
interfering with the measurement of MTT-formazan)] adopted in 2015.
In vitro reconstructed human 
epidermis (RhE) test methods: 
Korean epidermis model
KoCVAM sponsored validation 
study is ongoing
KoCVAM
In vitro reconstructed human 
full-thickness model test 
methods: LbL model
JSAAE sponsored validation study 
is ongoing
JaCVAM
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Phototoxicity Test Methods
3T3 NRU Phototoxicity Test Completed OECD TG 432 (2004).
Updated version is undergoing  commenting.
ICH S10 (2014).
Test method battery to predict 
phototoxicity (yeast growth 
inhibition phototoxicity assay 
and red blood cell photohe-
molysis assay)
Japanese Regulatory Acceptance 
Board recommended additional 
work be performed.
JaCVAM
In vitro test method based 
on reactive oxygen species 
(ROS) and photostability 
Completed JaCVAM ICH S10 (2014)
Included in the OECD TGP work plan in 2016. The draft TG is undergoing commenting.. 
Ocular Toxicity Test Methods
Bovine Corneal Opacity and 
Permeability (BCOP) Test 
Method
Completed OECD TG 437 (2009)
Updated version (positive control, use in a bottom-up approach to identify non-clas-
sified chemicals and several other revisions) adopted in 2013. Updated version to 
include a new reference to OECD GD 236 on an IATA for Serious Eye Damage and 
Eye Irritation adopted in 2017. Updated version under consideration to include a laser 
light-based opacitometer and histopathological examination to revise the Decision 
Criteria for classification of chemicals requiring classification for eye hazard.
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Isolated Chicken Eye (ICE) 
Test Method
Completed OECD TG 438 (2009)
Updated version (use in a bottom-up approach to identify non-classified chemicals 
and several other revisions) adopted in 2013.
Updated version to include a new reference to OECD GD 236 on an IATA for Serious 
Eye Damage and Eye Irritation adopted in 2017. Updated version to include histo-
pathological examination as additional endpoint to identify UN GHS cat.1 non-extreme 
pH (2<pH<11.5) detergents and surfactants and modified decision criteria for chem-
icals requiring classification for eye hazard (taking into consideration the variability 
of the Draize eye test) adopted in 2018.
Use of Histopathology as 
an additional endpoint in 
Ocular Safety Testing
Completed  OECD GD 160 (2011)
Updated version [including: (i) the recommendation for having an internal peer-review 
process when evaluating histopathological effects, (ii) the use of semi-quantitative 
scoring systems for e.g. the ICE histopathology, and (iii) inclusion of an Atlas describing 
typical ICE histopathological effects] adopted in 2017. 
Updated version to provide more specific and detailed guidance on the preparation 
of corneas, the scoring of histopathological findings and the peer-review process of 
the histopathological evaluation, in particular for Test Guideline 438, where this is an 
additional endpoint in certain well-defined cases, adopted in 2018.
Cytotoxicity test: SIRC CVS Peer review coordinated by 
JaCVAM is ongoing
JaCVAM 
Cytotoxicity test: three-dimen-
sional dermal model (MATREX)
JaCVAM-sponsored validation 
study stopped
JaCVAM 
Cytotoxicity test: Short 
Time Exposure (STE) test
Completed OECD TG 491 (2015)
Updated version to include a new reference to OECD GD 236 on an IATA for Serious 
Eye Damage and Eye Irritation adopted in 2017.
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Use of anaesthetics, 
analgesics, and humane 
endpoints for routine use in 
TG 405
Completed OECD updated TG 405 (2012)
Updated version to delete the "Testing and Evaluation Strategy for Eye Irritation/
Corrosion" and include a new reference to OECD GD 236 on an IATA for Serious Eye 
Damage and Eye Irritation adopted in 2017.
In vitro approach for cate-
gorisation of anti-microbial 
cleaning products: recommen-
dations for further studies
Completed. EPA/OPP3 has con-
cluded from submission and 
review of alternative eye irritation 
tests conducted on antimicrobial 
pesticide products with cleaning 
claims (AMCPs) that the proposed 
testing approach is acceptable for 
determining the appropriate eye 
hazard classification and labelling 
for AMCPs (see https://www.epa.
gov/pesticides for the details of the 
scope of the policy).
ICCVAM
In vitro approach for cate-
gorisation of agrochemical 
formulations
Phase 1 testing completed (n=6 
formulations) to demonstrate 
proof-of-concept using six in 
vitro assays [BCOP, ICE, Neutral 
Red Release assay, PoCORA and 
EpiOcular (OECD TG 492 and 
time-to-toxicity protocols].
Phase 2A (n=10 formulations) 
currently being planned and will 
include all assays from Phase 1. 
Testing will continue into 2019.
NICEATM
3 Environmental Protection Agency/Office of Pesticide Programme
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Cytosensor Microphysiometer® 
(CM) Test method
The draft TG was submitted to 
OECD for comments including a 
set of Performance Standards
EURL ECVAM New draft TG discussed at WNT in 2013, 2015 and 2016 but not adopted. The additional 
data requested by the WNT that should have been submitted by US to support the 
project were not received and thus the project has been discontinued because of lower 
priority for the EC. The project is no longer on the OECD Work Plan.
Fluorescein Leakage (FL) 
test method
Completed OECD TG 460 (2012)
Updated version to include a new reference to OECD GD 236 on an IATA for Serious 
Eye Damage and Eye Irritation adopted in 2017
Reconstructed human 
Cornea-like Epithelium 
(RhCE)
EpiOcular™ EIT; SkinEthic™ 
HCE EIT, Labcyte CORNEA 
MODEL 24 EIT
Completed OECD TG 492 (2015)
Updated version to include SkinEthic™ HCE EIT and a new reference to OECD GD 
236 on an IATA for Serious Eye Damage and Eye Irritation adopted in 2017. Updated 
version to include Labcyte CORNEA MODEL 24 EIT adopted in 2018.
Vitrigel-EIT Validation and peer review coordi-
nated by JaCVAM completed
JaCVAM Included in the OECD TGP work plan in 2017. The draft TG is undergoing commenting
OptiSafe Validation Study coordinated by 
NICEATM. Phase I (qualification 
and training of naïve laboratories) 
completed. Phase II partially 
completed: inter-laboratory study 
with 30 chemicals completed; 
testing of 60 chemicals in the 
lead laboratory ongoing.
NICEATM
118
Method Current Status Lead 
Organisation
International Acceptance
In vitro reconstructed human 
Cornea-epithelium model 
(RhCE) test method: Korean 
Cornea-model
Validation study and KoCVAM-
coordinated peer review completed
KoCVAM Included in the OECD TGP work plan in 2018.
Hen's Egg Test-Chorioallantoic 
Membrane (HET-CAM) Test 
Method 
Validation study sponsored by 
Brazilian Ministry of Science, 
Technology Innovation and 
Communication (MCTIC). 
Preliminary phase of validation 
study finalised. Substances 
selection for phase 2 validation 
started.
BraCVAM
Immunotoxicity (Allergic Contact Dermatitis) Test Methods
Murine local lymph node 
assay (LLNA) for skin 
sensitization
Completed OECD TG 429 (2002)
ISO (2002)
Updated Murine local 
lymph node assay (LLNA) 
for skin sensitization (20% 
reduction)
Completed Update to TG 429 OECD (2010)
ISO (2010)
Reduced LLNA (rLLNA) Completed Update to TG 429 OECD (2010)
Nonradioactive LLNA 
protocol using BrdU ELISA or 
BrdU FCM method
Completed OECD TG 442B OECD (2010).
Updated version to include the BrdU FCM method adopted in 2018.
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Nonradioactive LLNA proto-
col, LLNA:DA
Completed OECD TG 442A OECD (2010)
Harmonized performance 
standards for the LLNA
Completed Update to TG 429 OECD (2010)
In vitro skin sensitisation 
assay (DPRA) 
Completed OECD TG 442C (2015)
In vitro skin sensitisation 
assay (h-CLAT)
Completed OECD TG 442E (2016).
Draft updated TG442E under consideration to include an adaptation to use human 
serum/antibodies.
In vitro skin sensitisation 
assay KeratinoSens™
Completed OECD TG 442D (2015).
Updated version to include an adaptation to animal-free conditions adopted in 2018
In vitro skin sensitisation 
assay IL-8 Luc assay
Completed OECD TG 442E (2017)
In vitro skin sensitisation 
assay U937 Cell Line Acti-
vation Test (U-SENS™)
Completed OECD TG 442E (2017)
In vitro skin sensitisation 
assay LuSens
Completed EURL ECVAM OECD TG 442D (2018)
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In vitro skin sensitisation assay
SENS-IS
External validation study finalised EURL ECVAM 
evaluation 
finalised. Revised 
submission 
awaited
Included in the OECD TG work plan in 2016
In vitro skin sensitisation assay
Genomic Allergen Rapid 
Detection
(GARDskin)
External validation study finalised EURL ECVAM 
evaluation 
stopped. 
Included in the OECD TG work plan in 2016
In vitro skin sensitisation assay 
Vitrigel-SST
MAFF4-sponsored validation study 
is pending
JaCVAM
In vitro skin sensitisation 
assay, Amino acid derivative 
reactivity assay (ARDA)
JCIA5 and JSAAE6 validation study 
and peer review completed
JaCVAM Included in the OECD TGP work plan in 2018. The draft TG is undergoing commenting.
IL-2 Luc assay for the eval-
uation of the immunotoxic 
potential of chemicals 
JaCVAM validation study is ongo-
ing. The experimental part was 
completed in 2017
JaCVAM
Electrophilic allergen screening 
assay (EASA)
Validation study coordinated by 
NICEATM is currently ongoing; con-
version of assay to 96-well format 
in progress; testing will continue 
into 2019
NICEATM 
4 Ministry of Agriculture, Forestry and Fisheries
5 Japan Cosmetic Industry Association
6 Japanese Society for Alternatives to Animal Experiments
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Defined approaches for skin 
sensitisation
ICATM partners developed and/
or evaluated defined approaches 
for skin sensitisation to support 
the development of an OECD 
guideline on Defined Approaches
IL-1β Luc assay for the eval-
uation of the immunotoxic 
potential of chemicals
JaCVAM validation study is ongoing JaCVAM
In vitro skin sensitisation assay: 
EpiSensA
JaCVAM validation study is ongoing JaCVAM
Acute Toxicity Test Methods
Up and Down Procedure 
(UDP)
Completed OECD TG 425 (2008)
In vitro cytotoxicity test 
methods for estimating 
starting doses for acute 
oral systemic toxicity tests
Completed OECD GD 129 (2010)
In vitro cytotoxicity test (3T3 
Neutral Red Uptake) for iden-
tifying substances with acute 
oral LD50 > 2000 mg/kg b.w.
EURL ECVAM ESAC peer review 
completed, and EURL ECVAM Rec-
ommendation published in 2013
EURL ECVAM
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EpiAirway human recon-
structed lung epithelium for 
identifying acute inhalation 
toxicity
Validation study is ongoing. 
Testing in the lead laboratory 
underway and chemical selection 
for testing in two additional lab-
oratories is in progress. ICCVAM 
agency representatives serving on 
the VMT
NICEATM/
ICCVAM
The Collaborative Acute Toxicity 
Modeling Suite (CATMoS)
The ICCVAM Acute Toxicity Work-
group organised a global project 
to develop in silico models of 
acute oral systemic toxicity that 
predict five specific endpoints 
needed by regulatory agencies. 
Thirty-two international groups 
across government, industry, and 
academia built and submitted 
models. Outputs from the different 
models are now being combined 
to generate consensus predictions 
(via CATMoS) for the acute oral 
toxicity endpoints of interest.
NICEATM/
ICCVAM
Toxicokinetic Test Methods
In vitro hepatic biotransfor-
mation – CYP induction: Hepa 
RG and cryopreserved human 
hepatocytes
EURL ECVAM ESAC peer review 
completed, and EURL ECVAM man-
uscript in preparation
EURL ECVAM SPSF for a PBTG approved in April 2013. Draft PBTG underwent a first commenting 
round in 2014. An OECD expert meeting was held in March 2015. 
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Endocrine Disruptor Test Methods
Stably transfected human 
estrogen receptor-α tran-
scriptional activation assay 
for detection of estrogenic 
agonist-activity of chem-
icals (STTA and BG1-Luc 
assays) 
Completed OECD TG 455 (2009), updated 2012 and 2015, inclusion of the antagonist 
protocols in addition to the agonist protocols, deletion of OECD TG 457 in parallel as 
it is no longer needed
H295R Steroidogenesis 
assay
Completed OECD TG 456 (2011)
BG1Luc® human estrogen 
receptor transcriptional 
activation assay: agonist 
and antagonist protocols
Completed OECD TG 457 (2012)
TG 457 has been deleted in parallel to TG 455 updates (see previous table entry)
CertiChem MCF-7 cell prolifer-
ation assay for the detection 
of human estrogen receptor 
agonists and antagonists
International validation study 
completed. Protocol must 
be revised for adequate 
transferability.
NICEATM Not in the OECD TGP work plan anymore
CertiChem MDA-Kb2 assay 
for the detection of human 
androgen receptor agonists 
and antagonists
NICEATM coordinated single lab 
validation study completed. Sum-
mary report in preparation.
NICEATM
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Stably transfected CHO 
Androgen receptor-α tran-
scriptional activation assay 
for detection of androgenic 
agonist and antagonist 
activity of chemicals 
(AR-STTA)
Completed OECD TG 458 (2016)
MELN® human estrogen recep-
tor transcriptional activation 
assay: agonist and antagonist 
protocols
Validation stopped
Stably Transfected Transacti-
vation in vitro Assay to detect 
Androgen Receptor Agonists 
and Antagonists
Validation study ongoing EURL ECVAM Included in the OECD TGP work plan in April 2013
AR-CALUX Stably Transfected 
Transactivation in vitro Assay 
to detect Androgen Receptor 
Agonists and Antagonists
EU-NETVAL validation study 
ongoing
EURL ECVAM Included in the OECD TGP work plan in April 2013
Transactivation assay for the 
detection of compounds with 
(anti)androgenic potential 
using 22Rv1/MMTV cells
Validation study ongoing Ministry of Food 
and Drug Safety 
(MFDS) South 
Korea
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Performance-Based Test 
Guideline for Human 
Recombinant Estrogen 
Receptor (hrER) In Vitro 
Assays to Detect Chemicals 
with ER Binding Affinity
Completed OECD TG 493 (2015)
CHO-K1 cells thyrotropin-re-
leasing hormone (TRH) 
receptor activation (beta-ga-
lactosidase) measuring agonist 
and antagonist activities
Preparation for EU-NETVAL 
Validation study ongoing
EURL ECVAM
In the context of the detection of chemicals with thyroid disrupting potential as called 
for by the OECD7
CHO-K1 cells thyrotro-
pin-stimulating hormone (TSH) 
receptor activation based on 
cAMP measurement
Thyroperoxidase (TPO) inhi-
bition based on oxidation of 
Amplex UltraRed
Thyroperoxidase (TPO) inhi-
bition based on oxidation of 
Luminol
Tyrosine iodination using liquid 
chromatography
7 http://www.oecd.org/chemicalsafety/oecd-encourages-development-of-non-animal-test-methods-for-detection-of-thyroid-disrupters.htm
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Activation of the sodium iodide 
symporter (NIS) based on San-
dell-Kolthoff reaction
Preparation for EU-NETVAL 
Validation study ongoing
EURL ECVAM
In the context of the detection of chemicals with thyroid disrupting potential as called 
for by the OECD
Thyroxine-binding prealbumin 
(TTR) / thyroxine-binding glob-
ulin (TBG) using fluorescence 
displacement (ANSA)
Thyroxine-binding prealbumin 
(TTR) using fluorescence dis-
placement (T4-FITC)
Deiodinase 1 activity based on 
Sandell-Kolthoff reaction
Glucuronidation of thyroid 
hormones (THs) using liquid 
chromatography/mass spec-
trometry (LC/MS)
Inhibition of thyroid hormones 
(THs)  sulfation using liquid 
chromatography
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Inhibition of monocarboxylate 
transporter 8 (MCT8) based on 
Sandell-Kolthoff reaction
Preparation for EU-NETVAL 
Validation study ongoing
EURL ECVAM
In the context of the detection of chemicals with thyroid disrupting potential as called 
for by the OECD
Human thyroid hormone 
receptor alpha (TRα) and 
Human thyroid hormone 
receptor beta (TRβ) reporter 
gene transactivation meas-
uring agonist and antagonist 
activities
CALUX human thyroid hor-
mone receptor beta (TRβ) 
reporter gene transactivation 
measuring agonist and antag-
onist activities
Measurement of intrafollicular 
thyroxine (T4) using zebrafish 
eleutheroembryos
Measurement of proliferation of 
rat pituitary-derived cell line GH3
Proliferation, migration and 
oligodendrocyte differen-
tiation of human neural 
progenitor cells
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Method Current Status Lead 
Organisation
International Acceptance
Genetic Toxicity Test Methods
In vitro mammalian cell 
micronucleus test
Completed OECD TG 487 (2010), updated TG  adopted in 2014
In vitro mammalian cell 
chromosome aberration 
assay8
Completed OECD TG 473 (1997), updated TG  adopted in 2014
In vivo comet assay Completed OECD TG 489 (2014)
In vitro comet assay Validation study for the in vitro 
comet assay stopped
JaCVAM 
Genotoxicity assays (micronu-
cleus and comet) in 3D skin 
models
Validation study ongoing Cosmetics 
Europe  (lead);
EURL ECVAM 
support
Carcinogenicity Test Methods
In vitro Bhas 42 cell trans-
formation assay (CTA)
Completed OECD GD  231 (2016)
In vitro Syrian hamster 
embryonic cells (SHE) cell 
transformation assays 
(CTAs)
Completed OECD GD 214 (2015)
8 The in vitro mammalian cell chromosome aberration assay has not been validated by any of the ICATM partners. It is added here for completeness as it has been adopted as 
an OECD TG.
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Method Current Status Lead 
Organisation
International Acceptance
Reproductive Test Methods
Hand-1 Luc assay METI9 -sponsored validation is 
completed. The peer review is 
on-going
JaCVAM Included in the OECD TGP work plan in 2017. The 1st step of the project  consists in 
drafting a Detailed Review Paper of available methods and the evaluation of utility 
and application of the Hand-1 Luc assay;
The 2nd step consists in a feasibility study on the development of a Test Guideline.
Mouse Embryoid Bodies 
(mEBT) assay
KoCVAM sponsored validation 
study is ongoing
KoCVAM
Developmental Neurotoxicity Test Methods
Pluripotent Stem Cells  differ-
entiation into neural precursor 
cells/neural stem cells NPC/NSC  
(embryonic phase)
Retrospective validation according 
to defined readiness criteria.
Prospective validation ongoing
EFSA/EC 
(through EURL 
ECVAM)/OECD
Development of an OECD  Guidance Document (GD) on the use of an in vitro testing 
battery for DNT.
Included in the OECD TGP work plan in 2017.
Validation of in vitro test methods based on experimental testing ongoing.
Drafting GD based on existing and newly produced data ongoing
Human neural precursor cells 
(hNPC) proliferation
Retrospective validation according 
to defined readiness criteria.
Prospective validation ongoing
hNPC migration Retrospective validation according 
to defined readiness criteria.
Prospective validation ongoing
hNPC neuronal differentiation Retrospective validation according 
to defined readiness criteria.
9 Ministry of Economy, Trade and Industry
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Method Current Status Lead 
Organisation
International Acceptance
hNPC differentiated neurons Retrospective validation according 
to defined readiness criteria
EFSA/EC 
(through EURL 
ECVAM)/OECD
Development of an OECD  Guidance Document (GD) on the use of an in vitro testing 
battery for DNT.
Included in the OECD TGP work plan in 2017.
Validation of in vitro test methods based on experimental testing ongoing.
Drafting GD based on existing and newly produced data ongoing
hNPC oligodendrocyte 
different.
Retrospective validation according 
to defined readiness criteria.
Prospective validation ongoing
hNPC oligodendrocyte mat-
uration and thyrod hormone 
disruption
Retrospective validation according 
to defined readiness criteria.
Neural Crest Cells (NCC) prolif-
eration and migration (cMINC) 
Retrospective validation according 
to defined readiness criteria.
Prospective validation ongoing
Morphological differentiation 
of embryonic stem cells  (ESC 
to neurons)
Retrospective validation according 
to defined readiness criteria
Differentiation towards 
astrocytes, oligodendrocytes, 
myelination, microglia in 3D 
rat model
Retrospective validation according 
to defined readiness criteria
Differentiation towards 
astrocytes, oligodendrocytes, 
myelination, microglia in 3D 
human foetal phase model
Retrospective validation according 
to defined readiness criteria
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Method Current Status Lead 
Organisation
International Acceptance
Neurite outgrowth of central 
neurons,
Retrospective validation according 
to defined readiness criteria.
Prospective validation ongoing
EFSA/EC 
(through EURL 
ECVAM)/OECD
Development of an OECD  Guidance Document (GD) on the use of an in vitro testing 
battery for DNT.
Included in the OECD TGP work plan in 2017.
Validation of in vitro test methods based on experimental testing ongoing.
Drafting GD based on existing and newly produced data ongoing
Neurite outgrowth of periph-
eral neurons
Retrospective validation according 
to defined readiness criteria.
Prospective validation ongoing
Neuronal sub-type ratio, neu-
ronal maturation
Retrospective validation according 
to defined readiness criteria
Synaptogenesis Retrospective validation according 
to defined readiness criteria
Neuronal network formation 
and function
Retrospective validation according 
to defined readiness criteria.
Prospective validation ongoing
Zebrafish assays Retrospective validation according 
to defined readiness criteria
Acute Aquatic Toxicity Test Methods
Zebrafish Embryo Acute 
Toxicity test (ZFET)
Completed OECD TG 236 (2013)
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Method Current Status Lead 
Organisation
International Acceptance
Fish Bioaccumulation Test Methods
Determination of in vitro 
intrinsic clearance using 
cryopreserved rainbow 
trout hepatocytes as 
included in OECD TG 319A
Determination of in vitro 
intrinsic clearance using 
rainbow trout liver S9 
sub-cellular fraction as 
included in OECD TG319B
Completed EURL ECVAM 
and US EPA
OECD TG 391A and 391B (2018) 
Various
Zebrafish assays NTP SEAZIT: the Systematic 
Evaluation of the Application of 
Zebrafish in Toxicology (SEAZIT) 
program, jointly led by NTP and 
NICEATM scientists. Summarized 
below are four key SEAZIT pro-
gram activities:
• Zebrafish information gathering
• A webinar series focused on the 
use of informatics to improve 
data analysis for zebrafish 
screening studies (2017)
• A n interlaboratory zebrafish 
study (2018)
• A zebrafish best practices 
workshop
NICEATM
GETTING IN TOUCH WITH THE EU
In person
All over the European Union there are hundreds of Europe Direct information centres. You can 
find the address of the centre nearest you at: http://europa.eu/contact
On the phone or by email
Europe Direct is a service that answers your questions about the European Union. You can contact 
this service:
- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls),
- at the following standard number: +32 22999696, or
- by electronic mail via: http://europa.eu/contact
FINDING INFORMATION ABOUT THE EU
Online
Information about the European Union in all the official languages of the EU is available on the 
Europa website at: http://europa.eu
EU publications
You can download or order free and priced EU publications from EU Bookshop at:
http://bookshop.europa.eu. Multiple copies of free publications may be obtained by contacting 
Europe Direct or your local information centre (see http://europa.eu/contact).
JRC Mission
As the science and knowledge servicew 
of the European Commission, the Joint 
Research Centre’s mission is to support  
EU policies with independent evidence 
throughout the whole policy cycle.
@EU_ScienceHub
EU Science Hub - Joint Research Centre
Joint Research Centre
EU Science Hub 
EU Science Hub 
ec.europa.eu/jrc
The European Commission’s 
science and knowledge service 
Joint Research Centre
doi:10.2760/818599
ISBN 978-92-79-97417-5
KJ-N
A-29455-EN
-N
